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Abstract 
 
For women in the United States, ovarian cancer (OVCA) represents the deadliest 
gynecological cancer with over 14,000 deaths predicted to occur in 2019 [13]. Although innovative 
treatment strategies have improved the 5-year outcome for these patients, the overall survival 
has not changed in over 40 years [14]. This is largely due to the challenges in detecting this 
heterogenous disease at an early stage, as there are multiple potential precursors that may give 
rise to different histological subtypes [14]. This dissertation is thus focused on investigating pro-
survival pathways involved in the pathogenesis of endometriosis (a proposed precursor) and 
epithelial ovarian cancers. 
Endometriosis occurs when glands (comprised of both epithelial and stromal cells) from 
the endometrium are located in the pelvic cavity [15]. A cellular homeostasis process known as 
autophagy is characterized as being dysregulated in patients with endometriosis [16-20], but the 
contribution of this pathway to the formation of endometriotic lesions has been uncertain. 
Furthermore, studies have identified that patients diagnosed with endometriosis also have an 
increased risk for developing more rare epithelial OVCA (EOC), namely endometrioid and clear 
cell OVCAs [21, 22], which suggests that endometriosis is a likely precursor. In Chapter 2 of this 
dissertation, we characterized the mRNA and protein expression of autophagy markers in 
endometriosis-induced mice and from patient specimens. We further identified that inhibiting the 
autophagy pathway with an FDA-approved anti-malarial drug, hydroxychloroquine (HCQ), 
significantly reduced human endometriotic cell viability in vitro and reduced the number of 
endometriotic lesions that developed within an in vivo endometriosis model. These results 
suggest that autophagy may be an important contributor to the establishment of endometriosis. 
xiv 
 
EOCs are characterized by genomic aberrations which can help in distinguishing the 
different histological subtypes [23-25]. Furthermore, recent studies suggest that iron dependency 
may be an important characteristic of OVCA [26], but further research into the contribution of iron 
dysregulation to ovarian cancer pathogenesis is needed. Thus, in Chapter 3, we generated 
transformed human endometriotic cell lines by inhibiting p53 (which is commonly inactivated via 
mutations in ~95% of high-grade serous OVCA (HGSOC) [25]) and overexpressing human 
telomerase reverse transcriptase (hTERT, which is commonly amplified in HGSOC [27]). These 
cells were also expressing oncogenic c-Myc (which is amplified at 8q24 in HGSOC [28]) as well 
as mutated (constitutively activated) H-Ras (which is commonly activated in OVCA [29]). We 
characterized increased colony forming ability and reduced senescence compared to non-
transformed control cells, as expected, but also identified mRNA expression changes in key 
regulators of the iron pathway. One such regulator, NCOA4 (nuclear receptor coactivator 4), 
promotes the release of iron from the ferritin storage complex through a targeted autophagy 
process, ferritinophagy [3, 30]. Interestingly, NCOA4 mRNA and protein expression were elevated 
in transformed endometriotic cells relative to controls. We further identified increased NCOA4 
mRNA and protein in malignant OVCA cell lines relative to non-malignant cells, as well as 
increased NCOA4 protein in human OVCA tumors relative to control adjacent tissues. These 
findings suggest a potential role for NCOA4 and iron dysregulation in OVCA pathogenesis. 
Iron is an essential metal required for many cellular processes [31-33], but it can also be 
detrimental through its ability to produce reactive oxygen species (ROS) [34, 35]. Excess iron has 
been implicated in the development of epithelial cancers, such as hepatocellular cancer [36]. 
Recent evidence also supports a role for iron in ovarian cancer pathogenesis [26], but the 
molecular events mediating this process have not been identified. We thus investigated the 
contribution of iron to the transition of precursors to OVCA in Chapter 4 by chronically exposing 
fallopian tube secretory epithelial cells (FTSECs, another proposed precursor to OVCA [14]) to a 
source of non-transferrin bound iron (NTBI). In addition, we generated transformed FTSECs and 
xv 
 
compared the functional and expressional changes between the two cell lines. We found that both 
chronic iron exposure and cellular transformation increased cell numbers and observed altered 
protein and mRNA expression of MECOM genes, which are commonly aberrant in OVCA [14]. 
Specifically, the expression of tumor suppressive MDS1/EVI1 was reduced while the expression 
of oncogenic EVI1 and EVI1Del190-515 was elevated in both conditions. Interestingly, we also 
observed differences between these cell lines, such as increased migratory capacity and elevated 
-catenin protein expression with chronic iron treatment (but not with oncogenic transformation). 
Together, these findings demonstrate that iron may mediate the transition of fallopian tube 
precursors to a transformed-like state. 
Altogether, these findings have improved our knowledge of pathways that may be involved 
in the pathogenesis of endometriosis and epithelial ovarian cancers, namely the autophagy and 
iron regulatory pathways. Additional research is needed, however, in order to identify the 
respective underlying mechanisms. Such studies would also expand our understanding of the 
contribution of iron to the transition of endometriotic and fallopian tube precursor cells to OVCA. 
Understanding these mechanisms will promote innovative strategies to detect these diseases 
early and help improve current treatment strategies, thus improving on the clinical outcome for 
women diagnosed with ovarian cancer. 
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0336. 2: Rockfield, S., Chhabra, R., Robertson, M., Rehman, N., Bisht, R., and Nanjundan, M. 
Pharmaceuticals. 2018. 11(4). pii: E113. doi: 10.3390/ph11040113.). This reproduction was 
approved by De Gruyter and MDPI, respectively (see Appendix A for copyright permissions). 
 
Epithelial Ovarian Cancer (EOC)  
Ovarian cancer (OVCA) is the deadliest gynecological cancer, and overall the 5th leading 
cause of cancer-associated deaths, for women in the United States [13]. Recent reports estimate 
that there will be over 22,000 new cases diagnosed in 2019, with a reported estimate of nearly 
14,000 deaths caused by ovarian cancer in the US [13]. Moreover, the overall survival of these 
patients has not improved in the past ~40 years although progress has been made recently 
towards increasing the 5-year survival rate [14]. Strategies to improve surgical tumor removal, to 
enhance treatment using combination (dose-dense) chemotherapeutics, and to efficiently treat 
patients who experience OVCA recurrence are largely responsible for these positive results [14]. 
However, difficulties in diagnosing patients at early stages and treating drug resistant tumors 
continue to hamper progress in this field [14].  
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Of the patients diagnosed with OVCA, more than 95% are diagnosed with epithelial 
ovarian cancer (EOC, [23]) as opposed to the atypical germ cell OVCA (arising from cells involved 
in producing ova, [37, 38]) or stromal cell OVCA (also known as granulosa cell tumors [38]). 
Epithelial OVCAs are further divided into either the more indolent type I or the more aggressive 
type II [39] and histologically identified based on cellular features and tumor location. Type I is 
comprised of low-grade serous as well as the more rarely diagnosed endometrioid, clear cell, 
transitional cell (also known as Brenner tumors), and mucinous histological subtypes, while type 
II is comprised of high-grade serous ovarian cancer (HGSOC [23, 40]). Differentiating between 
these subtypes can be challenging due to the heterogenous nature of OVCA tumors [24]. For 
instance, mucinous OVCA are histologically similar to intestinal cancers and thus pathologists 
may be challenged in distinguishing a primary mucinous ovarian tumor from a metastatic 
mucinous gastrointestinal tumor [23]. In addition, granulosa cell tumors on the ovary may be 
misdiagnosed as ovarian cancer, which can result in complications with effective treatment 
strategies [41, 42]. Therefore, advances in early detection, in diagnosis, and in improving our 
understanding of the precursors that give rise to these OVCA subtypes are direly needed to 
improve treatment strategies and increase survival rates for patients afflicted with this deadly 
cancer. 
 
Current treatment strategies for OVCA 
The first strategy towards treating patients diagnosed with ovarian cancer is surgery to 
remove the tumor (also known as primary debulking surgery, or PDS) [43]. Surgical removal may 
include only the tumor and adjacent tissue if the diagnosis is made at an early stage, as is the 
case in ~80% of patients diagnosed with mucinous OVCA [44]. This strategy can help to preserve 
fertility of the patient, but may not be an option in patients with more advanced-stage disease due 
to an elevated risk of disease recurrence [44]. Thus, treatment strategies for advanced-stage 
OVCA patients tend to be more aggressive, using combined administration of the 
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chemotherapeutic drugs carboplatin and paclitaxel [43]. Carboplatin is a platinum-based drug 
similar to cisplatin, which is able to crosslink DNA to impair DNA replication [45], whereas 
paclitaxel halts dividing cells in the mitotic phase of the cell cycle by preventing microtubule 
disassembly [46]. In addition, bevacizumab targets the vascular endothelial growth factor (VEGF) 
and may be administered to inhibit angiogenesis [43, 47, 48]. Gemcitabine is a pyrimidine 
nucleoside analog which prevents DNA synthesis from continuing once it has incorporated into a 
replicating strand [43]. This is another treatment strategy for advanced-stage OVCA patients, 
particularly for platinum-resistant, recurrent disease [49, 50]. Furthermore, treatment with agents 
to inhibit PARP (poly-ADP ribose polymerase) to prevent DNA repair have been successful in 
treating patients with recurrent OVCA [43, 51]. As mentioned above, the combination of these 
chemotherapeutics has contributed to improving the 5-year survival rate for patients diagnosed 
with OVCA. However, survival for these patients over 10 years remains the same at ~24% [52]. 
It is thus important to understand the molecular events involved in ovarian cancer pathogenesis 
in order to improve upon these treatment strategies. 
 
Table 1. Common genomic and expression profiles in type I and type II ovarian cancers. 
 
EOC Gene Chromosome Alteration Prevalence References
Deleted 40-50% Weigand et al.  2010; Koshiyama et al.  2014
Mutated (Inactivated) 30-60% Takeda et al.  2016
PIK3CA 3q26.3 Mutated (Activated) 12%; 33-46% Levine et al.  2005; Kuo et al.  2009
PTEN 10q23.31 Mutated (Inactivated) 15-20%; 43% Koshiyama et al.  2014; Obata et al.  1998
-catenin 3p22.1 Mutated (Activated) 16%; 30% Wright et al.  1999; Koshiyama et al. 2014
Ki67 10q26.2 Overexpressed 10-15% Koshiyama et al. 2014
p53 17p13.1 Mutated (Inactivated) 50-80%; 87% Koshiyama et al. 2014; TCGA (Provisional)
BRCA1 17q21.31 Mutated (Inactivated) 4%; 90% (hereditary) TCGA (Provisional); Koshiyama et al. 2014
BRCA2 13q13.1 Mutated (Inactivated) 4%; 90% (hereditary) TCGA (Provisional); Koshiyama et al. 2014
Ki67 10q26.2 Overexpressed 50-75% Koshiyama et al. 2014
c-MYC 8q24.21 Amplified 41% TCGA (Provisional)
EVI1/MECOM 3q26.2 Amplified 34% TCGA (Provisional)
TERC 3q26.2 Amplified 33% TCGA (Provisional)
SnoN/SkiL 3q26.2 Amplified 31% TCGA (Provisional)
PIK3CA 3q26.3 Amplified 29% TCGA (Provisional)
TERT 5p15.33 Amplified 14% TCGA (Provisional)
H-Ras 11p15.5 Activated ND Patton et al.  1998
-catenin 3p22.1 Activated ND Bast et al.  2010
Cyclin D1 11q13.3 Amplified 8% TCGA (Provisional)
BMI1 10p12.2 Amplified 4% TCGA (Provisional)
Summary of Common Aberrations in EOC
*Data from TCGA (Provisional) Obtained March 2019
Type II (HGSOC)
Type I (e.g. LGSOC, 
Endometrioid, Clear 
Cell)
1p36.11ARID1A
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Genomic Aberrations in EOC 
Table 1 summarizes the common aberrations that have been identified in type I and type 
II OVCA. K-Ras (Kirsten rat sarcoma viral oncogene homolog, which participates in the MAPK 
signaling cascade) activating mutations are more frequent in mucinous ovarian tumors (at ~23%) 
than in endometriosis-associated ovarian tumors [53], for which the mutation rate is ~7-14% [53, 
54]. Other type I OVCAs, such as endometrioid and clear cell OVCA, commonly harbor mutations 
in ARID1A, a member of the SWI/SNF chromatin remodeling complex that is mutated in 30-60% 
of ovarian cancer [55]. ARID1A is located at chromosome 1p36, and it is interesting that 
advanced-stage OVCAs have frequent deletions in this region [56, 57]. PIK3CA 
(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) is involved in activating 
the AKT pathway and is mutated in ~50% of endometriosis-associated clear cell OVCA [54]. Type 
I OVCAs are also characterized by PTEN (phosphatase and tensin homolog, which antagonizes 
PI3K) inactivating mutations [39, 58]. Furthermore, activating mutations in -catenin (which is 
involved in regulating cell adhesion as well as transcription through the Wnt signaling pathway) 
have also been identified in 16 to 30% of type I OVCAs [39, 59]. Intriguingly, p53 inactivating 
mutations are rarely identified in type I OVCAs but are prevalent in type II OVCAs [25, 39], and 
p53 missense mutations, especially within the DNA binding region, are the most common type of 
p53 mutation identified in ovarian cancer [25]. Although there is one report of p53 mutations 
similarly detected in HGSOC, mucinous OVCA, and clear cell OVCA [60], there is also evidence 
that p53 mutations may be important for the transition from type I to type II OVCA [61]. Inactivating 
mutations in the breast cancer susceptibility protein genes (BRCA1 or BRCA2), which are 
involved in mediating DNA repair, are generally low in HGSOC at ~4% (TCGA analysis assessed 
via cBioPortal [62]). However, mutations in these genes are remarkably high (~90%) in patients 
with a family history of ovarian cancer [39]. PIK3CA is mutated at only ~12% in advanced-stage 
OVCA [63]. In addition, the proto-oncogene and transcriptional regulator c-Myc, located at 
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8q24.21, is amplified in ~40% of serous ovarian cancers [62] and may contribute to 
chemotherapeutic resistance [28]. 
 
3q26 genes in EOC 
One of the most commonly amplified genomic regions identified in type II ovarian cancer 
is that of 3q26 [64, 65]. Genes located at this region include the RNA component of telomerase 
(TERC), PIK3CA, PKC, and negative regulators of the TGF pathway, namely SnoN/SkiL and 
MDS1/EVI1 complex locus (MECOM). Figure 1 presents a schematic of these genes located on 
the 3q arm, which have all been implicated in ovarian cancer. Specifically, amplification of 
SnoN/SkiL promoted proliferation in OVCA cell lines although its overexpression in immortalized 
(non-malignant) ovarian epithelial cells actually promoted senescence [66]. Human telomerase 
reverse transcriptase (hTERT) complexes with hTERC to form the active telomerase protein, 
which is important for maintaining telomere length to prevent cellular senescence [67, 68]. hTERT 
 
Figure 1. Schematic of key genes on the 3q chromosomal arm implicated in ovarian 
cancer. Figure created by Stephanie Rockfield. 
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is overexpressed in cancers [68] and is transcriptionally regulated by Myc [69, 70]; this regulatory 
mechanism may have an important role in ovarian cancer pathogenesis [27]. In addition, PKC 
regulates the expression of cyclin E to promote cell cycle progression in ovarian cancer cells [71], 
while amplification of PIK3CA is associated with chemoresistance in OVCA patients [72].  
The MECOM locus is comprised of two genes, namely myelodysplastic syndrome 1 
(MDS1) and ecotropic viral integration site 1 (EVI1). MDS1 transcript is encoded by 4 exons 
spanning ~500 kilobases and is predicted to encode an 20kDa protein, although the precise 
function of this protein has not been elucidated [73]. The EVI1 gene is comprised of 16 exons (14 
of which are coding exons) spanning ~60 kilobases to generate ~145kDa product [74-76]. EVI1 
 
Figure 2. Organization of the MECOM locus at 3q26.2. The EVI1 gene, comprised of 16 
exons, is transcribed into alternative splice variants resulting in the wildtype EVI1 or the 
EVI1Del190-515 variants (amongst others not depicted here). Additionally, splicing may occur 
between the transcripts of the MDS1 gene and EVI1 to generate MDS1/EVI1. Figure created 
by Stephanie Rockfield. 
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is a transcriptional regulator containing two distinct zinc finger (ZF) domains (10 ZFs in total, [74-
76]). The 1st and 2nd exons of the MDS1 transcript can become spliced to the 2nd exon of the EVI1 
transcript to form a fusion product known as MDS1/EVI1 [74-77] (see Figure 2). This fusion 
protein is ~250kDa and contains a novel positive regulatory-domain 1-binding factor 
1/retinoblastoma-interacting zinc-finger protein 1 homologous (PR) domain [75]. Both EVI1 and 
MDS1/EVI1 were originally identified in patients with myelodysplastic syndrome [73, 75], although 
the transcript expression of these variants have been identified in normal human tissues such as 
heart, placenta, kidney, and pancreas [77, 78]. Furthermore, the MDS1/EVI1 fusion antagonizes 
EVI1 by promoting the transcription of targets that EVI1 represses [79]. Another variant known as 
EVI1Del190-515 (previously referred to as 324, [75]) is missing an internal sequence of 324 amino 
acids including two ZFs in the second ZF domain. While other variants exist [74, 80, 81], these 
are the most characterized variants that have been identified [74-76]. However, the role of 
MECOM in ovarian cancer pathogenesis has not yet been clearly identified. 
 
Functions of EVI1 variants in OVCA 
EVI1 expression was first identified in 1996 as being elevated in ovarian cancer cell lines 
relative to controls [82], and its expression is correlated with OVCA resistance to TGF signaling 
[83]. Furthermore, the expression ratio of EVI1 and EVI1Del190-515 differs between OVCA and 
control samples; EVI1 and EVI1Del190-515 showed similar transcript levels in OVCA whereas 
EVI1Del190-515 transcript expression was less in normal samples relative to EVI1 expression [81]. 
However, overexpressing either EVI1 or EVI1Del190-515 in EVI1-null OVCAR8 ovarian cancer cell 
lines did not increase cell proliferation [81]. Despite this, the expression of these EVI1 variants 
correlated with ovarian cancer patient prognosis; the expression of tumor suppressive 
MDS1/EVI1 was associated with good clinical outcome while the expression of oncogenic EVI1 
and EVI1Del190-515 was associated with poor clinical outcome [65]. Interestingly, promotor activity 
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analyses using TGF downstream targets AP1 (activator protein 1) and PAI1 (plasminogen 
activator inhibitor 1) demonstrated that EVI1 inhibited promoter activity in the presence of TGF, 
but EVI1Del190-515 had the opposite effect [80]. In addition, EVI1 expression in ovarian and breast 
cancer cell lines increased protein expression of Cyclin E1 while concurrently promoting 
progression through the cell cycle, but EVI1Del190-515 did not [80], suggesting distinct roles for these 
variants. These results demonstrate that more information is needed to identify the importance of 
EVI1, MDS1/EVI1, and EVI1Del190-515 in OVCA pathophysiology. 
 
EVI1 interactions 
EVI1 knockout mice are embryonically lethal, which may be a result of the critical role for 
EVI1 in hematopoiesis [84, 85], whereas overexpressing EVI1 transformed Rat1 fibroblasts and 
myeloid progenitor cells [76, 86]. As a transcriptional repressor, EVI1 is known to regulate myeloid 
differentiation via the GATA2 promoter [84, 85, 87]. There are instances where EVI1 may promote 
transcriptional expression; for instance, EVI1 may bind to the deacetylase SIRT1 to enhance 
transcription [88]. However, binding to SIRT1 results in a negative feedback loop whereby 
deacetylation of EVI1 promotes its degradation [88]. EVI1 is also known to repress TGF 
signaling, either through its interaction with SMADs [84, 89-92] or with histone deacetylases 
(HDACs) [90, 91]. In addition, EVI1 binds to histone methyltransferases (e.g. SUV39H1, G9a, and 
DNMT3a or DNMT3b) to repress its transcriptional targets [93-95]. Alternatively, it can bind 
directly to the promoter region and recruit polycomb complex proteins (e.g. EZH2, SUZ12, and 
BMI1) to inhibit transcription, as is the case for PTEN regulation by EVI1 [96]. Phosphorylation of 
EVI1 at either S538 or S858 regulates its transcriptional activity, including its ability to bind to 
PTRF (polymerase I and transcript release factor) or bind to proteins involved in DNA repair [97]. 
The functions of EVI1 and its potential role in cancer development are uncertain, however, and 
require further investigation. 
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Endometriosis: Precursor Lesions to EOC  
Endometriosis is a benign gynecological disorder in which endometrial tissues are located 
in the pelvic cavity [15]. Patients diagnosed with endometriosis are afflicted by severe and 
debilitating pelvic pain and other co-morbidities, such as difficulty conceiving [98, 99]. 
Endometriosis is classified by the American Fertility Association as stage I (minimal), stage II 
(mild), stage III (moderate), and stage IV (severe), depending on the number and location of the 
endometriotic lesions [100]. The lesions themselves also vary in size and color, which may 
change based on the “age” of the lesion [101-103]. Specifically, earlier lesions are red in color, 
then progress to a dark brown to black (also known as a chocolate cyst) before becoming white, 
although a single lesion can also be multi-colored [101, 102]. Regrettably, endometriosis is usually 
not diagnosed early since proper diagnosis currently requires expensive and invasive 
 
Figure 3. Theories on the pathogenesis of endometriosis. Figure created by Stephanie 
Rockfield, with adaptations from [1, 2]. 
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laparoscopic techniques [104-108]. In addition, it is not clear how endometriosis develops 
although multiple theories exist [15, 109-111] (see Figure 3). Coelomic metaplasia is the theory 
that non-endometrial coelomic cells residing outside the uterus transform into endometrial glands 
in response to stimuli, such as the altered presence of hormones at the onset of puberty [112]. 
This theory may help to explain the presence of endometriotic lesions in regions far from the 
reproductive system (such as the lungs, [109, 113]) as well as the diagnoses of endometriosis in 
women born without a uterus [114, 115]. Another theory, known as the Müllerian remnant theory, 
postulates that segments of the Müllerian duct remain in the developing embryo after the 
presence of anti-Müllerian hormone (AMH) causes this duct to regress resulting in the maturation 
of the male reproductive system [109, 116]; this theory may explain the rare instances of 
endometriosis in males [117]. The prevailing theory is that endometrial glands are carried from 
the uterus to the pelvic cavity via the fallopian tubes in a process known as retrograde 
menstruation [109, 118]. However, retrograde menstruation may be a common event for women 
of reproductive age [119], while the overall presence of endometrial cells in the peritoneal fluid of 
menstruating women was low [120], suggesting that other factors may be involved in the onset of 
endometriosis. 
 
 
Figure 4. Schematic of cell death (anoikis) induced when epithelial cells detach from the 
extracellular matrix (ECM). Cells which upregulate the autophagy pathway are able to resist 
anoikis-mediated cell death [4, 5]. Figure created by Stephanie Rockfield. 
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Contribution of autophagy to endometriosis pathogenesis  
The theory of retrograde menstruation raises questions regarding the mechanism by 
which the endometrial cells survive detachment from the uterine wall and subsequent carriage to 
the pelvic cavity. As shown in Figure 4, epithelial cells that become detached from the 
extracellular matrix (ECM) lose contact with their nutrient supply as well as with adjacent cells 
and thus typically undergo cell death (a process called anoikis [4, 121]). Cells that are able to 
survive this process were found to upregulate a cellular homeostasis pathway called autophagy, 
which promotes the degradation and recycling of damaged proteins and organelles [5]. In the 
initiating steps of autophagy, the developing phagophore originates from the endoplasmic 
reticulum (ER) membrane, where a series of ubiquitin-like conjugation reactions (involving the 
 
Figure 5. The autophagic pathway. From the endoplasmic reticulum, the developing 
phagophore extends and elongates to ultimately form the autophagosome. During this 
process, a series of E3 ubiquitin-like conjugation reactions occur to facilitate binding of LC3 
to the developing autophagosome. Concurrently, sequestosome (SQSTM1, or p62) binds to 
ubiquitinated substrates (damaged proteins and organelles) to guide them to the phagophore 
by interacting with LC3. The autophagosome encloses around the cargo and ultimately fuses 
with a lysosome to form an autophagolysosome, and all interior components are degraded 
and recycled (see [8-11]). Figure created by Stephanie Rockfield. 
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autophagy-related genes ATG3, ATG4, ATG5, ATG7, ATG12, and ATG16) promotes the binding 
of LC3 (microtubule-associated protein 1A/1B-light chain 3, also known as ATG8) to the lipid 
phosphatidylethanolamine (see Figure 5, as well as comprehensive reviews [8-11, 122]). Figure 
6 depicts the structural similarities between ubiquitin and LC3 [10, 122]. In addition, ULK1 (unc-
51 like autophagy activating kinase 1) phosphorylates and activates PIK3CA at the developing 
phagophore while also promoting ATG9 translocation from the cytosol to the phagophore, 
bringing with it additional membrane components. During this process, sequestosome (SQSTM1, 
or p62) recognizes mono- or polyubiquitinated proteins and organelles and promotes their 
translocation to the phagophore through its direct interaction with LC3 on the developing 
phagophore membrane. The phagophore continues to develop until the ends meet and fuse, 
forming a double-membraned autophagosome containing the targeted cargo within. The final step 
occurs when the autophagosome fuses with a lysosome to form the autophagolysosome, thus 
resulting in the degradation of the interior components. This pathway is tightly regulated as well; 
while basal autophagy is important for clearing dysfunctional molecules, an overabundance can 
result in autophagy-mediated cell death [123]. Assessing the kinetics of the autophagy pathway 
is thus essential to properly interpret changes in autophagic activity [11].  
Since autophagy can be upregulated to promote survival from anoikis, it is possible that 
this may be the mechanism by which endometrial cells survive detachment from the ECM of the 
uterus and later implant to locations within the pelvic cavity. Indeed, observations have suggested 
that the autophagic pathway is dysregulated in endometriosis [16-20]. Specifically, one study 
identified increased protein expression of LC3-II and p62, as well as elevated mRNA expression 
of beclin-1 (ATG6), ATG7, ATG14, and LC3, in ovarian endometriomas relative to control eutopic 
endometrium [16]. Another studied identified consistent activation of autophagy in endometriotic 
cysts through the menstrual cycle; this profile differs from control endometrial cells, which showed 
increased protein expression of autophagic markers as the menstrual cycle progressed [17]. In 
contrast, endometriotic and endometrial stromal cells from patients with endometriosis displayed 
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reduced autophagosome numbers and reduced protein expression of autophagy markers relative 
to controls [19]. An independent study also identified reduced beclin-1 (ATG6) mRNA and protein 
expression in patients with endometriosis relative to control patient samples [20]. Another more 
recent study identified reduced LC3B-II and increased p62 protein expression in endometriotic 
cysts relative to control endometrium, although the expression of these markers was not different 
when comparing the eutopic endometrium of endometriosis patients with that of patients without 
endometriosis [18]. These studies were limited, however, as they only assessed RNA and protein 
expression of autophagy mediators; as mentioned in the above paragraph, the kinetics of the 
autophagy pathway must be assessed to properly interpret changes in autophagic activity [11]. 
Thus, further investigations into the contribution of autophagy to the development of endometriotic 
lesions are required. 
 
Immune responses in endometriosis 
Endometriosis is associated with impaired immunity [124]; specifically, there is an increase 
in alternatively activated (M2) macrophages [125] while the presence and cytotoxic capacity of 
natural killer cells in endometriosis patients is reduced [126]. In addition, the expression of CD36 
scavenger receptor (which promotes the formation of fatty deposits on arterial walls while also 
having a role in inflammatory response signaling) on peritoneal macrophages is reduced in 
patients with endometriosis and results in impaired phagocytic ability [127-129]. Finally, increased 
estrogen availability, a common feature of endometriosis [130], was found to promote over-
expression of the chemokine CXCL12, as well as the CXCR4 receptor, specifically by inhibiting 
autophagy [19]. 
The peritoneal cavity hosts a heterogeneous mixture of immune cells including 
macrophages, B-cells, T-cells, dendritic cells, natural killer cells, and neutrophils [131]. 
Macrophages may further differentiate into polarization states (M1, M2, tumor-associated (TAM), 
CD169+, and TCR+), each eliciting different immune responses upon sensing inflammatory 
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signals [125, 132]. Cytokines and chemokines are released by CD4+ T helper cells to regulate the 
equilibrium between M1 and M2 macrophage polarization [125]. CD4+ T helper cells are further 
classified as Th1 and Th2; Th1 cells produce pro-inflammatory cytokines (e.g., IFNγ, IL-2, and 
TNFβ) to activate macrophages while Th2 cells produce anti-inflammatory cytokines (e.g., IL-4, 
IL-10, and IL-13) to activate eosinophils and inhibit phagocytic (i.e. macrophage) cells [133, 134]. 
M2 macrophages may be able to promote tumorigenesis [135], potentially through the production 
of IL-10, which is known to inhibit production of IP-10 (a pro-inflammatory cytokine) [125]. IP-10 
is also referred to as CXCL10, and binds to the CXCR3 receptor on the cell surface of 
lymphocytes and peripheral eosinophils [136]. Interestingly, studies have shown that the 
autophagic pathway can regulate signaling responses in immune cells. For instance, inhibiting 
autophagy in myeloid cells prevented neutrophil degranulation and reduced the severity of 
autoimmune disorders [137]. Alternatively, inhibiting autophagy in macrophages resulted in 
increased liver injury in mice [138], and autophagy is also able to regulate the expression of the 
chemokine IP-10 [139]. Collectively these studies suggest a potential link between the autophagic 
pathway, immune response, and endometriosis, but further research is required to demonstrate 
these connections. 
 
Endometriosis and cancer 
Patients with endometriosis have an increased risk of being diagnosed with more rare 
ovarian cancer subtypes (endometrioid and clear cell OVCA, [21, 22]). Indeed, approximately 
40% of patients diagnosed with endometrioid or clear cell OVCAs were previously diagnosed with 
endometriosis [140]. Intriguingly, many of the genomic alterations identified in type I ovarian 
cancers (see Table 1), such as PTEN, ARID1A, PIK3CA, and K-Ras, have also been identified 
in deep endometriotic lesions [141, 142]. The patients in this study did not have evidence of OVCA 
tumors [141], which may suggest that these genomic events are important for the transition of 
endometriosis to ovarian cancer. In support of this, an in vivo mouse model with either PTEN 
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deletion or expression of oncogenic K-Ras in the ovarian surface epithelium resulted in 
spontaneous development of endometriotic lesions in the peritoneal cavity, while the combination 
of these aberrations resulted in ovarian cancer that was histologically similar to the endometrioid 
subtype [143]. However, further research is required to understand the molecular events 
underlying this transition. 
 
Ovarian Surface Epithelium: Precursor Lesions to EOC 
The ovarian surface epithelium (OSE) is a logical consideration as a precursor to epithelial 
ovarian cancers, and there is evidence to support this theory [144]. Specifically, intraepithelial 
neoplasms of the ovary have been documented in the epithelium regions nearby ovarian cancer 
tumors [145, 146], and the presence of cortical inclusion cysts on the contralateral ovary is 
elevated in patients with ovarian cancer compared to women without ovarian cancer [147, 148]. 
Furthermore, the mesothelial layer of the ovary and the Müllerian ducts both originate from the 
coelomic epithelium during embryogenesis, and metaplasia of the mesothelium to a Müllerian 
phenotype has been reported [144, 149]. Importantly, mouse xenograft studies with transformed 
human OSE cells (with inactivated p53, inactivated retinoblastoma, hTERT overexpression, and 
overexpression of activated Ras) resulted in tumors that recapitulated the genetic and phenotypic 
characteristics of high-grade OVCA [150]. In another study, primary human OSE cells were first 
immortalized via overexpression of mutant cyclin dependent kinase 4 (CDK4), cyclin D1, and 
hTERT [151]. These cells were then transformed via overexpression of mutant p53 and oncogenic 
K-Ras, but were not able to form subcutaneous tumors in immunocompromised mice [151]. 
However, further introducing c-Myc and B-cell lymphoma 2 (Bcl-2, a negative regulator of 
apoptosis [152]) in these immortalized cells resulted in the establishment of peritoneal tumors in 
vivo that recapitulated type II OVCA [151]. Together, these studies provide further support for the 
OSE as a precursor to ovarian cancer. 
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It is interesting that women who do not become pregnant have an increased risk of an 
OVCA diagnosis compared to women who do, suggesting that the process of ovulation may 
contribute to disease pathogenesis [149, 153, 154]. Indeed, the fluid within follicles of the ovary 
contains high concentrations of hormones and growth factors compared to serum, including 
~1000 times the amount of estrogen [153, 155]. Follicles also contain a high concentration of 
reactive oxygen species (ROS) as well as the iron carrier molecule transferrin [153, 156-158]. In 
vitro exposure to follicular fluid has been shown to increase ovarian surface epithelial cell 
proliferation [159, 160]. Thus, the bursting of the follicle during ovulation would release these 
components into the nearby region, which may then affect local epithelial cells and promote their 
transition to ovarian cancer [153]. 
 
Fallopian Tube Epithelium: Precursor Lesions to EOC 
The fallopian tube epithelial layer consists of two main cell types, namely the ciliated 
epithelial cells and secretory epithelial cells [161]. Recently, secretory epithelial cells from the 
fallopian tube (FTSECs) have been implicated as a precursor to OVCA [14]. One indication for 
this is the expression of the transcription factor paired box 8 (Pax8), which is important for the 
formation of the Müllerian tract, the renal and upper urinary tracts, as well as the thyroid gland, 
but is not involved in the formation of the ovaries [162]. Approximately 99% of HGSOC tumors 
showed positive Pax8 protein expression in the nucleus [162], and studies suggest that Pax8 may 
be a useful biomarker for distinguishing HGSOC from other epithelial cancers such as breast 
cancer [162, 163]. It is important to note the evidence that Pax8 may be expressed in OSE [164]. 
One potential explanation for this includes immunohistochemical evidence demonstrating the 
presence of normal, non-malignant fallopian tube cells that have adhered onto the surface of the 
ovary [165]; this may result from cellular shedding, which easily occurs in the fimbria [165]. 
Another indication that the fallopian tube may provide a precursor to HGSOC was the 
identification of abnormal growths (dysplasia) in the fallopian tubes, but not the ovaries, from 
17 
 
women who carried BRCA1 mutations [166, 167]. Since then, non-malignant cells harboring p53 
inactivating mutations (“p53 signatures”) and serous tubal intraepithelial carcinomas (STICs) have 
been identified in the fallopian tubes and are thus postulated to be a direct precursor to HGSOC 
[166, 168-170]. Genomic analyses, including whole exome sequencing and assessing copy 
number alterations, recently demonstrated that p53 signatures and STICS shared genomic 
features of HGSOC, including inactivated p53, BRCA1/2, and PTEN [171]. Furthermore, mouse 
xenograft studies with primary human FTSECs expressing SV40 LTAg (to inhibit p53 and Rb), 
hTERT, c-MycT58A, and H-RasV12A resulted in the formation of tumors that were histologically 
similar to serous ovarian cancer [172]. In vivo studies also demonstrated that oncogenic 
transformation of mouse oviductal cells via inactivation BRCA1 or BRCA2, PTEN, and p53 
promoted the formation of STICs as well as ovarian tumors [173]. In another study, conditional 
expression of SV40 LTAg in the mouse oviduct resulted in the formation of STICs as well as 
tumors characteristically similar to HGSOC, thus recapitulating the pathogenesis proposed to 
occur in human HGSOC [6]. 
Despite the evidence that FTSECs may give rise to ovarian cancer, the mechanisms by 
which this transition occurs has not been clearly identified. As mentioned above in “Ovarian 
Surface Epithelium: Precursor Lesions to EOC”, the bursting of the ovarian follicle would release 
a high concentration of hormones, ROS, and transferrin into the local environment. This process 
may affect the OSE, but is also likely to affect nearby fallopian tube epithelial cells (FTEs) located 
in the fimbria [153]. Indeed, in vitro research has shown that treating FTEs with follicular fluid can 
promote their survival and even result in mutagenesis [174, 175]. Furthermore, factors within the 
follicular fluid, such as stromal cell-derived factor 1 (SDF-1, also known as C-X-C motif chemokine 
12 (CXCL12)), promotes extra-ovarian malignant cells (such as STIC cells) to migrate and then 
attach to the ovarian surface [175]. Despite these advances, additional investigations will be 
important for understanding the mechanisms by which these precursors transition to ovarian 
cancer. 
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Iron and EOC  
The iron signaling pathway 
Iron is required for many cellular processes to maintain cellular homeostasis by acting as 
an enzymatic co-factor for key enzymes involved in cellular metabolism and DNA replication [31-
33]. Excessive or insufficient iron levels can be detrimental to the cell; as such, the influx of iron 
into cells is tightly regulated. Figure 6 summarizes iron transport pathways. Briefly, the uptake of 
dietary iron, which is reduced from Fe3+ to Fe2+ by duodenal cytochrome b in hepatocytes (Dcytb 
[176]), is mediated by the divalent metal transporter 1 (DMT1 [177]). Alternatively, two iron ions 
bind to transferrin (TF, referred to as holo-TF), which in turn binds to a transferrin receptor (TFRC) 
 
Figure 6. Schematic of intracellular iron trafficking. Transferrin-bound iron is imported into the 
cell via endocytosis, while non-transferrin bound iron may be imported by DMT1 or the 
ZIP8/ZIP14 transporters. Once internalized, iron may be transported to the mitochondria for 
metabolic processes (e.g. generating iron-sulfur proteins, heme formation, or binding to 
aconitase (which requires iron for its enzymatic activity in the Krebs cycle)) or stored in the 
ferritin complex, a process mediated by PCBP1. The release of iron from the ferritin complex 
requires NCOA4, which targets ferritin for degradation by a targeted autophagic process 
known as ferritinophagy. Iron can also be exported from the cell by ferroportin; see text for 
relevant references. Figure created by Dr. Meera Nanjundan, with modifications by Stephanie 
Rockfield. 
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for endocytosis into the target cell. Upon endocytosis the pH of the vesicle is decreased to ~5.6 
by hydrogen ion pumps, which facilitates iron release from TF [178]. This apo-TF and TFRC are 
then recycled back to the plasma membrane [31, 179], while endosomal iron is reduced to Fe2+ 
by the metalloreductase STEAP3 (six-transmembrane epithelial antigen of prostate 3) for 
transport into the cytosol by DMT1 [177, 180]. Recently, the zinc transporters ZIP8 and ZIP14 
were also found to mediate import of non-transferrin bound iron (NTBI [181-183]). Once inside 
the cell, the iron may remain in the labile iron pool (LIP) or may be transported to mitochondria 
[31]. In the mitochondria, the iron may be utilized to produce iron-sulfur clusters and heme [184] 
or to act as a cofactor for aconitase 1 (ACO-1, also known as iron response protein 1 (IRP1)), a 
critical enzyme in the Krebs (TCA) Cycle [184]. Iron may be transported out of the cell via 
ferroportin (FPN, after being converted to Fe3+ by hephaestin [31, 185]). Alternatively, iron may 
be stored within the ferritin complex, comprised of both ferritin heavy chain (FTH1) and ferritin 
light chain (FTL) proteins [31], a process mediated by poly (rC)-binding protein 1 (PCBP1 [186]). 
Under iron-deplete conditions, cells may initiate targeted degradation of the ferritin complex in 
order to release the stored iron [3, 30]. Nuclear co-activator 4 (NCOA4) mediates this degradation 
by binding to FTH1 and colocalizing with LC3B during autophagosome formation [30]. In response 
to increasing serum iron levels, liver hepatocytes produce the hormone hepcidin which binds to 
FPN, promoting its internalization and degradation and ultimately preventing additional iron from 
being released by the cell [187-189].  
The protein expression of these iron mediators are regulated by the iron response proteins 
IRP1 and IRP2; in particular, they bind to iron response elements (IREs) located within the mRNA 
untranslated regions (UTRs [31]). Specifically, FTH1, FTL, and FPN all have IREs within their 5’-
UTR region [31]. When intracellular iron is low, IRP1 is able to bind to these IREs and prevent 
ribosomes binding to the mRNA, thus inhibiting translation of these proteins [31]. Conversely, high 
iron concentrations prevent IRP1 from binding to the 5’-UTR to facilitate protein translation, which 
then increases iron storage or iron export [31]. On the other hand, TFRC and DMT1 each have 
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IREs within their 3’-UTR regions [31]. When intracellular iron is low, IRP1 binds to these IREs and 
stabilizes the mRNA transcript, thus increasing translation of the proteins and promoting iron 
uptake [31]. When intracellular iron is high, however, IRP1 does not bind to these IREs and the 
mRNA is degraded, preventing translation of these mRNAs [31]. Despite the role of NCOA4 in 
mediating targeted degradation of the ferritin complex, an IRE has not yet been identified in the 
UTR regions of the mRNA transcript [3, 190]. These results may suggest that NCOA4 is regulated 
an IRP-independent regulatory mechanism. Indeed, iron binds to the E3 ubiquitin ligase HERC2, 
which in turn poly-ubiquitinates NCOA4 protein to promote its degradation by the proteasome 
[191]. Furthermore, copy number variations in HGSOC show that NCOA4 was only amplified in 
~1.2% of patient samples [62]. It remains to be understood how these complexes may be involved 
in the pathogenesis of ovarian cancer; further research is still required to fill in this gap in 
knowledge. 
 
Iron and cancer 
Iron promotes the production of ROS via its participation in Fenton reactions [34, 35]. ROS 
damages not only DNA but also proteins and lipids, and even products of lipid peroxidation can 
themselves damage DNA [192]. Thus, an excess of iron may initiate carcinogenesis by increasing 
oxidative stress levels, resulting in DNA mutagenesis [193]. DNA damaging events could lead to 
(1) its repair, unless the damage is extensive leading to cell death, or (2) survival of mutant cells 
if other changes are present, leading to an accumulation of mutations [194]. ROS cause 
numerous types of DNA damage such as strand breakages, formation of apurinic/apyrimidinic 
sites, base modifications (8-OHdG), thymidine glycols, and ring-opened based products [195]. 
There are likely “specific” sites that are susceptible to such DNA damage [196], which can be 
mutagenic resulting in Ras activation and p53 inactivation [197]. Indeed, K-Ras and the MAPK 
signaling cascade have been shown to be hyperactivated in response to oxidative stress [35]. 
PTEN can be inactivated directly by hydrogen peroxide via oxidation, which was accompanied by 
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increased AKT activation [198]. Mutations in K-Ras (a codon 12 G to T transversion) can be 
induced by nickel (which has similar chemical and physical properties to iron [199]) in renal 
sarcomas. Additionally, mutations in p53 (G to T transversion) can be induced by iron in renal 
cancers [195]. Furthermore, K-Ras was identified to be mutated (GGT to GCT mutation at codon 
12) at 8 weeks in one rat out of 26 exposed to cigarette smoke (a source of oxidative stress) for 
a 1 hour time twice a day (8, 12, or 20 weeks) [200]. Oxidative stress can also lead to marked 
increases in c-Myc (a known mediator of cell proliferation) transcripts [195, 201, 202].  
Anti-oxidants counteract oxidative stress [203]. Ferritin, nuclear factor (erythroid-derived 
2)-like 2 (NRF2), and heme oxygenase 1 (HO-1), amongst others (i.e., NAD(P)H:quinone 
oxidoreductase 1 (NQO1), glutathione S-transferase Pi 1 (GSTP1), and glutathione-dependent 
peroxidases (GPX)), can contribute to such anti-oxidant defenses and may also contribute to 
tumorigenesis [204, 205]. This would enable a proliferative environment for survival advantage 
[204]. As an example, the incidence of hepatocellular carcinoma (HCC) is elevated 200-fold in 
patients with hereditary hemochromatosis and the resulting increase in ROS coinciding with 
unbalanced anti-oxidant defenses is suggested to promote tumorigenesis [36]. Altogether, these 
events may contribute to iron-induced persistent oxidative stress events, thereby leading to 
precursor lesions transitioning to various subtypes of ovarian cancer [35]. 
 
Iron and OVCA 
Menstrual effluent (via retrograde menstruation) carries iron and is suggested to contribute 
to endometriosis and the development of rarer endometrioid and clear cell ovarian cancers [206]. 
Importantly, OVCAs are characterized by elevated genomic mutations which is proposed to result 
from oxidative damage (i.e., DNA adducts, lipid peroxidation, and 8-OHdG, [35]). It is indicated 
that the pelvic region has an elevated iron level due to retrograde menstruation which may thus 
promote endometrial survival and implantation at ectopic sites [207]. Iron deposits (i.e., 
hemosiderin) have not only been identified in endometriotic lesions but also within the fallopian 
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tube of patients diagnosed with serous epithelial ovarian cancers [118, 208]. In addition to 
ovulation, another potential contributor to ovarian cancer pathogenesis is follicular fluid [153]. In 
particular, follicular fluid contains hormones such as estradiol [153], reactive oxygen species 
(ROS), and transferrin [209]. Additionally, transferrin levels and DNA adducts are increased in 
 
Figure 7. The proposed contribution of iron to the pathogenesis of ovarian cancers from 
precursor lesions. Elevated iron in the pelvic cavity from retrograde menstruation, from 
follicular fluid, or even from endometriotic lesions is likely to have a detrimental effect on the 
local microenvironment due to the presence of reactive oxygen species (ROS) generated by 
Fenton reactions. However, ROS are well known mutagenic agents and have been shown 
to mutate DNA to result in K-Ras activation, p53 inactivation, increase c-MYC mRNA 
expression, or directly modify and inhibit PTEN protein activity. We hypothesize that the 
culmination of these events in response to elevated ROS will then promote proliferation and 
anti-oxidant responses in precursors to ovarian cancer. Figure created by Dr. Meera 
Nanjundan and Stephanie Rockfield. 
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follicular fluid of endometriosis patients compared to infertile controls [210, 211]. Iron and 
transcript levels of FTH, FTHL, and TFRC were increased in follicles close to an endometrioma 
(characterized by elevated iron levels [208]), although another study did not identify any 
differences in iron content or ferritin levels [212]. In addition, exposing fallopian tube epithelial 
cells to follicular fluid led to a small increase in cell proliferation along with IL-8 cytokine levels 
[213]. Furthermore, high ROS containing follicular fluid was capable of inducing early onset B-cell 
lymphoma in mammary fat pads in mice lacking p53 [174]. Thus, these reports support a role by 
which iron and ROS may contribute to disease pathogenesis. 
The detailed molecular mechanism underlying initiation of ovarian cancers remains 
unclear (Figure 7). As mentioned above in “Iron and cancer”, iron promotes the formation of ROS 
which may then result in mutagenesis to initiate carcinogenesis [193]. Precursor cells postulated 
to contribute to specific subtypes of ovarian cancers (i.e., endometriotic cells, fimbrial secretory 
epithelial cells, and ovarian epithelial cells) may be exposed to a sublethal dose of oxidative stress 
and thus may have the potential to undergo tumorigenesis due to persistent antioxidant defenses 
[205]. In endometriotic cysts, iron was measured to be ~100mM and was associated with the 
presence of lipid peroxides, 8-OHdG positivity, as well as evidence for the presence of iron 
deposits [208]. Iron deposits have also been identified in the fallopian tube [118]. Fimbrial 
secretory epithelial cells treated with increasing doses of iron elicited increased cellular 
proliferation along with changes in p53, MAPK, AKT, and c-Myc proteins, as well as increased 
ROS species (0.05-100mM) [214]. Furthermore, vitamin D3 could oppose the oxidative stress-
induced events mediated by iron in these fimbrial cells [215]. In support of the transition from 
precursor cells to cancer, it is notable that a clear cell ovarian cancer gene signature was induced 
upon iron treatment in immortalized ovarian surface epithelial cells; this was regulated partially by 
DNA methylation [216]. Thus, it is possible that an increased presence of iron and ROS may 
contribute to the transition of precursor lesions to epithelial ovarian cancers. 
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Hypothesis and Aims 
Understanding the mechanisms involved in the transition of precursor lesions to epithelial 
ovarian cancer (EOC) is critical for improving early detection and treatment strategies for these 
patients. While endometriotic lesions are well known as the precursor for more rare endometrioid 
and clear cell EOCs, both the ovarian surface epithelium and fallopian tube (fimbrial) epithelium 
have been implicated as precursors to the more common high grade serous EOC. Importantly, 
research suggests that the expression of autophagy pathway mediators are dysregulated in 
endometriotic lesions. Further, excess iron (via iron overload conditions (i.e. hemochromatosis) 
or dysregulated iron regulation (i.e. ferritinophagy, mediated by NCOA4)) may be involved in the 
transition of these precursors to EOC although the mechanisms by which this occurs have not 
been elucidated. Thus, our overall hypothesis is that “the autophagic and iron regulatory pathways 
are important for the establishment of endometriotic lesions and the transition of precursor lesions 
to EOCs, respectively.” We will address this hypothesis via the following specific aims:  
 
Specific aim 1 (presented in Chapter 2): We will assess the contribution of the autophagic pathway 
in the development of endometriotic lesions using an established endometriosis mouse model. 
We will assess changes in expression of key autophagy mediators and treat endometriosis-
induced mice with the autophagic flux inhibitor, hydroxychloroquine. 
 
Specific aim 2 (presented in Chapter 3): We will characterize the expression of key iron regulators 
in transformed human endometriotic cells and investigate the role of NCOA4 in ovarian cancer 
pathophysiology. 
 
Specific aim 3 (presented in Chapter 4): We will investigate the contribution of iron in promoting 
the transition of fallopian tube precursors to a transformed-like state, using in vitro culturing 
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methods, and compare any observed changes in proliferation and oncogenic expression to 
fallopian tube epithelial cells transformed via overexpression of oncogenes. 
 
Overall Impact and Significance 
These studies proposed herein will improve our understanding of the mechanisms which 
promote the transition of endometriotic, ovarian, and fimbrial precursors to EOCs. Identifying the 
processes that are important for these transition events may allow for improved detection so 
patients with ovarian cancer can be diagnosed at an earlier (and less deadly) stage. Furthermore, 
understanding these events may facilitate the development of novel therapeutics which in turn 
could lead to an improvement in the survival of patients with this deadly cancer. 
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Chapter 2 
 
Effect of Hydroxychloroquine and Characterization of Autophagy in a Mouse Model of 
Endometriosis 
 
Note to Reader 
The results presented herein are as published (*Ruiz, A., *Rockfield, S., Taran, N., Haller, 
E., Engelman, RW., Flores, I., Panina-Bordignon, P., and Nanjundan, M. Cell Death & Disease, 
2016. 7(1): p. e2059-e2059.), albeit reorganized and re-formatted for this dissertation. This 
reproduction was approved by SpringerNature (see Appendix A for copyright permissions). The 
*indicates equal contributions by the authors. 
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Introduction 
Endometriosis is a chronic, painful, and debilitating disease in which endometrium-like 
glandular and stromal cells grow outside the uterine cavity [217, 218]. It is an inflammatory and 
estrogen-dependent disease that affects 6-10% of women during their reproductive years and up 
to 50% of women receiving fertility treatments [219]. Sampson’s hypothesis (the most accepted 
theory) states that shed endometrial tissue during menses reaches the peritoneal cavity by exiting 
the uterus through the fallopian tubes by retrograde menstruation [109, 220, 221]. These shed 
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endometrial cells survive, implant, and grow at ectopic locations, developing into endometriotic 
lesions [15, 220]. 
Epithelial cells normally undergo anoikis, a mechanism of programmed cell death, upon 
detachment from the extracellular matrix [5]. One mechanism that we propose could potentially 
alter the anoikis response in endometrial cells is autophagy. This cellular pathway needs to be 
carefully regulated in order to maintain cellular homeostasis [9, 222]. Under conditions of stress, 
changes in autophagic flux can lead to altered cellular survival [9, 222]. Autophagy is a complex 
process that begins with the formation of double-membrane vesicles, termed autophagosomes, 
which engulf cytoplasmic components. For a comprehensive review of the autophagic pathway, 
refer to Feng and colleagues [9]. Briefly, autophagosomes fuse with lysosomes to degrade and 
recycle their cargo comprised of oxidized proteins, lipids, and damaged organelles. Presently, 
there is limited evidence that autophagy contributes to the development and progression of 
endometriosis. In a surgical induction model of murine endometriosis, increased expression of 
ATG9A, an autophagic mediator that is involved in vesicle formation [223], was detected in the 
eutopic endometria from endometriosis-induced mice [224]. In human endometriomas (ovarian 
endometriosis), there was a reduction of LC3-II (the conjugated form of LC3) protein compared 
to control eutopic endometrial tissue [17]. In contrast, an independent study reported that the 
protein expression of LC3-II was elevated while p62 (which binds ubiquitinated cargo for 
degradation) was decreased in ovarian endometriomas compared to eutopic endometria of 
disease-free participants [16].  
Herein, our main goal was to provide further evidence for a role of autophagy in 
endometriosis development. Specifically, we sought to determine the therapeutic effects of a 
lysosomotropic agent and known autophagic flux inhibitor, hydroxychloroquine (HCQ) [225-227], 
on human endometriotic cells and in an established mouse model of endometriosis. The results 
presented herein are of high clinical translational value, as we identify a potential new non-
hormonal treatment for this still incurable and common disease.  
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Materials and Methods  
Ethics and tissue microarray 
All protocols in this study were approved by the Institutional Review Board (IRB) at the 
Ponce Research Institute (Ponce, Puerto Rico). Samples in the tissue microarray (TMA) were 
obtained in a de-identified fashion from archived samples at a private pathology laboratory 
(Southern Pathology Laboratories in Ponce, Puerto Rico). Details regarding the human TMA used 
in this study have been previously described [228]. Briefly, the TMA contains 164 cores, which is 
comprised of lesions (from the ovaries (n=29), fallopian tubes (n=16), peritoneum (n=34), skin 
(n=4), and gastrointestinal tract (n=7)), eutopic endometrium from endometriosis patients (n=22), 
as well as secretory (n=38) and proliferative (n=14) endometrium from endometriosis-free 
patients. The patients and controls recruited into this biobank were not currently or have been for 
at least 3 months prior to surgery on any hormonal medication.  
  
Animal handling  
C57BL/6J mouse model 
Five-week-old C57BL/6J female mice were purchased from Jackson laboratories. All 
animals were maintained under standard 12 h photoperiod; food and water were available ad 
libitum throughout the study. All experimental procedures and animal care were approved by the 
Animal Care and Use Committee (IACUC) of the University of South Florida (R IS00000101), in 
accordance with the principles described in the Guide for the Care and Use of Laboratory Animals 
of the National Institutes of Health. All surgical procedures were performed under aseptic 
conditions using anesthesia. The mouse model of endometriosis was performed as previously 
described [229, 230]. Donor animals received a peritoneal injection of 3 g/mouse of -estradiol-
17-valerate (Sigma, St. Louis, MO); the dose utilized was based on previously reported data [229]. 
One week after estrogen injection, donor animals were euthanized and each uterine horn was 
collected and minced using a Kirkland Tissue Mincer (Kirkland Products) with sterile normal 
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saline. The minced material was centrifuged at 1,500 rpm for 1 min. Endometriosis was induced 
by injecting the uterine horn fragments intraperitoneally into the recipient animal. Mice were then 
randomly divided into two groups: HCQ-treatment animals were intraperitoneally injected with 100 
l of 60 mg/kg of HCQ (#AC26301, Fisher Scientific, Pittsburgh, PA) while control treatment 
animals received an intraperitoneal injection of 100 l sterile PBS. The dose for HCQ utilized was 
based on previously published data and was comparable to doses used in treating patients with 
autoimmune diseases [231]. A second HCQ treatment was administered one week after 
endometriosis induction, using the same dose. Two weeks after induction, mice were euthanized 
and tissues (including lesions) were snap-frozen into liquid nitrogen. Lesions were measured 
using a caliper. Volume of the lesions was calculated according to the formula: 4/3r2R [232].  
 
Balb/c mouse model 
Eight-week-old Balb/c female mice were obtained from the Charles River Laboratories 
(Calco, Como, Italy) and handled as previously described [229, 230] and in accordance with the 
European Union guidelines as well as with the approval of the Institutional Animal Care and Use 
Committee of San Raffaele Scientific Institute (Protocol n. 484; Milan, Italy). Briefly, donor mice 
were injected with 17-estradiol (AMSA, Rome, Italy; 3 g/mouse) and sacrificed one week later. 
The uterus was removed and fragmented, after scraping to remove the myometrium, using 
scissors. The endometrial tissues were weighed and resuspended in saline with ampicillin (1 
mg/ml). Two recipient mice received an intraperitoneal injection, using a syringe containing half 
of the resuspension (Day 0). Mice were euthanized by administering a lethal dose of anesthetic 
on day 12. The abdomen was opened and lesions were isolated and collected by an operator 
blinded to the experiment. 
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Cell culture of life-extended human endometriotic and T-HESC cells, HCQ treatment, siRNA 
transfection, and survival assay 
Primary human endometriotic cells culture conditions and life extension have been 
previously described [233]. These cells were derived from two different types of lesions (two 
independent patients) which were assessed separately as described below. Briefly, cells were 
maintained in MCDB 131:Medium 199 (1:1 ratio) supplemented with 8% FBS, 
penicillin/streptomycin, and insulin/transferrin/selenium (ITS). Cells were life-extended using 
SV40 Large T antigen. Retroviral particles generated in HEK293T were used to infect the primary 
cells. Media containing puromycin (2.5 g/ml) was used to select primary cells resistant colonies. 
In addition, we obtained the T-HESC cell line, which are human endometrial stromal cells derived 
from a uterine myoma (ATCC, Manassas, VA). This cell line was maintained in phenol red-free 
DMEM/F12 (1:1) containing 8% charcoal-dextran treated FBS, 500ng/mL puromycin, 1% ITS+ 
Premix (BD Bioscience, San Jose, CA), and 15 mM HEPES. The cell lines used in the present 
study were tested to be mycoplasma negative and STR (short tandem repeat) profiled (Genetica 
DNA Laboratories, Cincinnati, OH). Endometriotic cells were seeded at 50,000 cells/well in a 24-
well plate, whereas T-HESC cells were seeded at 250,000 cells/well in a 6-well plate. A 50 mM 
hydroxychloroquine (HCQ; #AC26301, Fisher Scientific, Pittsburgh, PA, USA) stock was 
prepared in phosphate-buffered saline (PBS; 0.22 m filter sterilized); it was used at a final 
concentration of 25 M in complete media [233, 234]. Cells were treated for 18 hours with HCQ 
prior to protein harvest and western blotting analyses. For survival studies, cells were seeded at 
a density of 5,000 cells/well in a 96-well opaque plate and treated with 25 M HCQ during five 
days. Cell viability was then assessed using CellTiter-glo reagent (Promega, Madison, WI) [233].  
For siRNA transfection studies, T-HESC cells were seeded at 350,000 cells/well in a 6-
well plate. After overnight adherence, cells were then transfected with either non-targeting control 
siRNA, ATG5, beclin-1, ATG7, PIK3C3, or LC3B siRNA according to previously described 
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methods [233, 235]. The day after the second round of siRNA transfection, cells were re-seeded 
at 5,000 cells/well in opaque 96-well plates. Three days post re-seeding, cell viability was 
assessed using CellTiter-glo reagent as described above. 
 
Immunohistochemistry of LC3B 
Samples in the TMA were collected in a de-identified fashion from archived samples in a 
Pathology Lab as described in Human Subjects above. Briefly, slides were deparaffinized and 
stained using the automated system Ventana Discovery XT (Ventana Medical Systems, Tucson, 
AZ) with EZ Prep solution. The heat-antigen retrieval method was performed at a pH of 8.0. The 
primary antibody, LC3 (AP1802a) which detects LC3B was obtained from Abgent (San Diego, 
CA) and diluted at a ratio of 1:25 in Dako antibody diluent (Carpenteria, CA) followed by a 32 min 
incubation at room temperature. Human breast cancer tissue was used as a positive control and 
the primary antibody was omitted for the negative control. Ventana OmniMap Anti-Rabbit 
Secondary antibody and the Ventana ChromoMap kit as the detection system were used. 
Hematoxylin was used as the counterstain.   
The LC3 stained TMA was then scanned using the Aperio™ ScanScope XT (Vista, CA) 
with a 200X magnification and a 0.8 numerical aperture objective lens via the Basler tri-linear-
array detection. Each core was then segmented using the TMA block software associated with 
the Spectrum program (version 10.2.5.2352) followed by manual segmentation into epithelial and 
stromal regions under the supervision of a pathologist. Image analysis was performed using an 
Aperio Positive Pixel Count® v9.0 algorithm with the following thresholds: Hue Value =0.1; Hue 
Width =0.5; Color Saturation Threshold =0.04; IWP(High) = 220; IWP(Low)=IP(High) = 175; 
IP(low) =ISP(High) =100; ISP(Low) =0 to segment positive staining of various intensities. The 
data was then compiled for each core in the separate epithelium and stromal regions, which was 
represented by percent positivity, then directly correlated with protein expression.  
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RNA isolation, real-time PCR, and RT2-PCR 
Total RNA was isolated using the RNeasy kit following the manufacturer’s instructions 
(QIAGEN, Valencia, CA). RNA concentration and purity was determined using a 1000 NanoDrop 
(Thermo Scientific, Pittsburgh, PA). Lesion mass varied by samples, and this was reflected in the 
RNA amounts obtained (range of mass: 0.9 mg to 25 mg). 
Three RNA samples from uterine horns, having a 260/280 ratio higher than 1.8 and a 
260/230 ratio higher than 1.7, were selected from recipient, donor, HCQ-treated, and PBS-treated 
animals (12 samples in total) for RT2-PCR analyses. Synthesis of cDNA was performed using 0.5 
g of total RNA, after DNA elimination step using the RT2 First Strand kit per manufacturer 
instructions (QIAGEN, Valencia, CA). After DNA elimination, the reaction mix was incubated at 
42°C for 15 min, followed by 95°C for 5 min using a DNA Engine® Peltier Thermal cycler (Bio-
Rad, Hercules, CA). A total of 102 l of the cDNA reaction mix was added to the master mix 
containing 1,248 l of RNAse-free water and 1,350 l of 2x RT2 SYBR green master mix. Twenty-
five l of the master mix were carefully added to each well of the RT2 profiler PCR autophagy 
array. Quantification was performed using the Applied Biosystems cycler (Life Technologies, 
Grand Island, NY). The PCR cycling program included activation for 10 min at 95°C, followed by 
40 cycles for 15 seconds at 95°C with 1 min at 60°C. The PCR cycling program finalized with a 
melt curve analysis and data was analyzed using the QIAGEN web-based software 
(www.SABiosciences.com/pcrarraydataanalysis.php). 
For real-time PCR studies, the One-step Master Mix (Applied Biosystems, Foster City, 
CA) was utilized with the following probes and primers as previously described [233]: LC3B, 
Mm00782868_sH; ATG4B, Mm01701111_m1; ATG9A, Mm01264420_m1; ATG5, 
Mm00504340_m1; ATG7, Mm00512209_m1; ATG3, Mm00471287_m1; PIK3C3, 
Mm00619489_m1; ULK1, Mm00437238_m1; ATG9B, Mm01157883_g1; Beclin-1, 
Mm01265461_m1; ATG2B, Mm00512973_m1; ATG4C, Mm01259886_m1; BNIP3, 
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Mm01275600_g1; EIF2AK3, Mm00438700_m1; FAS, Mm01204974_m1; LC3A, 
Mm00458725_g1; GABARAPL1, Mm00457880_m1; IGF1, Mm00439560_m1; IRGM1, 
Mm00492596_m1; SQSTM1 (p62), Mm00448091_m1; PRKAA1, Mm01296700_m1; PTEN, 
Mm00477208_m1. CT values were normalized to Actin (Mm00607939_s1) and RNA-fold 
changes were determined using the 2-ΔΔCT equation. 
 
Protein isolation, SDS-PAGE, and western blot analyses 
Tissues used for protein analyses included uterine horns, ectopic lesions, ovaries, thymus, 
kidneys, heart, pancreas, spleen, and liver. Samples were flash frozen in liquid nitrogen and 
stored at -80°C until use. Tissues were homogenized in ice-cold lysis buffer containing 1% Triton 
X-100, 50 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 10% glycerol, and protease 
inhibitor cocktail (Roche, Indianapolis, IN) using a PowerGen 125 homogenizer (Fisher Scientific, 
Pittsburgh, PA). Samples were centrifuged at 14,000 rpm for 10 min at 4°C. The supernatants 
were collected and total protein concentration was determined using the BCA assay 
(ThermoScientific, Rockford, IL), and a Bio Tek synergy 2 microplate reader (Winooski, VT). 
Samples were normalized and then run onto 10 or 12% SDS-polyacrylamide gels prepared in a 
Criterion® Cassette system (Bio-Rad, Hercules, CA) as previously described [235]. The following 
antibodies and dilutions were used: LC3B rabbit polyclonal (#2775, 1:1,000), LC3A rabbit 
monoclonal (#4599 (D50G8), 1:1,000), Beclin-1 rabbit polyclonal (#3738, 1:1,000), GABARAPL1 
rabbit monoclonal (#13733 (E1J4E), 1:1,000), AMPKα rabbit monoclonal (#2603 (23A3), 1:500), 
FOXO1 rabbit monoclonal (#2880 (C29H4), 1:1,000), and Pan-Actin rabbit polyclonal (#4968, 
1:500) were all obtained from Cell Signaling Technology (Danvers, MA). The p62 mouse 
monoclonal antibody (#610832, 1:1,000) was obtained from BD Biosciences (San Jose, CA). 
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Hematoxylin/eosin staining, tissue microarray construction, and immunohistochemistry 
Collected samples were immediately preserved in 10% neutral buffered formalin at the 
animal facility. Samples were embedded in paraffin, sectioned, and transferred to slides for 
hematoxylin/eosin and immunohistochemical staining. A pathologist reviewed each case and 
delimited the region of interest, containing epithelial and stromal cells, for each specimen. A 
mouse tissue microarray was prepared at the Tissue Core Facility at the Moffitt Cancer Center. 
The mouse tissue microarray contained a total of 113 core samples, which included 10 uterine 
horns and 10 ovaries from both PBS and HCQ treated mice. As control specimens for the utilized 
antibodies, the TMA included mouse mammary tissue, liver, small intestine, and lymph nodes 
from a PBS treated mouse. Lesions were analyzed from independent blocks. Slides were stained 
using a Leica Bond RX automated system (Leica Biosytems, Buffalo Grove, IL) following 
manufacturer's instructions with proprietary reagents. Slides were deparaffinized on an 
automated system with Dewax Solution (Leica Biosystems). The antigen retrieval method used 
for Progesterone Receptor (PR) was enzymatic with Enzyme Solution 1 at 15 min (Leica), for 
vimentin and Estrogen Receptor (ER) was heat induced with Epitope Retrieval Solution 1 at 20 
min (Leica), for cytokeratin 8 (CK-8) was heat induced with Epitope Retrieval Solution 2 at 10 min 
(Leica), and for LC3B was heat-induced with Epitope Retrieval Solution 1 at 10 min (Leica 
Biosystems). All antibodies were diluted in Dako antibody diluent (Carpenteria, CA): PR 
(#ab131486, 1:500, Abcam, Cambridge, MA), vimentin (#5741 (D21H3), 1:100, Cell Signaling, 
Danvers, MA), ER (#ab32063 (E115), 1:200, Abcam, Cambridge, MA), Cytokeratin-8 (#ab53280 
(EP1628Y), 1:200, Abcam, Cambridge, MA), and LC3B (#ab51520, 1:1,500, Abcam, Cambridge, 
MA) and incubated for 30 min. The Leica Bond Polymer Refine Detection System was used with 
a polymer incubation for 8 min. Hematoxylin was used as counterstain and slides were 
dehydrated and covered with a coverslip, following standard histological protocol.   
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Analysis of murine peritoneal inflammatory molecules 
After animals were euthanized, 1 ml of sterile PBS was injected into the peritoneal cavity, 
the abdominal area was gently massaged, and the fluid collected. The collected fluid was 
centrifuged at 1,390 rpm for 5 min at 4°C and the resulting supernatant was then stored at -80°C. 
Levels of chemokines and cytokines were analyzed using a MCYTOMAG-70K-PX32 (Millipore, 
Billerica, MA) following manufacturer’s instructions. Briefly, 200 l of wash buffer was added to 
each well and incubated for 10 min at room temperature in a plate shaker. After incubation, the 
wash buffer was decanted and the plate was inverted and tapped on absorbent towel several 
times. Then, 25 l of assay buffer was added to each well followed by 25 l of concentration 
standards, assay controls, or samples. The premixed bottle was vortexed and 25 l of the beads 
were added to each well. The plate was incubated overnight at 4°C, protected from light. Then 
the plate was incubated for 1 min on the hand-held magnet and the well content was gently 
decanted and tapped on absorbent pads. Each well was washed twice using 200 l of wash 
buffer, followed by the incubation on the hand-held magnet. Antibody detection solution was 
allowed to warm to room temperature, and then 25 l was added to each well and incubated for 
1 h at room temperature on a plate shaker, protected from light. Next, 25 l of Streptavidin-
Phycoerythrin was added to each well containing the detection antibodies and incubated for 30 
min at room temperature protected from light on a plate shaker. After the incubation, the plate 
was washed twice as previously described and 150 l of Sheath Fluid was added to each well. 
The plate was analyzed using MAGPIX™ instrument and xPONENT software solutions, version 
4.2. 
 
Flow cytometry 
The pellet obtained after centrifugation of the peritoneal fluid wash (see above) was 
utilized for macrophage staining. When necessary, red blood cell lysis was performed according 
37 
 
to the manufacturer’s protocol (eBioscience, San Diego, CA). The cell pellets were resuspended 
in 1 ml cold PBS and transferred to flow cytometry tubes.  Samples were centrifuged for 1 min at 
1,390 rpm. The supernatant was decanted and cells were resuspended in 100 l of PBS. Cells 
were blocked using 0.5 g of Mouse BD Fc, Block™ (#553141, BD Pharmingen, San Jose, CA) 
for 5 min on ice. The cells were incubated in 0.4 g of APC Rat anti-mouse CD11b clone M1/70 
(#553312, BD Pharmingen, San Jose, CA) and anti mPE-F4/80/EMR1 (#FAB5580C, R&D 
Systems, Minneapolis, MN)) at room temperature for 30 min, protected from light. After 
incubation, 700 l of PBS was added to each tube and centrifuged for 1 min at 4°C. The 
supernatant was decanted, and the cells were resuspended in 300 l in PBS and analyzed by 
flow cytometry. 
 
Transmission electron microscopy 
Following induction of anesthesia, the abdominal cavity of the mice was opened to expose 
the uterine horns. Both uterine horns were removed and cut in cross sections of 2-3 mm long 
pieces, which were then rinsed in 0.1 M phosphate buffer to remove excess blood, and placed in 
2.5% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.2 at 4˚C. The tissue was fixed in 
glutaraldehyde at 4˚C for 24 h. Following fixation, the tissue was rinsed in buffer, sliced into 1mm 
thick rings and post-fixed in 1% osmium tetroxide at 4˚C for 2 h. Following buffer and distilled 
water rinses, the tissue was dehydrated through a graded series of acetone dilutions, cleared with 
propylene oxide, infiltrated overnight, embedded in LX 112 epoxy resin mix (Ladd Research, 
Williston, VT) and polymerized at 70˚C. Entire cross sections of the uterine horns were obtained 
at 0.25 m-0.35 m thickness and 70-80 nm thickness, and stained with 1% toluidine blue stain 
(for light microscopy) or 8% uranyl acetate and Reynold’s lead citrate (for electron microscopy) 
respectively. The endometrium of both control and experimental animals was observed and 
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photographed using an FEI Morgagni TEM (Hillsboro, OR) with an AMT ActiveVu camera 
(Woburn, MA). 
 
Statistical analyses 
All analyses were performed using GraphPad Prism software (version 6.04, La Jolla, CA). 
To calculate the significance of the observed disorganization of epithelial cells in eutopic 
endometria from endometriosis-induced mice treated with HCQ (compared to those treated with 
PBS, as a control), we used the Fisher’s exact test. All other statistical analyses were calculated 
using the non-parametric student t-test and error bars displayed represent standard errors of the 
mean (SEM). Statistical significance was set at p≤0.05 (* indicates p≤0.05, ** indicates p≤0.01, 
*** indicates p≤0.001, and **** indicates p≤0.0001). 
 
Figure 8. Hydroxychloroquine reduces human endometriotic cell survival. (A) Representative 
images of life-extended endometriotic cells using human endometriotic cells derived from two 
different lesion types: “C” and “D” treated for 18 h with 25M HCQ. (B) Cell survival of life-
extended endometriotic cells treated with 25M HCQ for five days was assessed by CellTiter-
glo and measuring luminescence. (C) Cell lysate from life-extended endometriotic cells treated 
with 25M HCQ for 18 h were analyzed by western blotting using the indicated antibodies. 
Three independent experiments were performed.  
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Results  
Hydroxychloroquine alters human endometrial and endometriotic cell survival as well as lesion 
number and histopathology in a mouse model of endometriosis 
To assess whether an autophagic flux inhibitor could alter the survival capacity of cells 
isolated from human endometriotic lesions, we treated life-extended human endometriotic cells 
(isolated from two individual patients derived from different types of lesions and thus were tested 
separately) with 25M hydroxychloroquine (HCQ). This dose was selected based on our previous 
studies [233]. As shown in Figure 8A and 8B, we observed a marked reduction in cell survival of 
human endometriotic cells from two different types of lesions (p<0.0001) following 5 days of HCQ 
 
Figure 9. Hydroxychloroquine reduces human immortalized endometrial stromal cell survival. 
(A) Representative light micrographs of T-HESC cells treated with 25M HCQ for 18 h are 
shown. (B) Cell survival of T-HESC cells treated with 25M HCQ for five days was assessed 
by CellTiter-glo followed by luminescence measurements. Three independent experiments 
were performed. (C) Cell lysates from T-HESC cells treated with 25M HCQ for 18 h were 
analyzed by western blotting using the indicated antibodies. Three independent experiments 
were performed.  
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treatment. To validate the activity of HCQ, we performed western blot analysis for LC3B, which 
showed that LC3B-II increased with HCQ treatment in these human endometriotic cells (Figure 
8C). A similar reduction in cell survival and increase in LC3B-II protein was noted in the T-HESC 
human endometrial stromal cells (derived from myoma, Figure 9A-C). To confirm the effect of 
autophagy inhibition, we performed siRNA knockdown for ATG5, beclin-1, ATG7, PIK3C3, and 
LC3B in our human endometrial and endometriotic cells. Although we failed to obtain suitable 
numbers of viable cells upon transfection of human endometriotic cells for further analysis, we 
successfully obtained greater than 90% knockdown efficiency of the above described autophagic 
mediators in T-HESC cells (Figure 10A). Interestingly, protein levels of p21 (a cyclin-dependent 
kinase inhibitor involved in cell cycle arrest) increased with siRNA targeting beclin-1, ATG7, and 
LC3B. Therefore, we selected these autophagic mediators to investigate their effects on cell 
viability using the CellTiter-glo assay in these cells. Indeed, as shown in Figure 10B, the cell 
 
Figure 10. Autophagy inhibition reduces cells survival of T-HESC cells. (A) Cell lysates were 
collected from T-HESC cells treated with siRNA targeting ATG5, beclin-1, ATG7, PIK3C3, and 
LC3B. These samples were analyzed by western blotting using the indicated antibodies. (B) 
Cells were treated as described in Figure 10A; cell viability was then assessed after three days 
following the second round of siRNA transfection, using CellTiter-glo.  
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viability of T-HESC was significantly reduced in all of these knockdown conditions, particularly 
with ATG7. These observations suggest that the use of HCQ (or targeting autophagic mediators) 
 
Figure 11. Hydroxychloroquine reduces endometriotic lesion number in a mouse model of 
endometriosis. (A) Schematic representation of the experimental design. The mouse strain 
used was C57BL/6J. Mice were intraperitoneally injected with -estradiol at 6-weeks of age. 
After 1 week, these mice were euthanized and their uterine horns were removed, minced, and 
injected into the peritoneal cavity of the same-age mice (recipients at 7 weeks of age). The 
same day of endometriosis-induction, mice received an intraperitoneal injection of HCQ or 
PBS. A second dose was administered one week later. Two weeks after induction, mice were 
euthanized and samples were collected. (B) Mice in the control group were maintained without 
any treatment. Donor mice received an intraperitoneal injection of -estradiol and two weeks 
later, mice were euthanized and the uterine horns were removed, minced, and injected into 
the peritoneal cavity of recipient mice. Two weeks after endometriosis induction, the recipient 
mice were euthanized and samples were collected. (C) Representative images of control 
(annotated as N (n=4), left panel) and recipient (annotated as R (n=3), right panel) mice. The 
peritoneal cavity was opened and images were captured after exposing the uterine horns. No 
lesions were present in any of the control mice and a total of 5 lesions were found amongst all 
three recipient mice. White arrow (right panel) indicates a lesion. (D) The lesion numbers, 
area, and volume per mouse are shown for HCQ and PBS-treated endometriosis-induced 
mice. A subset of lesions (PBS (n=12) and HCQ (n=10) treated mice) was measured 
lengthwise and widthwise to determine the area and volume. 
B
A
L
e
si
o
n
 A
re
a
 (
m
m
2
)
NS
L
e
si
o
n
 v
o
lu
m
e
 (
m
m
3
)
NS
Estradiol Injection
Endometriosis 
Induction and
PBS or HCQ 
Treatment 
2 40
Donor Mice
0
PBS or HCQ
Treatment
Sample 
collection
Weeks
Weeks
1
3
Recipient Mice
Estradiol Injection
Endometriosis 
Induction
2 40
Donor Mice
0
Sample 
collection
Weeks
Weeks
1
Recipient Mice
Control Mice
0Weeks 4
Sample 
collection
C
D
P
B
S
 C
on
tr
ol
H
C
Q
 T
re
at
ed
0
2
4
6
N
u
m
b
e
r 
o
f 
E
n
d
o
m
e
tr
io
ti
c
L
e
s
io
n
s
***
N
u
m
b
e
r 
o
f 
E
n
d
o
m
e
tr
io
ti
c
 
L
e
si
o
n
s 
p
e
r 
M
o
u
se
6
42 
 
may be detrimental to both human endometrial and endometriotic cell survival.  
To determine whether treatment with HCQ alters the formation of endometriotic lesions, 
we utilized an induced model of murine endometriosis in which mice receive injections of uterine 
horn fragments that develop into lesions within 2 weeks [229, 230]. We treated recipient 
(endometriosis-induced) mice with 60mg/kg HCQ [231] or phosphate-buffered saline (PBS, 
Figure 11A). This treatment was repeated once every seven days post-induction. Mice that were 
neither injected with uterine horn fragments nor treated were used as controls (Figure 11B). All 
of the mice were euthanized at the same time (14 days after endometriosis induction for both the 
PBS and HCQ treatment groups). Ectopic lesions that developed in the recipient mice (white 
arrow, Figure 11C) were counted, measured, and collected for RNA and protein analysis, as well 
as for histological staining. No lesions were observed in the control group (labeled as N, Figure 
11C). The majority (87.5%) of endometriosis-induced mice developed lesions. At the time of 
collection, we noted that the endometriotic lesions varied in size, color, and location across the 
treatment groups. As shown in Figure 11D, there was a significant reduction in the number of 
lesions that developed in mice treated with HCQ compared to those treated with PBS (p=0.0007; 
PBS-treated mice, n=24 (with a total of 46 lesions) and HCQ-treated mice, n=25 (with a total of 
18 lesions)). However, there was no significant difference in lesion size or volume between these 
two treatment groups (Figure 11D).  
A randomly selected subset of the collected lesions and uterine horns were processed for 
staining with hematoxylin and eosin (H&E, pathologically confirmed endometriotic lesions from 
PBS and HCQ-treated mice, n=15 each; uterine horns derived from PBS-treated mice, n=10; and 
uterine horns derived from HCQ-treated mice, n=10). Interestingly, as shown in Figure 12, we 
observed an irregular epithelium pattern in 5 out of 10 uterine horns derived from HCQ-treated 
mice compared to those derived from PBS-treated mice. In addition, we noted that the ectopic 
growths from HCQ-treated mice did not histologically resemble endometriotic lesions (i.e., did not 
contain the expected glandular components) while those treated with PBS did (Figure 12, black 
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arrowheads indicate glandular compartments while black arrows indicate epithelial cells within the 
lesions; p=0.03, per Fisher’s exact test). Together, these results reveal that HCQ reduces the 
number of endometriotic lesions and alters the cellular organization within these tissues.  
 
Altered levels of peritoneal macrophages and IP-10 cytokine from HCQ-treated mice 
To investigate changes in the inflammatory response to endometriosis, we quantified 32 
cytokines/chemokines in the peritoneal fluid collected from control (n=4) and recipient (n=3) mice 
using a mouse cytokine and chemokine magnetic bead panel assay. Of the 32 analyzed 
cytokines/chemokines, we identified that G-CSF, eotaxin, and IP-10 (also known as CXCL10) 
were within the sensitivity and detection limits of the assay; however, there were no significant 
differences in these proteins between control and recipient mice (Figure 13A). In contrast, we 
identified that IP-10 was significantly increased (p=0.0079) in peritoneal fluid obtained from HCQ-
 
Figure 12. Hydroxychloroquine alters endometriotic histopathology in a mouse model of 
endometriosis. Uterine horns and lesions from PBS- and HCQ-treated mice were subjected to 
hematoxylin and eosin (H&E) staining. Black arrowheads indicate glandular compartments (top 
panels). Black arrows indicate epithelial cells (bottom panels). All images were captured at 10X 
magnification. 
PBS HCQ
U
te
ri
n
e
 H
o
rn
L
e
s
io
n
44 
 
treated mice (n=5) compared to PBS-treated mice (n=5) while G-CSF and eotaxin remained 
unchanged (Figure 13B). 
Since previous research identified a significant increase in macrophage numbers in 
endometriosis-induced mice [236] and that HCQ can inhibit cytokine production in human 
macrophages [237], we therefore assessed macrophage numbers in control, recipient 
(untreated), PBS-treated, and HCQ-treated recipient mice. There was no significant change in the 
macrophage numbers present in the peritoneal cavity of control and endometriosis-induced mice 
 
Figure 13. HCQ treatment increases the numbers of peritoneal macrophages and chemokine 
levels of IP-10. (A) Peritoneal fluid collected for control and recipient mice were analyzed for 
32 cytokines/chemokines. The data is presented as a dot plot (showing individual sample 
values), and the line indicates the average ± SEM. (B) Peritoneal fluid was collected from HCQ- 
and PBS-treated mice for cytokine/chemokine analysis. The data is presented as a dot plot 
(showing individual sample values) and the line represents average ± SEM. (C) Macrophages 
were stained with CD11b and F4/80 antibodies and then analyzed by flow cytometry. 
Representative images of the raw flow cytometry data are shown. The data is presented as a 
dot plot (showing individual sample values) and the line represents average ± SEM. (D) 
Macrophages were collected from the same specimens analyzed in Figure 13B. Macrophages 
were stained as described in Figure 13C. Representative images of the raw flow cytometry 
data are shown. The data is presented as a dot plot (showing individual sample values) and 
the line represents average ± SEM. 
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at the time of sample collection (2 weeks post-induction), using the canonical macrophage 
markers CD11b and F4/80 (Figure 13C). However, we did find a significant increase (p=0.0079) 
in macrophage numbers in HCQ-treated mice compared to PBS-treated mice (Figure 13D). 
These data indicate that HCQ alters the inflammatory response of endometriosis-induced mice. 
 
HCQ induces cellular disorganization in murine endometriotic lesions and eutopic endometria 
To determine whether HCQ treatment alters the histopathology (tissue organization) of 
the recipient’s uterine horns and other tissues, we developed a murine tissue microarray (TMA) 
comprised of 113 cores and performed H&E as well as immunohistochemical staining. The TMA 
 
Figure 14. Immunohistochemical analyses of murine endometria and ovaries. Representative 
immunohistochemical images of uterine horns and ovaries from PBS- and HCQ-treated mice 
are shown. The cores were processed for H&E staining as well as epithelial and stromal 
markers (CK8 and vimentin, respectively), ovarian hormone receptors (estrogen receptor 
(ER) and progesterone receptor (PR)), and the autophagy marker LC3B. 
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contained uterine horns and ovaries from 10 PBS- and 10 HCQ-treated mice, as well as a 
mammary gland, a kidney, a lymph node and a small intestine from a PBS-treated mouse for use 
as antibody controls. Based on H&E staining, we observed that the luminal epithelium of the 
uterine horn endometrium from HCQ-treated mice had an irregular pattern (Figure 14). However, 
vimentin and cytokeratin 8 (CK8) appeared to be appropriately localized to the stromal and 
epithelial compartments, respectively, independently of HCQ treatment. As expected, estrogen 
receptor  (ER) was primarily localized to the epithelial cell layer of the endometrial glands, while 
progesterone receptor (PR) appeared to be evenly distributed between the stromal and epithelial 
cell compartments [143]; however, the PR staining was comparatively much weaker to that for 
 
Figure 15. Immunohistochemical analyses of murine endometriotic lesions. (A) Representative 
immunohistochemical images are shown from lesions collected from PBS- and HCQ-treated 
mice. The sections were stained as described in Figure 14. (B) Representative images of 
antibody immunohistochemical staining controls (both positive and negative staining) are 
shown. For LC3B, mouse brain was used as a positive staining control tissue. For Progesterone 
Receptor (PR) and Estrogen Receptor (ER), mouse mammary glands were used as positive 
staining control tissues. For vimentin and cytokeratin-8 (CK8), mouse uterine horns were used 
as positive staining control tissues. Negative staining controls were performed in the absence 
of primary antibody. The images of PR positive and negative staining controls are shown at 
20X magnification; all other images are shown at 10X magnification.  
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ER. Again, no differences were noted in the tissues from PBS and HCQ-treated mice for ER 
and PR staining pattern or intensity. LC3B expression appeared more intense in HCQ-treated 
mice relative to PBS-treated mice in both the stromal and epithelial compartments (Figure 14). 
We also stained for the same immunohistochemical markers in ovaries, but we did not observe 
any marked differences in the intensity or localization pattern of any of these proteins in these 
tissues from HCQ-treated mice relative to those from PBS-treated mice.  
A certified pathologist confirmed epithelial and stromal components in the lesions 
analyzed. Lesions (independent blocks and not on the above-described TMA (see Materials and 
Methods)) were also immunostained for CK8, vimentin, ER, and PR, and LC3B (Figure 15). The 
epithelial cells of the glands were positive for CK8, ER, and PR expression which provides 
supporting data that the collected lesions originated from endometrial tissue (Figure 15A). 
Interestingly, there was an absence of glandular components in four out of the seven stained 
lesions from HCQ-treated mice as demonstrated by CK8, ER, and PR immunohistochemical 
staining. These results (with the H&E data presented in Figure 15A) suggest that HCQ alters the 
organization of ectopic growths in the murine model of endometriosis. Figure 15B displays 
representative images of positive and negative staining controls for the antibodies used. 
 
Induction of endometriosis down-regulates mRNA and protein expression of autophagic markers 
in ectopic compared to eutopic murine endometrium 
To determine whether the expression of autophagic mediators in uterine horns and lesions 
differs between PBS and HCQ-treated mice, we utilized real-time PCR to quantify the mRNA 
transcript levels of 10 major molecules involved in the autophagic pathway. In PBS-treated 
animals, we determined that the mRNA levels of ATG5 (p=0.0294), ATG4B (p=0.0004), ATG2B 
(p=0.0440), and beclin-1 (p<0.0001) were significantly decreased in the analyzed endometriotic 
lesions compared to uterine horns (uterine horns from PBS-treated mice, n=14; lesions from PBS-
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treated mice, n=28; uterine horns from HCQ-treated mice, n=15; and lesions from HCQ-treated 
mice, n=7; Figure 16). Due to limited sample availability, LC3B and ATG2B were analyzed using 
a smaller number of samples (i.e., For LC3B: uterine horns from PBS-treated mice, n=9; lesions 
from PBS-treated mice, n=18; uterine horns from HCQ-treated mice, n=10; and lesions from 
HCQ-treated mice, n=4. For ATG2B: uterine horns from PBS-treated mice, n=5; lesions from 
PBS-treated mice, n=10; uterine horns from HCQ-treated mice, n=5; and lesions from HCQ-
treated mice, n=2). No significant differences were noted between lesions and uterine horns from 
HCQ-treated C57BL/6J mice (likely due to smaller lesion numbers available in the HCQ group 
although similar trends were apparent). However, lesions obtained from these HCQ-treated mice 
had a significant increase in ATG5 (p=0.0499) and ATG3 (p=0.0248) compared to lesions from 
PBS-treated mice (Figure 16). 
Recent studies indicate that mouse strains may elicit differing responses to stimuli [238-
240]. Specifically, corneal infection with Aspergillus fumigatus resulted in an increased 
 
Figure 16. Autophagy gene expression is decreased in uterine horns and lesions from 
endometriosis-induced mice, independently of HCQ treatment. A subset of samples was 
analyzed to quantify transcript levels of autophagic markers by real-time PCR. The line 
indicates average ± SEM. 
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inflammatory response in C57BL/6J mice relative to Balb/c mice, and this was associated with a 
disparate induction of autophagy between these strains [241]. We thus used the Balb/c mouse 
strain for the induction model to demonstrate that the changes observed in autophagy gene 
expression are independent of the mouse genetic strain used [229]. In this model, we identified 
that the mRNA levels of ATG7 (p=0.0174), ATG4B (p=0.0020), and beclin-1 (p<0.0001) were 
significantly reduced in endometriotic lesions (n=8) compared to uterine horns (n=8) derived from 
the same recipient mice (Figure 17).  
We next analyzed the protein levels of autophagic markers in both lesions and uterine 
horns from PBS and HCQ-treated mice (Figure 18) from the following groups: (1) PBS-treated 
mice: uterine horns (n=15), (2) HCQ-treated mice: uterine horns (n=15), (3) PBS-treated mice: 
lesions (n=10), and (4) HCQ-treated mice: lesions (n=7). LC3B-I, LC3B-II, LC3A-I, and LC3A-II 
were decreased in lesions compared to uterine horns from both PBS- and HCQ-treated mice. 
 
Figure 17. Autophagy markers are decreased in lesions compared to uterine horns from 
endometriosis-induced recipient mice. Uterine horns and lesions were collected from 
endometriosis-induced Balb/c mice and analyzed for autophagic gene expression. RNA-fold 
change was assessed by real-time PCR for the indicated autophagic markers. The line 
indicates the average values ± SEM. 
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Expression of GABARAPL1-I was detected in uterine horns collected from both groups of treated 
mice and was decreased in the lesions; however, the conjugated form, GABARAPL1-II, was not 
observed in any of the murine specimens. We also observed a decrease in p62 in endometriotic 
lesions relative to uterine horns that was independent of HCQ treatment. FOXO1 and 
AMPKprotein levels in the uterine horns were variable amongst the samples analyzed, although 
they were both reduced within the lesions (Figure 18 and 19). To determine whether HCQ 
treatment altered expression of autophagic mediators in other organs, we harvested various 
tissue specimens (kidneys, thymus, spleen, lung, pancreas, heart, and liver) from each treatment 
group (5 PBS-treated mice and 5 HCQ-treated mice) and assessed LC3B levels. Amongst these 
 
Figure 18. Autophagy protein levels are decreased in uterine horns and lesions from 
endometriosis-induced mice, independently of HCQ treatment. Protein expression was 
assessed by western blot analyses across the indicated groups using the indicated antibodies. 
Pan-Actin was used as a loading control. The selected western presented in the panel is 
representative of the data obtained across all of these specimens analyzed and includes: (1) 
PBS-treated mice: uterine horns (n=5), (2) HCQ-treated mice: uterine horns (n=5), (3) PBS-
treated mice: lesions (n=5), and (4) HCQ-treated mice: lesions (n=2). UH, uterine horns; FM, 
mass located near fat; LL, lesion located on liver; SL, lesion located near surface of peritoneal 
cavity; UHL, lesion located near uterine horn; FBFL, blood-filled lesion located near fat; FRL, 
red lesion located near the fat; ML, lesion located near mesentery. 
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tissues, only the lung and heart showed differences in LC3B-II expression following HCQ 
treatment (results available with the original publication, in Supplementary Figures). Overall, these 
results suggest that the protein expression of autophagic mediators is dysregulated in 
endometriotic lesions and is not affected by treatment with HCQ in the majority of tissues 
analyzed, including uterine horns.  
 
RNA expression of autophagic markers is dysregulated in eutopic endometria upon induction of 
endometriosis 
Evidence is accumulating that the eutopic endometria from patients with endometriosis 
differs markedly from the eutopic endometria from endometriosis-free subjects [242, 243]. To 
identify changes in the expression of key autophagic markers in this context, we used an RT2-
PCR autophagy focused profiler array to analyze RNA isolated from uterine horns from control 
(non-induced) and recipient (untreated). In addition, we compared the uterine horns from recipient 
mice with those from PBS-treated recipient mice to verify there was no significant change that 
occurred upon intraperitoneal injection with PBS. Three representative samples were selected 
 
Figure 19. Autophagy protein levels are decreased in uterine horns and lesions from 
endometriosis-induced mice, independently of HCQ treatment. Densitometric analyses of the 
presented western blots (see Figure 18) are shown (presented as average ± SEM). For 
GABARAPL1 and p62, analysis of the short exposure is shown. For FOXO1, analysis of the 
long exposure is shown.  
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from each group based on RNA quality. A heat map comparing gene expression in RNA isolated 
from uterine horns from control mice to recipient mice is shown in Figure 20; the results indicate 
that there is a subset of autophagy genes that is differentially expressed. A volcano plot is shown 
in Figure 21 that displays the fold-changes in autophagy genes in eutopic endometria between 
recipient and control mice. We identified 13 dysregulated genes (with statistical significance) 
between these two groups of samples. IGF1 was the only autophagic marker that was significantly 
increased (p=0.044); the remaining 12 markers were all significantly decreased (BNIP3, p=0.015; 
ATG9B, p=0.015; LC3A, p=0.007; LC3B, p=0.0012; PRKAA1, p=0.023; ATG4C, p=0.031; FAS, 
p=0.003; IRGM1, p=0.025; GABARAPL1, p=0.045; PTEN, p=0.048; EIF2AK3, p=0.043; and 
SQSTM1, p=0.054). We did not observe any significant changes upon PBS treatment in the RT2-
PCR array (results available with the original publication, in Supplementary Figures).  
 
 
Figure 20. Decreased RNA expression of autophagic markers in eutopic endometria from mice 
with endometriosis relative to controls. The selected RNA samples from non-induced (control) 
and endometriosis-induced mice were analyzed using an RT2-PCR profiler array specific for 84 
autophagy-related genes. A heat map shown depicting the measured CT values across these 
specimens is presented.  
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To validate these “top hits” (i.e., increased by at least 2-fold with p<0.05) identified from 
the autophagic pathway RT2-PCR profiler array, we performed real-time PCR using TaqMan 
FAM-labeled probes/primers. Using this approach, we validated 10 of the 13 “top hits” (Figure 22 
and Table 2): ATG4C (p=0.0167), ATG9B (0.0113), EIF2AK3 (p=0.0068), FAS (p=0.0034), LC3A 
(p=0.0306), LC3B (p=0.0040), GABARAPL1 (p=0.0360), PTEN (p=0.0295), SQSTM1 
(p=0.0008), and PRKAA1 (p=0.0065) were significantly reduced. Although the majority of the 
tested autophagic markers were not significantly changed upon PBS treatment relative to 
recipient (untreated), we did identify that the expression of EIF2AK3 (p=0.0014) was increased 
(Figure 22). Taken together, these data suggest that autophagy is dysregulated in the eutopic 
endometria of endometriosis-induced mice. 
 
Figure 21. Decreased RNA expression of autophagic markers in eutopic endometria from mice 
with endometriosis relative to controls. A volcano plot is shown from the analyzed data 
presented in Figure 20. The horizontal axis indicates significance (p=0.05) if targets are above 
the line; the dotted vertical bars denote at least a 2-fold change in gene expression if targets 
are equal or greater than -1 or 1 Log2 units. Red arrows indicate the autophagic markers that 
were decreased > 2-fold with a p-value of p<0.05. 
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Figure 22. Decreased RNA expression of autophagic markers in eutopic endometria from mice 
with endometriosis relative to controls. Validation using TaqMan real-time PCR and specimens 
utilized in Figure 20 (presented as average ± SEM). 
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Table 2. Validation using TaqMan real-time PCR and specimens utilized in Figure 20. 
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Increased LC3 protein and lipid droplets in eutopic endometria of endometriosis-induced mice 
compared to eutopic endometria of controls 
To determine whether the RNA level changes of key autophagic markers observed 
between the eutopic endometria of endometriosis-induced mice (n=10) and non-induced (control) 
mice (n=10) translated to protein level changes, we assessed their protein levels via western blot 
analyses. As shown in Figure 23 and Table 3, beclin-1 (2.20-fold change, p=0.0330), LC3B-I 
(4.00-fold change, p=0.0185), LC3B-II (6.76-fold change, p=0.0364), LC3A-II (1.97-fold change, 
p=0.0135), and GABARAPL1 (1.95-fold change, p=0.0334) were significantly increased in uterine 
horns from endometriosis-induced mice relative to those from control mice. LC3A-I and LC3B-I 
have an expected molecular weight of approximately 16kDa, while LC3A-II and LC3B-II have an 
expected molecular weight of approximately 14kDa [244]. When we assessed GABARAPL1 
 
Figure 23. Increased protein expression of autophagy markers in the eutopic endometria from 
endometriosis-induced mice relative to controls. Tissue homogenates from uterine horns from 
non-induced and endometriosis-induced mice were analyzed for protein expression by western 
blotting (left panels). Pan-Actin was used as the loading control. A representation for eight out 
of ten total samples for both control and recipient groups is shown. Densitometric analyses of 
the presented western blots (right panels) are shown (presented as average ± SEM). 
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expression, we did not detect the conjugated form suggesting that the primary form expressed in 
these tissues is the cytosolic form (GABARAPL1-I). To assess if the increased levels of LC3B 
were specific to the uterine horns in the endometriosis-induced mice, we analyzed LC3B protein 
levels in homogenates prepared from kidneys, thymus, spleen, lung, pancreas, heart, liver, and 
ovaries from both recipient (n=3) and control (n=4) mice. Out of the nine tissues analyzed, only 
the left kidney, spleen, and liver appeared to show differences in LC3B-II levels (results available 
with the original publication, in Supplementary Figures). 
To test whether the observed increases in LC3A and LC3B correlated with an increase in 
autophagosome formation in the eutopic endometria of endometriosis-induced mice, we 
performed TEM (Figure 24). Although no autophagosomes were identified in eutopic endometria 
from control mice (Figure 24, subpanels A-D) and eutopic endometria from endometriosis-
induced mice (Figure 24, subpanels E-G), we observed an increase in lipid droplet numbers in 
the epithelial cells of eutopic endometria from endometriosis-induced mice. In addition, we also 
observed more “unhealthy” electron-dense epithelial cells in uterine horns from endometriosis-
induced mice (Figure 24, subpanel E) compared to control mice (Figure 24, subpanel A). 
Together, these results suggest that expression of autophagic mediators (i.e., LC3) is 
dysregulated in the eutopic endometria of endometriosis-induced mice which is associated with 
an accumulation of lipid droplets in the epithelial cells. 
 
Table 3. List of the p-values from the data presented in Figure 23. 
 
Gene
Fold 
Change
P value
Beclin-1 2.20 0.0330
p62 1.00 NS
LC3B-I 4.00 0.0185
LC3B-II 6.76 0.0364
LC3A-I 1.29 NS
LC3A-II 1.97 0.0135
GABARAPL1 1.95 0.0334
AMPKa 0.86 NS
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Immunohistochemical staining of LC3B in the epithelium and stromal components of eutopic and 
ectopic endometrium in patients with endometriosis 
We next addressed the cellular localization of LC3B within human eutopic and ectopic 
endometrium by applying an immunohistochemical (IHC) approach using a human endometriosis 
and endometrium tissue microarray [228]. Representative IHC images for endometrium (controls 
and patients) and lesions (fallopian tubes, ovaries, peritoneal, gastrointestinal, and skin) are 
shown (Figure 25). We noted that LC3B was localized primarily to the epithelium although 
staining was also noted in the stroma. To quantify the intensity of LC3B expression at these 
 
Figure 24. Increased lipid droplets in uterine horns of endometriosis-induced mice. Uterine 
horns from control and endometriosis-induced mice were analyzed by TEM and representative 
images of epithelial cells are shown. Subpanels A-D show eutopic endometria from control 
mice; subpanels E-G show eutopic endometria from endometriosis-induced mice; and the 
images on the right are magnifications of the indicated boxed region in the respective left image. 
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specific cellular locations, we segmented the sections using the H-score system into strong, 
moderate, weak, or no expression (Figure 25A and 25B). The proportion of strong expression 
was elevated in the epithelial cells of the proliferative endometrium from cases (40.6%) and those 
from ovarian and fallopian tube lesions (38.8% and 38.0%, respectively). The endometriotic tissue 
with the highest proportion of strong stromal expression was the gastrointestinal tract (GI) 
(17.4%), followed by proliferative endometrium from controls (14.1%), proliferative endometrium 
from endometriosis patients (13.6%), and secretory endometrium from controls (12.0%) (Figure 
 
Figure 25. LC3B is predominantly localized in the epithelium of ectopic and eutopic 
endometrium. (A) LC3B immunostaining was performed on a TMA containing biopsy cores: 
eutopic endometrium (from controls and endometriosis patients) and endometriotic lesions 
(from ovaries, fallopian tubes, peritoneal, gastrointestinal, and skin). Mammary glands were 
used as a positive control tissue and the negative antibody staining control was performed in 
the absence of primary antibody. All images were captured at 20X magnification. LC3B 
immunostaining was analyzed using the H-score system. The average immunostaining in the 
(B) stromal and (C) epithelial compartments were categorized as strong, moderate, weak, and 
no expression. 
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25C). We noted a significant difference in LC3B expression in the epithelium of secretory 
endometrium compared to proliferative endometrium (p=0.0193; Figure 26, lower panel). We also 
found significantly increased expression in the epithelium of fallopian tube and ovarian 
endometriotic lesions compared to epithelium from the secretory endometrium of controls 
(p=0.0220 and p=0.0097, respectively). In the stroma of peritoneal endometriotic lesions, LC3B 
was decreased compared to the stroma of proliferative endometrium from controls (p=0.0101). In 
addition, relative to the stroma, positive LC3B immunostaining was significantly more elevated in 
the epithelial component of the lesions in the fallopian tube, ovarian, and peritoneum but not in 
lesions derived from the gastrointestinal tract and the skin (Figure 26, upper panel). Thus, 
collectively, LC3B expression and localization was predominant in the epithelium relative to the 
stromal components in all tissue types assessed.  
 
 
Figure 26. LC3B analysis of the positive and strong positive staining intensity. The data obtained 
from the H-score system described in Figure 25 is presented as percent total positive intensity 
(upper panel) and percent strong intensity (lower panel) across the tissues described above 
(average ± SEM).  
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Discussion  
To our knowledge, our work presented herein is the first to investigate the effect of an 
autophagic flux inhibitor, HCQ, on endometriotic lesion development and histopathology. Our 
main findings are summarized in Figure 27. We found that HCQ treatment affected the survival 
of human endometrial and endometriotic cells in vitro as well as decreased lesion numbers using 
an in vivo mouse model of endometriosis. The drug also appeared to have an effect on lesion 
histopathology (absence of glandular components), but not on lesion size. We also identified that 
HCQ increases the number of macrophages and the IP-10 chemokine within the peritoneal cavity 
of a mouse model for endometriosis. Furthermore, we have identified that autophagic markers 
are differentially expressed in uterine horns from endometriosis-induced mice compared to those 
from control mice. Although we noted that LC3B protein level was increased in eutopic endometria 
of endometriosis-induced mice (compared to controls), we did not identify increased 
 
Figure 27. Schematic of overall results presented in Chapter 2. Injected fragmented uterine 
horns implanted and developed in endometriotic lesions. LC3B and lipid droplets were elevated 
in recipient uterine horns compared to uterine horns from recipients, as indicated by protein 
analyses and transmission electron microscopy, respectively. HCQ reduced lesion numbers 
relative to PBS treatment. Moreover, IP-10 levels and macrophages increased in the peritoneal 
cavity of HCQ-treated mice compared to those treated with PBS. 
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autophagosomes by TEM in these tissues. However, TEM showed that endometria from 
experimental mice are less healthy and contained an increased number of lipid droplets compared 
to endometria from control mice. Finally, we noted that LC3B was expressed and localized 
predominantly to the epithelia in all tissue types (relative to the stroma) of human endometrium 
and endometriotic lesions from diverse locations using a TMA approach.  
Chloroquine, and derivatives of this agent (including HCQ), have been used to treat 
malaria as well as inflammatory and autoimmune diseases [245]. Endometriosis shares some 
characteristics with autoimmune disorders, such as increased inflammation, altered tissue-
remodeling components, dysregulated cell death pathways, and increased local and systemic 
cytokine levels [246]. Inflammatory changes in the peritoneal cavity may be associated with lesion 
development [247]. Other co-morbid autoimmune disorders (i.e. systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), multiple sclerosis (MS)) can coincide with the presence of 
endometriosis [248, 249]. These autoimmune disorders can be treated with HCQ, which can 
antagonize communication among cells in the immune system that are inappropriately activated 
[245, 250]. Therefore, HCQ could potentially be used as an effective therapeutic agent for other 
autoimmune related disorders, such as endometriosis. As described earlier, HCQ is considered 
a lysosomotropic agent where it increases the pH of acidic compartments and also inhibits the 
fusion of the autophagosome with the lysosome [225-227]. We identified a marked reduction in 
cell survival with this agent in human endometriotic and T-HESC cells. The involvement of 
lysosomes in endometriosis has yet to be investigated in detail; to our knowledge, only one study 
describes changes in numbers of lysosomes in the endometrium of women with endometriosis 
[251]. We also successfully knocked down ATG7 (in addition to other autophagic mediators) in T-
HESC; we noted a marked increase in p21 protein expression which was associated with 
attenuated cell viability. It has been previously reported that ATG7 can lead to increased p21 via 
a DNA damage pathway [252], which appears to be independent of its canonical role in the 
autophagic pathway. Since we did not observe the expected reduction in LC3B-II/I ratio upon 
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ATG7 knockdown in the T-HESC cell line, it is possible that the reduction in cell viability could 
have occurred via a similar mechanism as described above.  
Although we identified increases in ATG5 and ATG3 in lesions from HCQ-treated mice 
relative to PBS-treated mice, the majority of the remaining autophagic markers that we studied 
were unchanged; however, we recognize that this may be due to a limited lesion number sample 
size obtained from HCQ-treated mice. Since we observed fewer glandular structures and 
epithelial cells in lesions from endometriosis-induced mice treated with HCQ, it is possible that 
this drug is affecting the epithelial cells of endometriotic lesions more than the stromal cells, thus 
leading to a decrease in lesion number and quality. Our analyses of autophagic markers (by real-
time PCR or western blotting) did not distinguish between stromal and epithelial cells; therefore, 
further tests would be required to dissect the response between the two cell types that may be 
leading to the observed decrease in lesion number.  
HCQ treatment increased the levels of IP-10 and the numbers of macrophages in the 
peritoneal cavity in our mouse model of endometriosis. In humans, IP-10 has been reported to 
attract monocytes and T lymphocytes as well as decrease angiogenesis [253, 254]. A decrease 
in IP-10 peritoneal levels has been reported in advanced stages of endometriosis in patients, and 
thus decreased levels of IP-10 may contribute to lesion development, permitting angiogenesis, 
and decreasing recruitment of natural killer cells and their cytolytic effects [255]. Therefore, an 
increase in peritoneal IP-10 levels in HCQ-treated mice may have created an unfavorable 
environment for lesion development. Whether IP-10 modulates the autophagic pathway requires 
further investigation. It is interesting that another chemokine CXCL12 has recently been 
implicated in modulating autophagy in human secretory phase endometrial stromal cells [19]. 
Additional experiments will be required to determine whether the HCQ effects leading to the 
increased IP-10 levels corresponds with the observed decrease in lesion number and the 
mechanisms whereby IP-10 could be exerting its anti-endometriotic growth effects.  
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A previous study reported altered gene expression in eutopic endometria from patients 
with endometriosis compared to those of controls [256], suggesting that endometriosis may be 
altering the endometria of patients. In our study, we noted that the mRNA expression of 
autophagic markers was generally decreased in eutopic endometria from endometriosis-induced 
mice when compared to eutopic endometria of control mice. Specifically, we found that transcript 
levels of beclin-1, ATG5, ATG4B, and ATG2B were significantly decreased in endometriotic 
lesions compared to uterine horns (from endometriosis-induced mice treated with PBS). Beclin-1 
is required for vesicle nucleation during autophagosome formation and forms a complex with 
UVRAG to regulate PIK3C3 [9]. ATG5 and ATG4B are required to generate the cytosolic form of 
LC3, LC3-I [10, 257, 258]. In addition, we found that LC3B protein levels were decreased in 
lesions compared to uterine horns. Together, these changes suggest that dysregulation of 
autophagic markers may alter the autophagic response in endometriosis. Further research is 
needed to determine whether autophagosome numbers are altered within ectopic lesions. In 
contrast to the observations in the lesions, we identified increased protein levels of beclin-1, 
LC3B, LC3A, and GABARAPL1 in uterine horns from endometriosis-induced mice compared to 
uterine horns from controls, with a concurrent increase in lipid droplets. Lipid droplets have been 
previously described in bovine endometrial epithelial cells [259], and recent findings have 
implicated LC3 in intracellular lipid droplet formation [260]. It is possible that the observed 
increases in LC3B protein are associated with the accumulated lipid droplets, but further work is 
needed to understand the clinical implications of this finding. 
The observed changes in the expression of autophagic markers in eutopic endometria 
from induced mice could be explained by an activated local immune/inflammatory response 
caused by transferring endometrial fragments into the peritoneal cavity [219]. Although we did not 
observe an increase in inflammatory markers or macrophage levels two weeks post-induction, we 
propose that any inflammatory response that occurred may have been diminished by the time of 
sample collection. Together, these observations may reveal why endometriosis is able to recur in 
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women after surgical removal of endometriotic lesions [261]. Whether the eutopic endometrium 
of women with endometriosis is altered prior to lesion establishment or whether it becomes more 
compromised after the initiation and establishment of the disease remains unclear and requires 
further study. 
In contrast to the reduced expression of LC3B protein in lesions obtained from the mouse 
model of endometriosis (relative to uterine horns isolated from the same diseased-mice), we 
identified an increase in LC3B levels in epithelial cells of endometriotic lesions and in eutopic 
endometria of endometriosis patients compared to endometrium from controls using IHC. We 
propose that this difference may be due to the possibility that the murine endometriosis lesions 
are equivalent to an early stage of endometriosis in patients. Since the human disease is not 
diagnosed until a delay period of 7-10 years [104, 262], the nature of the isolated lesions from 
human may be more advanced. In addition, the endometrium controls on the TMA are from 
women with other gynecological problems, which is a limitation of our study. Despite these 
limitations, the results obtained with the human TMA are more close to the real-life scenario of 
patient heterogeneity in clinical presentations and history of disease (previous treatments, years 
with disease) and still the changes in LC3B remained significant.  
Whether the aforementioned observed expression changes implicate autophagy 
dysregulation in a pro-survival or pro-death manner is currently unknown in regards to 
endometriotic lesion establishment. Additional studies will be required to determine how 
autophagy is regulated to allow development of endometriosis. Our results also show potential 
for a novel therapeutic approach for treating patients with this disease. Patients with autoimmune 
diseases (i.e., lupus and arthritis) appear to tolerate HCQ treatment well; side effects include 
retinal damage with only rare reports of systemic reactions [263]. Thus far, there seems to be no 
adverse effects of this drug on fertility [264], which makes HCQ superior to the current use of 
estro-progestinic treatments. 
  
65 
 
 
 
 
 
 
Chapter 3 
 
Expression and Function of Nuclear Receptor Coactivator 4 Isoforms in Transformed 
Endometriotic and Malignant Ovarian Cells 
 
Note to Reader 
The results presented herein are as published (Rockfield, S., Flores, I., and Nanjundan, 
M. Oncotarget, 2018. 9(4): p. 5344-5367.), albeit reorganized and re-formatted for this 
dissertation. This reproduction was approved by Oncotarget (see Appendix A for copyright 
permissions). 
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Introduction 
Ovarian cancer (OVCA) is one of the deadliest gynecological cancers in women [140]. 
Precursors to OVCA include endometriotic lesions (proposed to transition to clear 
cell/endometrioid) as well as fallopian tube fimbriae and/or ovarian surface epithelium (proposed 
to transition to serous) [111]. The mechanisms underlying the transition of these precursors, such 
as endometriosis, to OVCAs remain unclear. Evidence implicates an array of mutations and 
genomic aberrations that contribute to OVCA development [62]. These include the (a) c-Myc 
proto-oncogene, located at 8q24.21, which is frequently amplified in >20% of OVCAs [62], (b) p53 
tumor suppressor, located at 17p13.1, which is mutated in ~95% of OVCAs [62], and (c) K-Ras 
proto-oncogene, located at 12p12.1, which is amplified in >10% of OVCA patients [62]. In addition, 
the H-Ras proto-oncogene, located at 11p15.1, is frequently activated due to upstream alterations 
in signaling pathways; mutations in its gene have been rarely identified [29]. There are reports 
that alterations in the above described genes can be mediated by reactive oxygen species (ROS) 
[199]. It is suggested that ROS may be generated by high levels of redox-active iron (mM levels) 
in endometriomas [208] as well as in the fallopian tube [118]. Indeed, as a result of its ability to 
undergo Fenton reactions, iron is considered to be highly mutagenic [34, 35]. Furthermore, 
increased DNA damage is noted in fallopian tube secretory epithelial cells in response to 
transferrin [209] and cellular treatment with iron leads to their increased proliferative capacity 
[214]. Nonetheless, the exact role of iron in mediating OVCA pathogenesis requires clarification. 
Iron levels need to be balanced appropriately within the cell; excess iron is frequently stored in 
ferritin as a storage complex (for a comprehensive review on iron regulation, see [265]). When 
iron is required by the cell, it may be released via the process of ferritinophagy, which is mediated 
by Nuclear Receptor Coactivator 4 (NCOA4) [32] leading to increased redox-active iron that may 
be utilized for regulation of enzymatic activities which requires formation of iron-sulfur clusters 
[266]. Two well-studied NCOA4 isoforms (NCOA4 and NCOA4) have been functionally 
assessed in breast and prostate cancers [267-270]. Specifically, NCOA4 inhibits proliferation in 
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prostate cancer whereas NCOA4 increases proliferation in both prostate and breast cancer cells 
[269, 270]. Thus far, there is only limited data describing increased NCOA4 transcripts in ovarian 
carcinomas [271]; thus, the contribution of NCOA4 to the progression of OVCA has not yet been 
thoroughly investigated. 
Herein, we successfully developed a transformed endometriotic cell line via 
overexpression of H-RasV12A and c-MycT58A with p53 inactivation. These cells were able to 
overcome cellular senescence and displayed altered mRNA expression of genes involved in the 
EMT and iron pathways, notably NCOA4. Knockdown of this nuclear receptor coactivator in 
normal/benign and malignant gynecological cells resulted in reduced cell survival. In malignant 
gynecological cells compared to non-malignant, we identified increased mRNA transcripts for two 
NCOA4 isoforms (NCOA4 and NCOA4) as well as increased NCOA4 protein. We additionally 
identified increased NCOA4 expression in ovarian tumors (serous, serous papillary, and 
mucinous) compared to adjacent normal tissues via tissue microarray analyses. Together, our 
results demonstrate that NCOA4 expression is elevated in transformed endometriotic cells 
(relative to non-transformed endometriotic cells) as well as malignant OVCA cells (relative to non-
malignant cells) and furthermore, this molecule appears to regulate survival of these 
gynecological cells. 
  
Materials and Methods 
Ethics and human OVCA tissue microarray 
We obtained a TMA (US Biomax, Inc. (#BC11115b, Derwood, MD)) containing a total of 
100 core samples including 5 clear cell carcinomas, 48 serous papillary adenocarcinomas, 14 
serous adenocarcinomas, 12 mucinous adenocarcinomas, 1 endometrioid adenocarcinoma, 10 
lymph node metastasis adenocarcinoma, and 10 adjacent normal tissues which were de-identified 
and cannot be linked to the human subjects. The studies that were performed using this array as 
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reported in this manuscript received an assessment of Not Human Subjects Research 
Determination (IRB#: Pro00029616) from the University of South Florida IRB Review Board 
whose Chairperson is Dr. Jorgensen. The TMA was stained using previously published methods 
[272] with a 1:100 dilution of the NCOA4 antibody (Novus Biologicals, #H00008031-M05) for a 45 
minute incubation with an epitope retrieval solution 2 for 20 minutes. The stained TMA was 
scanned using the Aperio ScanScope XT (Aperio Vista, CA, USA) as described previously [272]. 
Representative images were captured at 6X magnification. Positive core analyses were 
determined using the Positive Pixel Count v.9.0 algorithm. Thresholds are as follows: Hue Value 
(Center)=0.1; Hue Width=0.5; Color Saturation Threshold=0.04; Intensity Threshold Weak (Upper 
Limit)=220; Intensity Threshold Weak (Lower Limit)=175; Intensity Threshold Medium (Upper 
Limit)=175; Intensity Threshold Medium (Lower Limit)=100; Intensity Threshold Strong (Upper 
Limit)=100; Intensity Threshold Strong (Lower Limit)=0. Statistical Analysis (student’s 
nonparametric t-test) was completed in GraphPad Prism, and error bars represent the mean  
SD (*) p<0.05, (**) p<0.01.  
 
Cell culture 
Human normal immortalized (with LTAg and hTERT) ovarian surface epithelial T80 cells 
and serous ovarian epithelial HEY carcinoma cells were kindly provided by Dr. Gordon Mills (MD 
Anderson Cancer Center, Houston, TX) and were maintained in RPMI 1640 supplemented with 
8% FBS and 1% penicillin/streptomycin as previously described [233]. Human immortalized (with 
hTERT) endometrial stromal T-HESC cells were obtained from ATCC (Manassas, VA, USA) and 
were maintained in phenol-red free DMEM/F12 (1:1) supplemented with 8% charcoal-dextran 
treated FBS, 500ng/ml puromycin, 1% ITS+ Premix (#354352, BD Biosciences, San Jose, CA, 
USA), and 15mM HEPES as previously described [272]. Human clear cell ovarian TOV21G 
carcinoma cells were kindly provided by Dr. Jonathan Lancaster (Moffitt Cancer Center, Tampa, 
FL, USA) while human endometrioid ovarian TOV112D carcinoma cells were obtained from ATCC 
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(Manassas, VA, USA); both cell lines were maintained in MCDB 131/Medium 199 (1:1) 
supplemented with 8% FBS and 1% penicillin/streptomycin. Fallopian tube secretory epithelial 
cells (FTSEC (FT194)) were kindly provided by Dr. Ronald Drapkin (University of Pennsylvania, 
Philadelphia, PA) and maintained in DMEM/F12 (1:1) supplemented with 2% Ultroser G (Crescent 
Chemical Company, #67042.1/S) and 1% penicillin/streptomycin. T80, T-HESC, HEY, TOV21G, 
and TOV112D were authenticated by STR profiling (Genetica Laboratories, Cincinnati, OH). The 
STR profiles for human endometriotic cells were confirmed to not match any profiles representing 
commercial cell lines deposited within the repository cell line database (Genetica Laboratories, 
Cincinnati, OH, USA). Furthermore, all cell lines were confirmed to be mycoplasma negative. 
 
Human primary endometriotic cell isolation 
Human primary endometriotic cell lines (kindly provided by Dr. Idhaliz Flores, Ponce, 
Puerto Rico) were obtained from four endometriotic lesions as follows: (a) PE-A cells, derived 
from a lesion in the posterior cul-de-sac, (b) PE-B cells, derived from a lesion in the right 
mesosalpinx, (c) PE-C cells, derived from a peritoneal lesion, and (d) PE-D cells, derived from an 
endometrioma located on the right ovary. These cells were maintained in MCDB 131/Medium 199 
(1:1) supplemented with 8% FBS and 1% penicillin/streptomycin. 
 
Generation of human transformed endometriotic cells 
HEK293T packaging cells were seeded at 1.5x106 cells in 6-well plates. Following 
overnight adherence, cells were transfected with a retroviral expression plasmid concurrently with 
pCGP and pVSVG plasmids (1:1:1 ratio) using Fugene HD (Promega, Madison, MI, USA). Control 
virus was generated using an empty pBABE-puro expression plasmid (Addgene plasmid #1764 
[273]). Oncogenic cocktail virus was generated using the following at equimolar quantities (a) H-
RasV12A (Addgene plasmid #9051, a gift from William Hahn), (b) c-MycT58A (Addgene plasmid 
#20076, a gift from Juan Belmonte [274]), (c) SV40 LTAg (Addgene plasmid #14088, a gift from 
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William Hahn [275]), and (d) HA-tagged hTERT (Addgene plasmid #1772, a gift from Bob 
Weinberg [276]). Forty-eight hours after transfection, media supernatant (containing retrovirions) 
was collected, filtered (0.45µm), and used to infect PE-A, PE-B, PE-C, and PE-D human primary 
endometriotic cells with 8g/ml polybrene. Following the initial retroviral infection, cells were 
maintained for 23 days at which time there was no further increase in cell growth in either the 
OCV (oncogenic virus cocktail) or CV (control virus) infected cells. Thus, two additional rounds of 
retroviral infections were completed and cells were maintained for 44 days, at which time both the 
PE-C and PE-D (CV and OCV infected cells) reached crisis. PE-A and PE-B control virus infected 
cells also eventually reached crisis, at which point the OCV infected cells, which continued to 
survive and proliferate, were considered to be transformed. We completed two additional rounds 
of infections in PE-A and PE-B cells (with CV and OCV retrovirions) to increase cell numbers 
available for analyses since the number of non-transformed cells was a limitation for the 
subsequent analyses. 
 
Cloning of NCOA4and NCOA4 into a retroviral expression plasmid for generation of retroviral 
cell lines 
RNA isolated from T80 cells using an RNeasy kit (QIAGEN, Germantown, MD, USA) was 
utilized for reverse transcriptase (RT)-polymerase chain reaction (PCR) to amplify the full-length 
form of NCOA4 (NCOA4). RNA isolated from TOV21G cells using an RNeasy kit (QIAGEN, 
Germantown, MD, USA) was utilized for reverse transcriptase (RT)-polymerase chain reaction 
(PCR) to amplify the shorter form of NCOA4 (NCOA4). The primers used are (1) 5’-GGG-
GAATTC-ACCGCC-ATG-AAT-ACC-TTC-CAA-GAC-3’ (forward primer) and (2) 5’-GGG-
GAATTC-TCA-CAT-CTG-TAG-AGG-AGT-TCG-3’ (reverse primer). The PCR conditions used 
were as follows: 30 min at 480C, 2 min at 940C followed by 40 cycles of 1 min at 940C, 1 min at 
550C (for both NCOA4 and NCOA4), 5 min at 680C. The final extension step was set for 15 min 
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at 720C. Products were analyzed on a 1% agarose gel and the appropriately sized PCR products 
for both NCOA4 and NCOA4 were gel purified using the QIAquick Gel Extraction kit (QIAGEN, 
Germantown, MD, USA) following the manufacturer’s protocol and then cloned into the pTOPO 
vector (Invitrogen, Carlsbad, CA, USA). Positive clones were validated by sequencing (Moffitt 
Cancer Center, Molecular Genomics Core, Tampa, Florida, USA). NCOA4 and NCOA4 were 
then subcloned into the EcoRI site in the retroviral pBABE-puro (Addgene plasmid #1764 [273]) 
and pQCXIN (Clontech, Mountain View, CA, USA) expression vectors. Large plasmid stocks of 
NCOA4 and NCOA4 in these retroviral plasmids were generated using the EndoFree Plasmid 
kit (QIAGEN, Germantown, MD, USA).  
HEK293T packaging cells were transfected with the appropriate expression vector 
(pBABE-puro or pQCXIN) or the corresponding empty vector (as control) as well as the pCGP 
and pVSVG vectors (at a 1:1:1 ratio). At 48 and 72 hours post-transfection, virus-containing 
supernatant was collected, filtered (0.45µm), and used to infect the appropriate target cells with 
8g/ml polybrene (first round of infection) or 16g/ml polybrene (second round of infection). Cells 
were then expanded to T75 flasks in appropriate antibiotic-containing media (1g/ml puromycin 
for T80 cells, 2g/ml puromycin for HEY cells, and 0.5mg/ml G418 for PE-A-OCV cells). 
 
Cellular treatments 
Media from senescent PE-A-CV and PE-B-CV cells was collected (conditioned media, 
COM), 0.22m filtered, and stored at -200C until use in migration assays. Ferric ammonium citrate 
(FAC) was obtained from Fisher Scientific (Pittsburgh, PA, USA); a 50mM stock was prepared in 
PBS and used at a final concentration of 250M according to our prior work (see Chapter 2, 
above, and [233]). To prepare serum factor-depleted media (-PR), phenol-red free DMEM/F12 
(1:1) was supplemented with 8% charcoal-dextran treated FBS and 1% penicillin/streptomycin. 
MG132 (Fisher Scientific, Pittsburgh, PA, USA), a proteasome inhibitor, was prepared in dimethyl 
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sulfoxide (DMSO) at 10mM and used at a final concentration of 5M while cycloheximide (CHX, 
Fisher Scientific, Pittsburgh, PA, USA), a protein synthesis inhibitor, was prepared in DMSO at 1 
mg/ml and used at a final concentration of 2g/ml as previously described [277] in the presence 
or absence of 250µM FAC for 18 hours. 
 
siRNA transfection 
Cells were seeded at 350,000 cells (T80, T-HESC, HEY, PE-A-OCV) or 1x106 cells 
(TOV21G) per well in 6-well plates and allowed to adhere overnight. Cells were then transfected 
with the appropriate siRNA using DharmaFECT 1 (Fisher Scientific, Pittsburgh, PA, USA) 
according to our previously published methods [235]. The following ON-TARGETplus siRNAs 
were obtained from GE Dharmacon (Lafayette, CO, USA): (1) non-targeting control (D-001810-
10-20), (2) NCOA4 (L-010321-00-0005), and (3) LC3B (L-012846-00-0005). To obtain efficient 
knockdown of NCOA4, two rounds of siRNA transfection were performed while one round was 
completed for LC3B. 
 
RNA Isolation and real-time polymerase chain reaction (PCR) 
The RNeasy Kit (QIAGEN, Valencia, CA, USA) was used to isolated total RNA following 
the manufacturer’s instructions. Using methods previously described (see Chapter 2, above, and 
[233]), real-time PCR was performed using the One-step Master Mix from Applied Biosystems 
(#4392938, Foster City, CA, USA) with the following FAM-labelled probes/primers: (1) NCOA4 
(Hs00428331_g1), (2) FTH (Hs01694011_s1), (3) CD71 (Hs00951083_m1), (4) FPN 
(Hs00205888_m1), (5) DMT1 (Hs00167206_m1), (6) ISCU (Hs00384510_m1), (7) IL-6 
(Hs00985639_m1), (8) SNAIL (Hs00195591_m1), (9) SLUG (Hs00950344_m1), (10) ZEB1 
(Hs00232783_m1), (11) ZEB2 (Hs00207691_m1), (12) TWIST1 (Hs00361186-m1), (13) LC3B 
(Hs00797944-s1), (14) LAMP1 (Hs00174766-m1), (15) SQSTM1 (Hs01061917-g1), and (16) 
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MCOLN1 (Hs01100653-m1). Using the Custom TaqMan® Assay Design Tool, FAM-labelled 
probes and primers specific for NCOA4 were designed to cross the junction between exon 8 
and exon 9 while FAM-labelled probes and primers specific for NCOA4 were designed to cross 
the junction between exon 7 and exon 9. CT values were normalized to -actin (#401846, Applied 
Biosystems, Foster City, CA, USA) and RNA-fold changes were calculated using the formula 
2−ΔΔCT. 
 
Protein isolation, SDS-PAGE, and western analyses 
Protein lysates were prepared according to previously published methods (see Chapter 2, 
above, and [278]). Proteins were then normalized and loaded onto appropriate (10%) SDS-PAGE 
gels which were next transferred onto polyvinylidene fluoride (PVDF) membranes. As indicated 
in the Figure legends, samples were re-run to prevent overlapping detection of similar molecular 
weight antigens. Western blotting was conducted according to previously described methods (see 
Chapter 2, above, and [235]). Total Ras rabbit monoclonal (#3339, 1:1000), FTH rabbit polyclonal 
(#3998, 1:500), c-Myc rabbit monoclonal (#13987, 1:500), LC3B rabbit polyclonal (#2775, 
1:1000), p21 mouse monoclonal (#2946, 1:250), phospho-p42/44 MAPK rabbit polyclonal (#9101, 
1:750), pAKT rabbit monoclonal (#4060, 1:1000), pan-AKT rabbit monoclonal (#4685, 1:1000), 
Lamin A/C mouse monoclonal (#4777, 1:2000), PARP rabbit polyclonal (#9542, 1:1000), GAPDH 
rabbit monoclonal (#5174, 1:1000), and pan-Actin rabbit polyclonal (#4968, 1:500) antibodies 
were obtained from Cell Signaling Technology (Danvers, MA, USA). SV40 Large T antigen mouse 
monoclonal (#554149, 1:1000) and p62 mouse monoclonal (#610832, 1:1000) were obtained 
from BD Biosciences (San Jose, CA, USA). NCOA4 rabbit polyclonal (#A302-272a, 1:1000) was 
obtained from Bethyl Laboratories (Montgomery, TX, USA). CD71 mouse monoclonal (#sc-
51829, 1:250) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). ID1 rabbit 
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antibody (1:300) was kindly provided by Dr. Miguel Pujana (Catalan Institute of Oncology, 
Barcelona, Spain). Densitometric analyses were completed using ImageJ (NIH). 
 
Immunofluorescence 
Human endometriotic cells (PE-A-CV and PE-A-OCV as well as PE-B-CV and PE-B-OCV) 
were seeded onto glass coverslips and grown until sufficient numbers of cells were present prior 
to staining. Cells were fixed for 30 minutes in 4% formaldehyde and then blocked (5% goat serum 
and 0.1% Triton X-100 in PBS) for 1 hour at room temperature. Rabbit monoclonal antibody 
targeting H2AX was applied at 1:400 dilution overnight at 40C (#9718, Cell Signaling Technology) 
in a humidifying chamber. The following day, the cells were incubated with the appropriate 
secondary antibody (Alexa Fluor 488 goat anti-rabbit used at 1:500 dilution in 1% goat serum and 
0.1% Triton-X-100 in PBS) for 1 hour (in the dark).  
For staining of actin filaments, cells grown on coverslips were fixed and blocked as 
described above. Cells were then incubated at room temperature for 30 minutes with 5 units of 
Alexa Fluor 488 Phalloidin (#A12379, Fisher Scientific) according to manufacturer’s guidelines. 
Slides were viewed and imaged at 63X and 20X magnification using a PerkinElmer UltraVIEW 
Confocal spinning disc microscope (PerkinElmer Corporation). 
 
Subcellular Fractionation 
Cytoplasmic and nuclear fractions were obtained using the Subcellular Protein 
Fractionation Kit (#78840, Fisher Scientific) according to manufacturer’s instructions. The 
separated fractions were then run on appropriate SDS-PAGE gels and analyzed by western 
blotting.  
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Cell viability assays 
Cells were seeded at 2,500 cells per well in a 96-well opaque plate. After 72 hours, the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) was performed 
according to manufacturer’s instructions. To assess changes in viability upon NCOA4 siRNA, 
cells (T80, HEY, and PE-A-OCV) were re-seeded following the last round of transfection with 
siRNA. The following day, wells were rinsed with PBS before incubating the cells in serum factor-
replete (+PR), serum factor-deplete (-PR), or FAC (250M) media for 24 hours. For control (empty 
vector) and NCOA4 overexpressing cells, cell viability was assessed following 72 hours post-
seeding. 
 
Migration assay 
The migration assay was performed according to manufacturer’s protocol (#CBA-110, Cell 
Biolabs, San Diego, CA, USA). Briefly, PE-A and PE-B (infected with CV and OCV) cells were 
seeded in 300l serum-free media at 15,000 cells/well in Boyden chamber inserts within a 24-
well plate. Complete (serum-containing) media (CM), as chemoattractant, was added (500l) to 
the bottom chamber of the well. After a 24 hour incubation, the upper chamber of the Boyden 
chamber insert was carefully cleaned using Q-tips and then stained for 10 minutes with 400l of 
the provided Cell Stain Solution. Following extensive washing, representative light microscope 
images were captured at 100X magnification. Furthermore, cells were counted twice 
independently to quantify migrated cells. For treatment with senescence-conditioned media 
(COM), PE-A-OCV and PE-B-OCV cells were seeded similarly to that described above and 
complete (CM, as control) or COM media were added as the chemoattractant to the bottom 
chamber. Following 24 hour incubation, cells were stained and images captured as described 
above. 
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3D morphogenesis assay 
Using published methods for sphere formation [279], 100% Matrigel Basement Membrane 
Matrix (#356234, Fisher Scientific, Pittsburgh, PA, USA) was thawed on ice (in a 40C refrigerator) 
overnight prior to use. The following day, 40l of the stock Matrigel was added to each chamber 
of an 8-well Chamber Slide (#PEZGS0816, Fisher Scientific) using pre-chilled pipet tips; this was 
then incubated at 370C for 15 minutes to solidify. PE-A and PE-B (CV and OCV) cells were next 
seeded at 5,000 cells in a total volume of 400l (containing a final concentration of 2% Matrigel 
in complete media) per chamber. Cells were re-fed every 4 days by removing the top layer of 
media and overlaying with fresh complete media containing 2% Matrigel. On the 10 th day, 
representative light microscope images were captured at 100X and 200X magnification (images 
were converted to grayscale in PowerPoint). 
 
Senescence assay  
Senescent cells were identified by using the Senescence -Galactosidase Staining Kit 
(#9860, Cell Signaling Technology) according to manufacturer’s instructions. Representative 
images were captured using a light microscope at 100X magnification. 
 
Colony formation assay 
Cells were seeded at 500 cells per well in 6-well plates and allowed to grow for the times 
indicated in the Figure Legends. The plates were then stained with crystal violet and scanned. 
 
Statistical analyses 
All analyses were performed using GraphPad version 6.04 Prism software (GraphPad, La 
Jolla, CA, USA) and p-values were calculated using the non-parametric Student's t-test. The 
displayed error bars represent the mean  SD. NS represents non-significant p-values; * 
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represents p-values ⩽ 0.05; ** represents p-values ⩽0.01; *** represents p-values ⩽0.001; and 
**** represents p-values ⩽0.0001. Where indicated, fold changes and percent reductions were 
calculated as an average of three independent replicates. 
 
Results  
Characterization of transformed endometriotic cells and their increased migratory response to 
conditioned media from primary senescent endometriotic cells 
To begin to delineate the process involved in the transition from endometriotic precursors 
to ovarian carcinomas, long-term culturable endometriotic cells are necessary. However, due to 
a limitation in the availability of characterized cell lines (i.e., immortalized and/or transformed 
human endometriotic cells), this remains a challenge. Thus, we made attempts to generate 
 
Figure 28. Transformation of human primary endometriotic cells. Schematic depicting the 
overall strategy involving retroviral infections (with control virus (CV) or oncogenic cocktail virus 
(OCV: comprised of H-RasV12A, c-MycT58A, SV40 LTAg, and HA-hTERT)) to generate 
transformed endometriotic from primary cells (PE-A, PE-B, PE-C, and PE-D; * refers to life-
extended PE-D cells with SV40 LTAg) isolated from endometriotic lesions. Two batches of 
transformed endometriotic cells were successfully obtained using PE-A and PE-B primary 
cells.  
Primary Endometriotic Cells
A B C D*
1st Batch 2nd Batch
1st Round of Retroviral Infection
2nd Round of Retroviral Infection
A B A B
PE-A-CV
&
PE-A-OCV
PE-B-CV
&
PE-B-OCV
PE-A-CV
&
PE-A-OCV
PE-B-CV
&
PE-B-OCV
CV = Control Virus 
(Empty pBABE-puro)
OCV = Oncogenic Cocktail Virus 
(H-RasV12A/c-MycT58A/SV40TAg/HA-TERT) 
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endometriotic cell lines that could be maintained in culture long-term without reaching 
senescence. As described in the Methods, we obtained primary cells derived from four different 
human endometriotic lesions: PE-A, PE-B, PE-C and PE-D. We infected these pools of 
endometriotic cells with an oncogenic retrovirion cocktail (termed OCV) containing SV40 LTAg 
(which targets p53 and Rb), hTERT, c-MycT58A, and H-RasV12A (as outlined in Figure 28) based 
on a similar strategy described for fimbrial epithelial cell transformation [172]. We were successful 
in obtaining transformants for the PE-A and PE-B endometriotic cells. We validated expression of 
the oncogenic markers via western blotting (Figure 29A and Figure 29B). While hTERT protein 
 
Figure 29. Western blot validation of cellular transformation of human endometriotic cells. (A) 
The first batch of retrovirally infected cells (PE-A and PE-B, CV and OCV) were utilized to 
obtain cell lysates for western blotting with the indicated antibodies (top panel). The dotted line 
specifies re-run samples to avoid the possibility of detecting overlapping bands of similar 
molecular weights. (B) The second batch of retrovirally infected cells (PE-A-CV and PE-B-CV 
as well as PE-A-OCV and PE-B-OCV) were utilized to obtain cell lysates for western blotting 
with the indicated antibodies (top panel). Densitometric analyses for pAKT and pMAPK are 
shown in the bottom panels.  
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was undetectable (data not shown), expression of LTAg, H-Ras, and c-Myc were clearly 
increased in OCV relative to CV infected cells. Additionally, we noted increased expression of ID1 
and pAKT with reductions in pMAPK, suggestive of bypassing senescence [280]. Indeed, results 
from the colony formation assay (Figure 30A) and -galactosidase staining (Figure 30B) support 
that CV infected cells senesced in contrast to OCV infected cells which were proliferative, lacked 
senescent cells, and demonstrated increased DNA damage foci upon staining with a H2AX 
antibody (Figure 30C). In addition, we noted that PE-A-OCV and PE-B-OCV cells elicited in vitro 
tumorigenic potential (in the 3D morphogenesis assay after 10 days of growth; Figure 31A). We 
also identified increased IL-6 mRNA in OCV infected PE-A and PE-B cells relative to controls  
 
Figure 30. Transformed human endometriotic cells demonstrate increased colony formation, 
reduced senescence, and elevated DNA damage. The first batch of retrovirally infected cells 
(PE-A and PE-B, CV and OCV) were utilized to: (A) perform colony formation assay and images 
were captured following 14 days in culture (representative images are shown, three 
independent experiments were conducted); (B) perform -galactosidase staining and images 
were captured at 100X magnification (representative images are shown, three independent 
experiments were conducted); and (C) assess DNA damage via H2AX immunofluorescence 
staining (representative images shown were captured at 63X magnification and the images of 
nuclei were enlarged and cropped using PowerPoint to focus on the DNA damage foci).  
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(Figure 31B), which has been correlated with increased tumorigenicity [281]. To note, although 
three biological replicates were available for PE-B cells (both CV and OCV infected), statistical 
significance could not be determined for PE-A cells due to limitations in available numbers of CV-
infected cells as a result of reaching senescence (one biological replicate). Collectively, these 
data indicate that we successfully obtained transformed endometriotic cells upon H-RasV12A and 
c-MycT58A overexpression together with p53 inactivation, which are characterized by increased in 
vitro tumorigenic potential.  
Further characterization of these transformed endometriotic cells (PE-A-OCV and PE-B-
OCV) identified markedly elevated mRNA transcripts for EMT pathway genes (SNAIL, SLUG, 
 
Figure 31. Transformed human endometriotic cells show increased sphere formation, IL-6 
mRNA expression, and mRNA expression for EMT markers. The second batch of retrovirally 
infected cells (PE-A and PE-B, CV and OCV) were utilized to: (A) assess the in vitro tumorigenic 
potential (by 3-dimensional morphogenesis assay in Matrigel). Representative images (from 
four independent experiments) were captured at 100X (left) and 200X (right) magnification; (B) 
to measure IL-6 transcript levels via real-time PCR. Three independent experiments were 
performed; and (C) assess transcript levels for genes in the EMT pathway via real-time PCR 
(for mRNA analyses, one experiment was performed with PE-A while three independent 
experiments were performed for PE-B). Error bars represent average ± SD. 
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TWIST, ZEB1, and ZEB2; Figure 31C) relative to their CV infected counterparts suggesting that 
the transformed endometriotic cells may have increased migratory potential. However, we 
unexpectedly discovered that the OCV infected cells were less migratory (~31-39%, p-
value=0.005-0.0014, for PE-A-OCV and PE-B-OCV, respectively; Figure 32 (top and bottom 
panels)) and more cuboidal compared to CV infected cells (Figure 33). Since senescent cells are 
capable of inducing cellular migration of those nearby via secretion of factors, namely the 
senescence-associated secretory phenotype (SASP [282]), we collected conditioned media 
(COM) from senescent cultures of endometriotic cells (CV-infected) and used it as a 
chemoattractant to assess motility (using complete media (CM) as a control). As shown in Figure 
34A (left and right panels), we noted increased migratory capacity of transformed endometriotic 
 
Figure 32. Transformed human endometriotic cells are less migratory than control cells. The 
second batch of retrovirally infected cells (PE-A and PE-B, CV and OCV) were utilized to 
perform migration assay. Representative images (from four independent experiments) were 
captured at 100X magnification (top panel). Manual cell counts are presented in the bottom 
panel. Error bars represent average ± SD. 
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cells with COM media (PE-A-OCV (2.4-fold, p = 0.0550) and PE-B-OCV cells (4.1-fold p < 
0.0001)) compared to CM. This increased migratory phenotype in response to COM media was 
not accompanied by dramatic alterations in EMT marker mRNA expression in the PE-A-OCV and 
PE-B-OCV cells relative to CM-treated (Figure 34B). We next investigated whether the above 
observed phenomena were accompanied by changes in cellular morphology via staining with 
phalloidin; indeed, COM mediated an elongated cell morphological change in the transformed 
endometriotic cells compared to CM-treated cells (Figure 35). Collectively, these data suggest 
that the senescent endometriotic cells are capable of increasing the migratory capacity of nearby 
cells. 
 
 
 
Figure 33. Assessment of Actin filamentation in transformed endometriotic cells. The second 
batch of retrovirally infected cells (PE-B and PE-B, CV and OCV) were utilized to assess actin 
filament organization using phalloidin staining. Representative images (from three independent 
experiments) are shown at 63X (top panel) and 20X (bottom panel) magnification.  
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Transformed endometriotic cells elicit alterations in iron pathway markers including NCOA4 
Oncogenic alterations (associated with increased growth potential) has been reported to 
lead to changes in intracellular iron levels as a result of changes in the expression of iron pathway 
signaling mediators such as the transferrin receptor (CD71), ferroportin (FPN), and ferritin 
complex amongst several others [26, 283-285]. However, whether oncogenic transformation of 
endometriotic cells (as a precursor lesion for specific ovarian cancer subtypes) leads to changes 
in the expression of iron pathway signaling mediators including NCOA4, a novel intracellular 
regulator of intracellular iron levels [3, 30], has not yet been investigated. As described earlier, 
there exists two well-studied NCOA4 isoforms (NCOA4 and NCOA4) with opposing functions 
in breast and prostate cancers [269, 270]. The alignment of NCOA4 (missing an internal 327 
 
Figure 34. Conditioned media from senescent primary endometriotic cells promotes migration 
of transformed endometriotic cells. The second batch of retrovirally infected cells (PE-A-OCV 
and PE-B-OCV) were utilized to: (A) assess migration using either complete media (CM) or 
senescence-conditioned media (COM) as the chemoattractant. Representative images (from 
four independent experiments) are shown at 100X magnification (left panel). Manual cell counts 
are presented in the right panel; (B) assess transcript levels for genes in the EMT pathway via 
real-time PCR using RNA from these cells treated for 24 hours with CM or COM media (three 
independent experiments were performed). Error bars represent average ± SD. 
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amino acid sequence) with a published NCOA4 protein sequence (accession #: Q13772) is 
presented in Figure 36. The role of these isoforms in ovarian cancer remains uninvestigated other 
than one report of increased NCOA4 mRNA levels in ovarian tumor specimens relative to ovarian 
surface epithelium (via in situ hybridization [271]). 
In our transformed endometriotic cells, we observed multiple alterations in iron pathway 
markers including an increase in CD71 and DMT1 (PE-A-OCV and PE-B-OCV) as well as FPN 
and ISCU (PE-B-OCV), with a reduction in FTH1 mRNA (PE-A-OCV and PE-B-OCV; Figure 37). 
To investigate the expression of the two NCOA4 isoforms in these cells, we first needed to 
generate custom-designed probes and primers to target NCOA4 (spanning the junction between 
exon 8 and exon 9) and NCOA4 (spanning the junction between exon 7 and exon 9 (Figure 38A 
depicts the binding location of these probes)) for real-time PCR. The specificity of these probes 
 
Figure 35. Conditioned media from senescent primary endometriotic cells alters Actin 
filamentation. The second batch of retrovirally infected cells (PE-A-OCV and PE-B-OCV) were 
utilized to assess actin filament organization via phalloidin staining in cells treated with CM or 
COM for 24 hours. Representative images (from three independent experiments) are shown at 
63X (top panel) and 20X (bottom panel) magnification.  
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was assessed using RNA isolated from NCOA4 overexpressing T80 cells and NCOA4 
overexpressing HEY cells. Figure 38B demonstrates these probes could distinguish between 
these two splice variants (NCOA4 and NCOA4 mRNA (~8-fold and ~147-fold  increase, 
respectively)) relative to their corresponding controls. As shown in Figure 39A and 39B, a 
corresponding ~2-fold and ~6-fold increase in NCOA4 (70 kDa) and NCOA4 (35 kDa) protein 
was noted. We next identified a ~2.2-2.6-fold (p=0.0084) increase for NCOA4 and a ~1.3-1.6-
fold increase (p=0.0026) for NCOA4 in PE-A-OCV and PE-B-OCV relative to non-transformed 
cells (Figure 40A). These data indicate that cellular transformation of primary endometriotic cells 
leads to increases in the mRNA levels of both NCOA4 isoforms.  
 
Figure 36. Alignment of the NCOA4 and NCO4 protein sequences. Using DiAlign 
software (Genomatix), the protein sequence from our NCOA4 clone was aligned with 
NCOA4 (accession #: Q13772). Dashes represent internally deleted sequence in the 
NCOA4 variant while highlighted regions represent defined binding domains (i.e., 
oligomerization domain (amino acid 17 to 125), two AhR interaction domains (amino acids 
235 to 321 and amino acids 441 to 556), ferritin binding domain (amino acids 383 to 522), 
and two androgen receptor binding motifs (amino acids 92 to 328).  
 
NCOA4-Alpha               1   MNTFQDQSGS SSNREPLLRC SDARRDLELA IGGVLRAEQQ IKDNLREVKA 
NCOA4-Beta                1   MNTFQDQSGS SSNREPLLRC SDARRDLELA IGGVLRAEQQ IKDNLREVKA 
 
NCOA4-Alpha              51   QIHSCISRHL ECLRSREVWL YEQVDLIYQL KEETLQQQAQ QLYSLLGQFN 
NCOA4-Beta               51   QIHSCISRHL ECLRSREVWL YEQVDLIYQL KEETLQQQAQ QLYSLLGQFN 
 
NCOA4-Alpha             101   CLTHQLECTQ NKDLANQVSV CLERLGSLTL KPEDSTVLLF EADTITLRQT 
NCOA4-Beta              101   CLTHQLECTQ NKDLANQVSV CLERLGSLTL KPEDSTVLLF EADTITLRQT 
 
NCOA4-Alpha             151   ITTFGSLKTI QIPEHLMAHA SSANIGPFLE KRGCISMPEQ KSASGIVAVP 
NCOA4-Beta              151   ITTFGSLKTI QIPEHLMAHA SSANIGPFLE KRGCISMPEQ KSASGIVAVP 
 
NCOA4-Alpha             201   FSEWLLGSKP ASGYQAPYIP STDPQDWLTQ KQTLENSQTS SRACNFFNNV 
NCOA4-Beta              201   FSEWLLGSKP ASGYQAPYIP STDPQDWLTQ KQTLENS--- ---------- 
 
NCOA4-Alpha             251   GGNLKGLENW LLKSEKSSYQ KCNSHSTTSS FSIEMEKVGD QELPDQDEMD 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
                                                                                     
NCOA4-Alpha             301   LSDWLVTPQE SHKLRKPENG SRETSEKFKL LFQSYNVNDW LVKTDSCTNC 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
 
NCOA4-Alpha             351   QGNQPKGVEI ENLGNLKCLN DHLEAKKPLS TPSMVTEDWL VQNHQDPCKV 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
 
NCOA4-Alpha             401   EEVCRANEPC TSFAECVCDE NCEKEALYKW LLKKEGKDKN GMPVEPKPEP 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
 
NCOA4-Alpha             451   EKHKDSLNMW LCPRKEVIEQ TKAPKAMTPS RIADSFQVIK NSPLSEWLIR 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
 
NCOA4-Alpha             501   PPYKEGSPKE VPGTEDRAGK QKFKSPMNTS WCSFNTADWV LPGKKMGNLS 
NCOA4-Beta              238   ---------- ---------- ---------- ---------- ---------- 
 
NCOA4-Alpha             551   QLSSGEDKWL LRKKAQEVLL NSPLQEEHNF PPDHYGLPAV CDLFACMQLK 
NCOA4-Beta              238   ---------- -----QEVLL NSPLQEEHNF PPDHYGLPAV CDLFACMQLK 
                                                                                     
NCOA4-Alpha             601   VDKEKWLYRT PLQM 
NCOA4-Beta              273   VDKEKWLYRT PLQM 
Oligomerization DomainAR Binding Motif
AR Binding Motif
AhR interacting Domain
Ferritin Binding Domain
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Figure 37. Expression of iron pathway mediators are altered in transformed endometriotic 
cells. Transcript levels for genes in the iron pathway were assessed via real-time PCR using 
RNA extracted from the second batch of PE-A and PE-B, CV and OCV cells. One experiment 
was performed with PE-A while three independent experiments were performed for PE-B. 
Error bars represent average ± SD. 
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Figure 38. Validation of real-time PCR probes/primers for NCOA4 isoforms. (A) The location 
of the probes to detect total NCOA4 (Assays-on-Demand) and NCOA4 and NCOA4 
(Assays-by-Design) are shown. (B) RNA isolated from NCOA4 overexpressing T80 and 
NCOA4 overexpressing HEY cells was utilized to validate the available NCOA4 probe/primer 
sets.  
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Figure 39. Validation of NCOA4 overexpression in T80 and HEY cell lines. (A) Cell lysates 
from control and NCOA4 overexpressing T80 cells were analyzed by western blotting with 
the indicated antibodies (left panel). Densitometric analysis is presented (right panel). (B) Cell 
lysates from control and NCOA4 overexpressing HEY cells were analyzed by western blotting 
with the indicated antibodies (left panels). Densitometric analysis for NCOA4 is presented 
(right panels).  
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Figure 40. Expression of NCOA4 variants are altered in transformed endometriotic cells. (A) 
Transcript levels for genes in the iron pathway were assessed via real-time PCR using RNA 
extracted from the second batch of PE-A and PE-B, CV and OCV cells. One experiment was 
performed with PE-A while three independent experiments were performed for PE-B. (B) 
Western analyses of cytoplasmic and nuclear fractions from T80, HEY, and the first batch of 
PE-A-OCV cells were performed using the indicated antibodies. Data shown is representative 
of three independent experiments, and error bars represent average ± SD. 
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NCOA4 is localized predominantly to the cytoplasm and modulates cellular viability of T80, HEY, 
and PE-A-OCV cells 
Since there is evidence describing the localization of NCOA4 isoforms in the cytosolic and 
nuclear compartments of prostate tissues (possibly to mediate its function as a hormone receptor 
coactivator [268, 286-288]), we next investigated the localization of this iron mediator in our 
gynecological cells. As shown in Figure 40B, we identified that NCOA4 was localized 
predominantly to the cytoplasmic fraction (with no detectable expression in the nuclear fraction) 
in T80, HEY, and PE-A-OCV cells; to note, NCOA4 protein was not detected in these cells (data 
not shown).  
To investigate the role of NCOA4 in gynecological cell survival and determine whether its 
activity is altered upon exposure to iron, we reduced NCOA4 levels (using an siRNA approach) 
in normal/benign immortalized cells (T80 and T-HESC), in transformed human endometriotic cells 
 
Figure 41. NCOA4 knockdown alters p21 protein expression in T80, HEY, and PE-A-OCV cells. 
Cell lysates from NCOA4 siRNA treated T80, HEY, TOV21G, T-HESC, and the second batch 
of PE-A-OCV (treated for 18 hours with 250M FAC) were analyzed by western blotting using 
the indicated antibodies. Data shown are representative of three independent experiments.  
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(PE-A-OCV), and in OVCA cell lines (HEY and TOV21G). In addition, we tested the effect of 
NCOA4 knockdown in the absence or presence of ferric ammonium citrate (FAC) as we previously 
tested the effects of iron overload conditions (using FAC) in HEY cells [233]. As shown in Figure 
41, NCOA4 protein was reduced upon knockdown by ~65% in T80, ~75% reduction in HEY, ~55% 
in T-HESC, ~65% in TOV21G, and ~50% in PE-A-OCV (we identified reduced NCOA4 mRNA 
using a real-time PCR probe/primer detecting all isoforms (~74% in T80, ~94% in HEY, and ~71% 
in PE-A-OCV cells (Figure 42); see Figure 43A for NCOA4 isoform specific probes/primers real-
time PCR data). NCOA4 protein was not further altered by FAC (Figure 41). The NCOA4 antibody 
also detected a ~55kDa immunoreactive band that has been previously reported [289] which we 
found to be reduced upon NCOA4 knockdown; the identity of this band remains unclear. Upon 
 
Figure 42. NCOA4 knockdown alters mRNA expression of iron mediators in T80, HEY, and 
PE-A-OCV cells. Using RNA isolated from T80, HEY and the second batch of PE-A-OCV 
treated with NCOA4 siRNA, transcript levels for genes in the iron, EMT, lysosome/autophagy 
pathways were measured via real-time PCR. Three independent experiments were performed, 
and error bars represent average ± SD.  
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reduction of NCOA4, we observed increases in FTH1 protein in all cell lines whereas increases 
in p21 (cyclin-dependent kinase inhibitor which is elevated under conditions of growth arrest [290]) 
were identified in T80 (~3.5-fold), HEY (~2-fold), and PE-A-OCV cells (~2-fold). In this respect, 
we determined that there was an association between elevated p21 (following NCOA4 
knockdown) with inactivated p53 (in T80 and PE-A-OCV cells which express LTAg which binds 
to p53 (results not shown and [150])) or undetectable p53 (in HEY cells (results not shown)) 
whereas T-HESC and TOV21G have wild type p53 levels (results not shown and [291]) and were 
not associated with changes in p21 levels with reduced NCOA4. Knockdown of NCOA4 reduced 
cellular viability by ~31%, 36%, and 33% in T80, HEY, and PE-A-OCV cells, respectively (Figure 
43B).  
 
Figure 43. NCOA4 knockdown reduces cellular viability in T80, HEY, and PE-A-OCV cells. (A) 
T80, HEY, and second batch of PE-A-OCV cells were treated with control or NCOA4 siRNA. 
Isolated RNA was utilized to assess transcript levels of NCOA4 and NCOA4 via real-time 
PCR. Three independent experiments were performed. (B) Cellular viability (via ATP 
measurements) was assessed upon NCOA4 knockdown in T80, HEY, and the second batch 
of PE-A-OCV (2nd batch) cells. Three independent experiments were performed, and Error bars 
represent average ± SD. 
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We additionally observed increases in FTH1 (T80 cells), CD71 (T80 and HEY cells), and 
FPN (T80 and PE-A-OCV cells) mRNA levels (Figure 42). Since NCOA4 is a regulator of 
ferritinophagy, we also examined the transcript profile for genes involved in autophagosome or 
lysosome formation. In this regard, we identified increases in SQSTM1 (~1.5-fold (T80) and ~2-
fold (HEY)) involved in autophagic flux [292] and in MCOLN1 (~1.2-fold (T80)) involved in iron 
transport to lysosomes [293]. Since cellular viability was reduced with NCOA4 siRNA, we next 
investigated the effect of NCOA4 knockdown on markers of tumorigenicity including those 
involved in EMT progression and identified an increase in SNAIL (~1.6-fold in both T80 and PE-
A-OCV cells) with a decrease in SLUG (~28% in PE-A-OCV cells) and TWIST (~55% in HEY 
cells) transcripts which further implicate NCOA4 in promoting cellular survival. 
 
 
Figure 44. Cellular responses to NCOA4 knockdown is altered in response to factors present 
in FBS. (A) HEY cells were treated with control or NCOA4 siRNA in the absence (-PR) or 
presence (+PR) of serum  factor-replete media. Cell lysates were analyzed by western blotting 
using the indicated antibodies. Data shown is representative of three independent experiments. 
(B) Cellular viability (assessed via ATP levels) of HEY cells was assessed following knockdown 
of NCOA4 (via siRNA) and treatment for 24 hours with +PR or -PR media. Three independent 
experiments were performed, and error bars represent average ± SD. 
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Expression of NCOA4 is regulated by factors present within serum 
Fetal bovine serum, commonly used for promoting cell growth and attachment, consists 
of multiple factors (such as growth factors, cytokines, hormones, and other lipophilic proteins) 
which can be removed by charcoal-dextran treatment [294]. To assess whether our observed 
biochemical and functional changes mediated by NCOA4 are dependent on these above-
described factors, we utilized media deficient in phenol red and charcoal-dextran treated FBS (–
PR) following NCOA4 knockdown. We completed these analyses using HEY as these cells 
showed a more robust cellular effect in response to NCOA4 knockdown relative to T80 and PE-
A-OCV cells. As shown in Figure 44A, the use of –PR media increased LC3B-II, FTH1, and p21 
basal protein expression relative to complete (+PR) media; FTH1 and p21 protein were not further 
altered upon NCOA4 knockdown in –PR media. We also noted that cell viability was reduced in 
HEY cells in –PR relative to +PR conditions, with either control or NCOA4 siRNA (Figure 44B). 
 
Figure 45. mRNA expression of NCOA4, CD71, and SQSTM1 are altered in response to factors 
present in FBS. RNA was isolated from HEY cells treated with NCOA4 siRNA in +PR or -PR 
media for 24 hours and utilized for real-time PCR to assess transcript levels for total NCOA4, 
CD71, TWIST, and SQSTM1. Three independent experiments were performed, and Error bars 
represent average ± SD. 
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While we observed significant reduction of NCOA4 mRNA upon NCOA4 knockdown under both 
media conditions (+PR and –PR), the NCOA4 mRNA (assessed with the commercially available 
Taqman probe and primers) increased by ~2-fold (p=0.0027) in –PR conditions suggesting that 
the presence of these serum factors could potentially inhibit NCOA4 transcription (Figure 45, top 
left panel). Although CD71 mRNA increased upon NCOA4 knockdown (relative to control siRNA) 
in +PR media (~3.6-fold, p=0.0046), this increase was reduced in –PR media (~1.4-fold, 
p=0.0761). We noted a further reduction in TWIST mRNA in –PR media upon NCOA4 siRNA 
treatment relative to control siRNA (~65% reduction, p=0.0012 compared to ~55% reduction, 
p=0.0002). Further, SQSTM1 mRNA was not as markedly increased with NCOA4 siRNA 
(compared to control siRNA) in -PR media (~10-fold (p=0.0027) relative to ~27-fold (p=0.0009)). 
 
Figure 46. NCOA4 overexpression in T80, HEY, and PE-A-OCV cells reduces colony forming 
ability. Control and NCOA4 overexpressing T80, HEY, and the first batch of PE-A-OCV cells 
were utilized to: (A) analyze protein lysates by western blotting with the indicated antibodies. 
Three independent replicates are shown and error bars represent average ± SD; (B) assess 
cellular viability (measured by ATP levels). Three independent experiments were performed; 
and (C) to assess colony formation ability after 14 days in culture. Representative images 
(from three independent experiments) are shown. 
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Collectively, these results implicate the involvement of these factors in the functional responses 
of NCOA4 in ovarian cancer cells. 
 
Overexpression of NCOA4 reduces colony forming potential 
Since NCOA4 appears to regulate cellular viability in our gynecological cells (see Figure 
43), we next investigated whether NCOA4 could elicit antagonistic function similar to that 
reported in breast and prostate cancers [269, 270]. We thus generated NCOA4 overexpressing 
T80, HEY, and PE-A-OCV cell lines. There were only slight changes in p21 protein expression (in 
T80 and HEY; Figure 46A), and no changes in short-term viability with the exception of PE-A-OC 
cells which elicited a ~40% reduction in growth (p=0.0129; Figure 46B). However, we did note a 
marked reduction in colony forming ability (Figure 46C). NCOA4 was primarily cytoplasmic in 
localization (Figure 47A) similar to prostate specimens [269, 287]. NCOA4 overexpression did 
 
Figure 47. Overexpressing NCOA4 does not alter response of HEY cells to factors present in 
FBS. Control and NCOA4 overexpressing HEY cells were used to: (A) analyze cytoplasmic 
and nuclear fractions by western blotting with the indicated antibodies. Data shown is 
representative of three independent experiments, and (B) assess cellular viability (measured via 
ATP levels) following a 3 day exposure to –PR media or 250M FAC. Three independent 
experiments were performed, and error bars represent average ± SD. 
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not alter cellular response of HEY cells to charcoal-dextran treated FBS containing media (–PR 
[295]) and iron overload conditions (250 M FAC [233, 296]; Figure 47B). However, we did 
observe that p21 protein was increased in –PR media (independently of NCOA4 overexpression) 
and in FAC-treated NCOA4 overexpressing cells (Figure 48A). FAC treatment increased FTH1 
protein (as expected) and was independent of NCOA4 overexpression. In contrast, LC3B-II was 
increased in response to -PR conditions and in response to FAC but was reduced with NCOA4 
overexpression in –PR conditions (Figure 48A). We additionally observed that NCOA4 protein 
was reduced and NCOA4 protein was increased –PR relative to +PR replete media (Figure 
48A). Specifically, in control cells relative to +PR, –PR media resulted in a reduction in NCOA4 
(~27%, p=0.0600) and an increase in NCOA4 mRNA (~1.3-fold, p=0.0191) levels (Figure 48B). 
Further, in NCOA4 overexpressing cells relative to +PR, –PR conditions resulted in a reduction 
in NCOA4 (~48%, p=0.0145) and an increase in NCOA4 mRNA (~5-fold, p<0.0001) levels. We 
 
Figure 48. Using control and NCOA4 overexpressing HEY cells: (A) cell lysates (in cells 
treated with serum factor-depleted (-PR) media for 24 hours or 250M FAC for 18 hours) were 
analyzed by western blotting with the indicated antibodies. Data shown is representative of 
three independent experiments; and (B) Transcript levels for NCOA4 and NCOA4 were 
assessed via real-time PCR (cells exposed to -PR media for 24 hours or 250M FAC for 18 
hours). Three independent experiments were performed, and error bars represent average ± 
SD. 
A
C
T
-p
B
p
 +
P
R
C
T
-p
B
p
 -
P
R
C
T
-p
B
p
 F
A
C
N
b
e
ta
-p
B
p
 +
P
R
N
b
e
ta
-p
B
p
 -
P
R
N
b
e
ta
-p
B
p
 F
A
C
0 .0
0 .5
1 .0
1 .5
N C O A 4 -a lp h a _ U P D A T E
R
N
A
-F
o
ld
 C
h
a
n
g
e
Column B
v s.
Column A
Unpaired t test
P v alue
P v alue summary
CT-pBp -PR
v s.
CT-pBp +PR
0.0600
ns
Column C
vs.
Column A
Unpaired t test
P value
P value summary
CT-pBp FAC
vs.
CT-pBp +PR
0.6699
ns
Column D
v s.
Column A
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp +PR
v s.
CT-pBp +PR
0.2484
ns
Column E
v s.
Column B
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp -PR
v s.
CT-pBp -PR
0.3583
ns
Column F
vs.
Column C
Unpaired t test
P value
P value summary
Nbeta-pBp FAC
vs.
CT-pBp FAC
0.9834
ns
Column E
v s.
Column D
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp -PR
v s.
Nbeta-pBp +PR
0.0145
*
Column F
vs.
Column D
Unpaired t test
P value
P value summary
Nbeta-pBp FAC
vs.
Nbeta-pBp +PR
0.3860
ns
*
R
N
A
 F
o
ld
 C
h
a
n
g
e
NCOA4
Control NCOA4 C T
-p
B
p
 +
P
R
C
T
-p
B
p
 -
P
R
C
T
-p
B
p
 F
A
C
N
b
e
ta
-p
B
p
 +
P
R
N
b
e
ta
-p
B
p
 -
P
R
N
b
e
ta
-p
B
p
 F
A
C
0
2
4
1 5 0
2 5 0
3 5 0
7 0 0
8 0 0
9 0 0
N C O A 4 -b e ta _ U P D A T E
R
N
A
-F
o
ld
 C
h
a
n
g
e
Column B
vs.
Column A
Unpaired t test
P value
P value summary
CT-pBp -PR
vs.
CT-pBp +PR
0.0191
*
Column C
v s.
Column A
Unpaired t test
P v alue
P v alue summary
CT-pBp FAC
v s.
CT-pBp +PR
0.4502
ns
Column D
v s.
Column A
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp +PR
v s.
CT-pBp +PR
< 0.0001
****
Column E
vs.
Column B
Unpaired t test
P value
P value summary
Nbeta-pBp -PR
vs.
CT-pBp -PR
< 0.0001
****
Column F
v s.
Column C
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp FAC
v s.
CT-pBp FAC
0.0002
***
Column E
vs.
Column D
Unpaired t test
P value
P value summary
Nbeta-pBp -PR
vs.
Nbeta-pBp +PR
< 0.0001
****
Column F
v s.
Column D
Unpaired t test
P v alue
P v alue summary
Nbeta-pBp FAC
v s.
Nbeta-pBp +PR
0.0179
*
*
****
*
****
****
***
R
N
A
 F
o
ld
 C
h
a
n
g
e
NCOA4
Control NCOA4
C
o
n
tr
o
l
HEY
N
C
O
A
4
β
+PR     
N
C
O
A
4
β
N
C
O
A
4
β
C
o
n
tr
o
l
C
o
n
tr
o
l
p21
17 kDa
FTH117 kDa
76 kDa
52 kDa
31 kDa
38 kDa
NCOA4
NCOA4β
Pan-Actin
LC3B-I
LC3B-II
17 kDa
12 kDa
52 kDa
-PR     +FAC    
B
96 
 
noted that these mRNA changes were consistent at the protein level (see Figure 48A). These 
results suggest that NCOA4 is negatively regulated by the presence of factors present in serum. 
 
NCOA4 protein expression is increased in malignant ovarian cancer cell lines and in subtypes of 
human OVCA  
To the best of our knowledge, there is limited information on the expression of NCOA4 in 
clinical specimens; one report describes an increase in NCOA4 mRNA in invasive ovarian 
carcinomas (compared to non-malignant controls) via in situ hybridization [271]. We therefore 
assessed the expression of NCOA4 splice variants in patient-derived cell lines and ovarian cancer 
 
Figure 49. Increased NCOA4 expression in malignant gynecological cells. (A) RNA isolated 
from T80, FT194, and PE-A-OCV (non-malignant) as well as HEY, TOV21G, and TOV112D 
(malignant) cells were used to assess transcript levels for NCOA4 and NCOA4 via real-time 
PCR. Three independent experiments were performed. (B) Cell lysates from these non-
malignant and malignant cell lines were analyzed by western blotting using the indicated 
antibodies. Densitometric analyses is shown in the right panel. Data shown is representative 
of three independent experiments, and error bars represent average ± SD. 
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tissue specimens. With regard to cell lines, we assessed non-malignant (T80, FT194, and PE-A-
OCV) and malignant (HEY, TOV21G, and TOV112D) gynecological cell types in which we 
identified increased NCOA4 (~2.5-fold, p=0.0173) and NCOA4 (~2.5-fold, p=0.06) mRNA in 
malignant compared to non-malignant cell lines (Figure 49A). We also identified increased 
NCOA4 protein in malignant gynecological cells (~2.5- and ~2.9-fold in HEY (relative to T80 and 
FT194, respectively, as precursors, and ~1.9-fold in TOV112D (relative to PE-A-OCV as 
precursor); Figure 49B). As shown in Figure 50, immunohistochemical staining for NCOA4 
revealed that it was significantly increased in a subset of ovarian tumors relative to normal 
adjacent tissues: 1) serous adenocarcinoma (total, moderate, and weak positive), 2) serous 
papillary (moderate and weak positive), and 3) mucinous (weak positive). Overall, these data 
 
Figure 50. Increased NCOA4 expression in human OVCA tissues. Protein expression of 
NCOA4 was assessed in a human ovarian cancer TMA. Positive analyses was completed 
using the scanned image in ImageScope. Representative images of individual cores were 
captured at 6X magnification (left panel) and positive core analyses is presented in the right 
panel. Error bars represent average ± SD. 
Normal Adjacent Tissue (NAT)
Clear Cell (CC)
Serous Papillary (SP)
Mucinous (M)
Endometrioid (E)
Metastatic (Met)
N
o
rm
a
l 
A
d
ja
c
e
n
t 
T
is
s
u
e
C
le
a
r  
C
e
ll
S
e
ro
u
s
 P
a
p
il
la
ry
S
e
ro
u
s
 A
d
e
n
o
c
a
rc
in
o
m
a
M
u
c
in
o
u
s
E
n
d
o
m
e
tr
io
id
M
e
ta
s
ta
s
e
s
0
2 0
4 0
6 0
%  T o ta l P o s it iv ity
P
e
r
c
e
n
t
Serous Adenocarcinoma
vs.
Normal Adjacent Tissue
0.0111
*
Yes
N
o
rm
a
l 
A
d
ja
c
e
n
t 
T
is
s
u
e
C
le
a
r  
C
e
ll
S
e
ro
u
s
 P
a
p
il
la
ry
S
e
ro
u
s
 A
d
e
n
o
c
a
rc
in
o
m
a
M
u
c
in
o
u
s
E
n
d
o
m
e
tr
io
id
M
e
ta
s
ta
s
e
s
0
1 0
2 0
3 0
4 0
%  W e a k  P o s it iv ity
P
e
r
c
e
n
t
Serous Adenocarcinoma
vs.
Normal Adjacent Tissue
0.0122
*
Yes
Clear Cell
vs.
Normal Adjacent Tissue
0.0068
**
Yes
Mucinous
vs.
Normal Adjacent Tissue
0.0083
**
Yes
N
o
rm
a
l 
A
d
ja
c
e
n
t 
T
is
s
u
e
C
le
a
r  
C
e
ll
S
e
ro
u
s
 P
a
p
il
la
ry
S
e
ro
u
s
 A
d
e
n
o
c
a
rc
in
o
m
a
M
u
c
in
o
u
s
E
n
d
o
m
e
tr
io
id
M
e
ta
s
ta
s
e
s
0
1 0
2 0
3 0
%  M o d e ra te  P o s it iv ity
P
e
r
c
e
n
t
Serous Papillary
vs.
Normal Adjacent Tissue
0.0482
*
Yes
Serous Adenocarcinoma
vs.
Normal Adjacent Tissue
0.0196
*
Yes
N
o
rm
a
l 
A
d
ja
c
e
n
t 
T
is
s
u
e
C
le
a
r  
C
e
ll
S
e
ro
u
s
 P
a
p
il
la
ry
S
e
ro
u
s
 A
d
e
n
o
c
a
rc
in
o
m
a
M
u
c
in
o
u
s
E
n
d
o
m
e
tr
io
id
M
e
ta
s
ta
s
e
s
0
2
4
6
8
%  S tro n g  P o s it iv ity
P
e
r
c
e
n
t
P
e
rc
e
n
t 
S
tr
o
n
g
 P
o
s
it
iv
e
P
e
rc
e
n
t 
M
o
d
e
ra
te
 P
o
s
it
iv
e
P
e
rc
e
n
t 
W
e
a
k
 P
o
s
it
iv
e
*
*
*
**
**
P
e
rc
e
n
t 
T
o
ta
l 
P
o
s
it
iv
e *
6
1
2
3
40
10
2
3
20
4
6
98 
 
show that NCOA4 mRNA (NCOA4 and NCOA4 as well as protein (NCOA4) expression is 
increased in ovarian cancers relative to controls. 
 
NCOA4 protein is regulated via a proteasome- and autophagy-independent mechanism 
NCOA4 has been shown to be regulated in an iron-dependent manner by the E3 ubiquitin 
ligase HERC2 when intracellular iron levels increase [191]. To assess NCOA4 protein regulation, 
we treated our gynecological cells (T80, HEY, TOV21G, T-HESC, and PE-A-OCV) for 18 hours 
with MG132 (a proteasome inhibitor, at 5 M) or cycloheximide (CHX, a translational inhibitor, at 
2g/ml) in the absence or presence of FAC (250M). We observed that NCOA4 protein was 
reduced upon MG132 treatment in all cell lines, independent of FAC treatment suggesting that 
 
Figure 51. NCOA4 protein is regulated in a proteasome-independent manner. Cell lysates from 
untreated T80, HEY, TOV21G, T-HESC, and PE-A-OCV or cells treated for 18 hours with 5M 
MG132, 2g/ml CHX, 250M FAC or a combination of MG132 with FAC or CHX with FAC were 
analyzed by western blotting with the indicated antibodies. Data shown is representative across 
three independent experiments. 
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NCOA4 is regulated in a proteasome-independent manner (Figure 51). Furthermore, NCOA4 
expression was reduced upon CHX treatment in all cell lines assessed, independent of FAC 
treatment suggesting that translation is an important contributor to NCOA4 protein levels (Figure 
51). Since we also observed an increase in LC3B-II upon MG132 treatment (implicating increased 
autophagic flux [297]), we next investigated whether NCOA4 was degraded via the autophagic 
pathway. As shown in Figure 52, LC3B knockdown in MG132 treated cells did not rescue NCOA4 
protein expression suggesting an alternative mechanism of NCOA4 regulation. 
 
Discussion 
In vitro studies for the investigation of the transition from endometriosis to clear cell and/or 
endometrioid ovarian cancers has been challenging due to the limitation and availability of long-
term cultures of endometriotic cells. Herein, we have successfully generated transformed 
endometriotic cells via overexpression of H-RasV12A, c-MycT58A, along with p53 inactivation. These 
alterations represent those that occur early in the development of ovarian cancers. Specifically, 
in clear cell ovarian cancers, Ras mutations [298] and c-Myc amplifications [27] are prominent in 
 
Figure 52. NCOA4 protein is regulated in a proteasome- and autophagy-independent manner. 
Cell lysates from non-targeting control or LC3B siRNA transfected HEY cells treated in the 
absence or presence of 5M MG132 were analyzed by western blotting with the indicated 
antibodies. Data shown is representative across three independent experiments. 
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addition to PIK3CA and PTEN alterations [299] which is expected to lead to increased tumorigenic 
potential associated with “iron addiction” [300]. Mutations in p53 are not commonly observed (only 
~10%) in ovarian clear cell carcinomas (OCCC) [301, 302], although one conflicting report 
suggests this is a common mutation in all OVCA subtypes [60]. Indeed, iron is a potent carcinogen 
that increases ROS causing cellular damage [199]. Endometriomas are characterized by elevated 
heme and iron content [208] which is thought to contribute to the transition to specific subtypes of 
ovarian cancers. Regulation of intracellular iron levels is mediated via various means including 
receptors (CD71 and FPN) that allow its import and export as well as storage molecules (ferritin) 
[265]. NCOA4 (represented by two well studied isoforms) is not only a recently identified molecule 
 
Figure 53. Schematic summarizing the results presented in Chapter 3. mRNA expression of 
NCOA4 and NCOA4 are increased in transformed endometriotic cells (compared to non-
transformed controls) and malignant OVCA cell lines (compared to non-malignant 
gynecological cell lines). NCOA4 protein is increased in malignant OVCA cell lines (compared 
to non-malignant gynecological cell lines). In addition, total NCOA4 protein was increased in a 
subset of human OVCA tumors (compared to normal adjacent tissues). Modulation of NCOA4 
expression in T80, HEY, and PE-A-OCV cells led to changes in cellular survival. 
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mediating regulation of intracellular iron content in a ferritinophagic pathway [3, 30] but also as a 
player in modulating hormone functions as a nuclear co-activator [267, 268, 288]. Other reported 
functions for NCOA4 include (a) regulation of DNA replication to modulate DNA stability [303], (b) 
modulation of DNA damage response and cellular senescence [304], and (c) increasing cellular 
proliferation and migration/invasion of breast as well as prostate cancer cells [269, 270]. Herein 
(as shown in Figure 53), we have defined that NCOA4 is elevated in transformed endometriotic 
cells (relative to non-transformed cells), in malignant ovarian cancer cells and in a subset of 
ovarian tumors. Moreover, we have demonstrated that NCOA4 isoforms have the capacity to alter 
gynecological cell survival.  
Transcriptional regulation of NCOA4 mediated by oncogenes has not been previously 
reported. Transformation of immortalized fallopian tube fimbriae with SV40 LTAg and c-Myc 
increases CD71 and decreases FPN protein [26]. Further, H-Ras, c-Myc, and E1A are reported 
to regulate ferritin levels which leads to increased intracellular labile iron and proliferative indices 
[265, 283-285, 305]. We propose that the combination of H-Ras, c-Myc, and p53 inactivation 
contributes to NCOA4 mRNA transcription. Further work is needed to identify potential c-Myc 
binding sites in the promoter region of NCOA4 as well as determining whether inhibition of the 
MAPK pathway could antagonize NCOA4 transcription or whether p53 inhibits NCOA4 
expression. Although we identified that reduction of NCOA4 levels led to reduced cellular survival, 
we did not measure intracellular labile iron pool in our transformed endometriotic cells which 
would clarify whether it supports cellular survival in an iron- and/or hormone-dependent manner. 
In this regard, our subcellular localization data placing NCOA4 in the cytoplasmic compartment 
for both isoforms implicates its role in both functions. This is in contrast to the NCOA4 localization 
in prostate cancer specimens in which the NCOA4 isoform is localized to the cytoplasmic 
compartment and the NCOA4 isoform is localized in the nuclear compartment [287].  
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From TCGA analyses, the DNA copy number of NCOA4 is not markedly altered compared 
to CD71 which is notably amplified (>25%). We propose that NCOA4 is instead dysregulated at 
the protein level as a result of altered HERC2 E3 ubiquitin ligase activity; indeed, HERC2 is 
mutated up to 20% in various cancers (obtained from cBioportal [306, 307]). While NCOA4 is 
known to be ubiquitinated by HERC2 (for proteasome degradation) in an iron-dependent manner 
[191], we found that proteasome inhibition with FAC treatment did not prevent NCOA4 protein 
degradation in our gynecological cells. Furthermore, NCOA4 protein remained reduced upon 
proteasome inhibition with autophagy inhibition (via siRNA-mediated knockdown of LC3B), 
suggesting that NCOA4 is regulated in a proteasome- and autophagy-independent manner in our 
gynecological cells. Our preliminary investigation to identify HERC2 mutations (which may inhibit 
its E3 ligase function) using the TCGA database [306, 307], uncovered a commonly mutated 
residue (R2126) which is expected to be “probably damaging” (assessed by PolyPhen-2 [308]) to 
the protein structure. Further investigations are needed to elucidate the mechanisms underlying 
NCOA4 protein dysregulation in ovarian cancer. 
Since we identified a marked further increase in NCOA4 mRNA in NCOA4 
overexpressing cells when maintained in –PR media (relative to +PR media), we propose that 
one or more factors contained within FBS may regulate NCOA4 expression; these factors may 
include lipophilic proteins including hormones, growth factors, and cytokines [309]. Indeed, 
NCOA4 is involved in regulating hormone responses (via its action as a nuclear receptor 
coactivator for androgen and estrogen receptors [268, 269, 288]) in addition to its novel role as a 
mediator of intracellular iron levels (as a ferritinophagic mediator [3, 30]); we propose that NCOA4 
may be involved in OVCA biology by both mechanisms of action. Prior data identifies links 
between estrogen/androgen levels (hormones) and iron signaling; for example, there is an inverse 
relationship between estrogen and body iron levels in post-menopausal women [310]. 
Furthermore, estrogen is well-established to regulate FPN by binding to estrogen response 
elements (ERE) within its promoter region [311]. Estrogen is an important contributor to ovarian 
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cancer development [312] and can itself modulate p53 expression [313] which transcriptionally 
regulates ISCU expression leading to changes in ferritin and CD71 levels [314]. However, further 
investigations are needed to fully elucidate the roles of NCOA4 and NCOA4 in OVCA biology 
as well as their response to –PR media conditions.  
Our findings support a need for further investigations on regulatory mechanisms 
underlying NCOA4 isoform expression and function in specific subtypes of ovarian cancers. To 
this end, developing a combination NCOA4 knockout mice [30] with an OVCA mouse model [6] 
may provide insight into the role of NCOA4 in OVCA biology. 
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Chapter 4 
 
Chronic Iron Exposure and c-Myc/H-Ras-Mediated Transformation in Fallopian Tube 
Precursors Alters Expression of EVI1, Amplified at 3q26.2 in Serous Epithelial Ovarian 
Cancer 
 
Note to Reader 
The results presented herein are as submitted in March 2019 (Rockfield, S., Kee, Y., and 
Nanjundan, M., 2019), albeit with minor modifications and re-formatted for this dissertation. 
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Introduction 
Ovarian Cancer (OVCA) is the 5th deadliest cancer, and the most lethal cancer in women 
in the United States [315]. The etiology of this disease remains unclear, which has made it difficult 
to improve early detection and therapeutic strategies for these patients [316-318]. Recent 
research supports the hypothesis that serous epithelial ovarian cancer (HGSOC, the most 
commonly diagnosed subtype [317]) may arise from fallopian tube epithelium (FTE [171]) or from 
ovarian surface epithelium (OSE) [319]). Well-defined characteristics of HGSOC include 
inactivated p53, mutant BRCA1/2, homozygous deletion of PTEN, hyperactive Ras-MAPK 
signaling, elevated expression of Pax8 (paired box protein 8, a transcription factor), and elevated 
telomerase reverse transcriptase (hTERT) [62]. In addition, TCGA-defined genomic amplifications 
include those at 3q26 (harboring ecotropic viral integration site 1 (EVI1) amongst other genes 
including the RNA component of telomerase (TERC)) and 8q24 (harboring the proto-oncogene c-
Myc) [29, 62, 65, 171, 173, 306, 307, 320]. However, the early events that mediate the transition 
from precursors such as fallopian tube secretory epithelial cells (FTSECs) to HGSOC have yet to 
be determined.  
Catalytic iron, which mediates the generation of reactive oxygen species (ROS) through 
its involvement in Fenton reactions leading to lipid peroxidation and DNA damage [34], can 
contribute to the pathogenesis of specific cancer types such as colorectal cancers [321]. 
Specifically in epithelial ovarian cancers, it is well defined that rare subtypes including 
endometrioid and clear cell may develop as a result of prolonged exposure to elevated catalytic 
iron present within endometriotic cysts (proposed precursor lesion) [35, 208]. Other sources of 
microenvironmental catalytic iron within the pelvic cavity (i.e., accumulating within the Douglas 
Pouch) could arise due to ovulation, retrograde menstruation, and follicular rupture; elevated 
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systemic iron may arise as a result of an iron overload condition such as hemochromatosis [153, 
206, 207, 322]. Iron overload is characterized by elevated non-transferrin-bound iron (NTBI) [323] 
and ferric ammonium citrate (FAC) is an appropriate source to investigate its effect [324]. To our 
knowledge, NTBI has not yet been previously investigated as a factor involved in ovarian cancer 
pathogenesis although a positive correlation between hemochromatosis and ovarian cancer risk 
has been reported [325]. Although recent published data using immortalized FTSECs 
demonstrates that transferrin-bound iron can increase intracellular ROS and DNA damage [209] 
and a NTBI source increases cellular proliferation in primary fimbrial cells (associated with 
increased c-Myc, MAPK, and AKT activation) [214], the contribution of physiological NTBI to 
HGSOC disease pathogenesis remains uninvestigated.  
Herein, we chronically maintained two proposed precursors to HGSOC (immortalized OSE 
cells (T80) or immortalized FTSECs) in media supplemented with FAC between two to four 
months. We compared their outcome to a FTSEC cell line that we transformed by overexpressing 
the constitutively active forms of H-Ras and c-Myc. While T80 cells showed reduced cell numbers 
in response to chronic NTBI treatment, we observed increased cell numbers, migratory capacity, 
and increased DNA damage/repair proteins (i.e., FANCD2) in FAC-treated relative to untreated 
FTSECs (maintained concurrently in culture). Although the transformed FTSECs similarly showed 
increased clonogenic potential and cell numbers, they displayed reduced cellular migration 
capacity. Assessment of the expression of oncogenes frequently associated with HGSOC 
(including EVI1 variants, Myc, BMI1, and Cyclin D1) identified that these were markedly elevated 
in FTSECs with either chronic iron treatment or cellular transformation. We also noted differences 
between their expression profiles of hTERT mRNA and -catenin protein, suggesting that the 
observed functional outcomes may be mediated via different mechanisms. EVI1 knockdown 
(using siRNA targeting multiple splice variants) attenuated the increased hTERT mRNA 
expression upon chronic iron treatment, whereas EVI1 itself was regulated independently of -
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catenin, BMI1, or autophagic pathways. The observed changes in EVI1 and Myc were not 
reversed when chronic FAC-treated cells were maintained in FAC-deficient media suggesting the 
acquisition of permanently acquired alterations. Together, our results suggest that iron may 
enable the transition of fallopian tube precursor lesions via altering the expression patterns for 
some of the key oncogenic factors identified in OVCA. Thus, the presence of iron within the pelvic 
cavity may be a potential risk factor in disease development and could be targeted as a strategy 
to reduce tumor burden.  
 
Materials and Methods  
Cell culture and treatments 
Human immortalized (expressing SV40 Large T Antigen (LTAg) and human telomerase 
reverse transcriptase (hTERT)) normal ovarian surface epithelial T80 cells were kindly provided 
by Dr. Gordon Mills (MD Anderson Cancer Center, Houston, TX), while H-Ras and K-Ras 
overexpressing T80 cells were kindly provided by Dr. Jinsong Liu (MD Anderson Cancer Center); 
these cells were maintained in RPMI 1640 supplemented with 8% FBS and 1% 
penicillin/streptomycin as previously described [233]. Human immortalized fallopian tube 
secretory epithelial cells (FTSECs: FT194) were kindly provided by Dr. Ronald Drapkin 
(Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA). 
These cells were immortalized via stable expression of SV40 LTAg and hTERT as previously 
described [161] and maintained in DMEM:F12 (1:1, #15-090-CV, Corning Incorporated, Corning, 
NY, USA) with phenol red, supplemented with 2% Ultroser G Serum Substitute (#67042, Crescent 
Chemical Company, Islandia, NY, USA) and 1% penicillin-streptomycin. Human lung 
adenocarcinoma cells (A549, obtained from the ATCC (Manassas, VA, USA)) were maintained 
in DMEM:F12 (1:1) with phenol red, supplemented with 8% FBS and 1% penicillin-streptomycin. 
For chronic iron treatment, immortalized FTSECs were maintained in phenol red-free DMEM:F12 
(1:1, #21041-025, ThermoFisher, Waltham, MA, USA) supplemented with 8% charcoal dextran-
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stripped FBS and 1% penicillin/streptomycin (annotated as -PR media), as previously described 
[12]. All cell lines were confirmed to be mycoplasma negative.  
Ferric ammonium citrate (FAC (a source of NTBI), #I72-500, Fisher Scientific, Pittsburgh, 
PA, USA) was prepared as a 50mM stock in PBS and used at final concentrations of 25nM, 
250nM, 2.5M, 25M, or 250M [12, 233]. The proteasome inhibitor, MG132 (Fisher Scientific, 
Pittsburgh, PA, USA), was prepared as a 10mM stock in dimethyl sulfoxide (DMSO) and used at 
a final concentration of 5M [277]. The transcriptional inhibitor Actinomycin D (Act D, Fisher 
Scientific, Pittsburgh, PA, USA) was prepared as a 1mg/ml stock in RPMI 1640 media (diluted to 
100g/ml in PBS) and used at a final concentration of 100ng/ml [326]. The autophagic flux 
inhibitor, hydroxychloroquine (HCQ, Fisher Scientific, Pittsburgh, PA, USA), was prepared as a 
50mM stock in PBS and used at a final concentration of 10M or 25M [272].  
 
Chronic iron exposure in FTSECs 
A schematic summarizing the chronic iron treatment strategy in FT194 cells is presented 
in Figure 55A. These cells were initially seeded at 500 cells/well (50 cells/cm2) in a 6-well plate. 
The following day, attached cells were rinsed with PBS, and media was exchanged to -PR media 
with 0nM, 25nM, 250nM, 2.5M, 25M, or 250M FAC; note that ammonium citrate was 
previously tested as a control for FAC [324]. Cell growth was monitored closely; after 16 days of 
treatment, FT194 cells (at 0nM, 25nM, 250nM, 2.5M, 25M) approached confluency and were 
thus independently expanded to T75 flasks in -PR media for continued treatment at the respective 
FAC doses. Since cells maintained in 250nM FAC appeared to be more numerous upon 
continued maintenance (compared to untreated or other FAC-doses), the FT194 cells undergoing 
250nM treatment were selected for prolonged maintenance in T75 flasks. Untreated cells were 
maintained in -PR media concurrently with the 250nM FAC-treated cells to account for 
spontaneous mutations (and other potential events) that could arise from long-term culturing 
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[327]. Upon nearing confluency (approximately every 12 days), both untreated and 250nM FAC-
treated FT194 cells were counted using a hemocytometer and re-seeded at a low density of 37 
500 cells (500 cells/cm2) into T75 flasks. Cells were functionally assessed between 2-4 months 
after initiating FAC treatment; these findings were functionally validated with two additional 
replicates generated in a similar manner.  
 
Generation of transformed FTSECs 
Transformed FTSECs were developed using a methodology similar to that previously 
reported [12, 172]. Briefly, HEK293T packaging cells, seeded at 1.5x106 cells/well in 6-well plates, 
were transfected with retroviral expression plasmids in combination with pCGP and pVSVG 
plasmids (at a 1:1:1 ratio) using Fugene HD (Promega, Madison, MI, USA). Specifically, control 
virus (CV) was generated using an empty retroviral pBABE-puro expression plasmid (Addgene 
plasmid #1764 [273]) whereas oncogenic cocktail virus (OCV) was generated using (a) H-RasV12A 
(Addgene plasmid #9051, a gift from William Hahn), (b) c-MycT58A (Addgene plasmid #20076, a 
gift from Juan Belmonte [274]), and (c) SV40 LTAg (Addgene plasmid #14088, a gift from William 
Hahn [275]) retroviral expression plasmids at equimolar concentrations. Forty-eight hours post-
transfection, retrovirion-containing media was collected, filtered (0.45m), and used to infect 
FT194 cells (seeded the day prior at 250 000 cells/well in 6-well plate) with 8g/ml polybrene. 
Puromycin selection up to 1g/ml was performed to allow for selection of cells expressing the 
transduced oncogenes; Figure 55B presents a schematic describing the retroviral transduction 
process for FTSEC cellular transformation. 
 
K-Ras sequencing analyses 
Genomic DNA was isolated from untreated and chronic FAC-treated FT194 cells using 
the DNA DNeasy Blood and Tissue kit per manufacturer’s protocol (Qiagen, Valencia, CA, USA). 
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K-Ras primers to amplify codon 12 were used for polymerase chain reaction (PCR) as previously 
described [233]. The amplified PCR product was analyzed on a 1% agarose gel and DNA purified 
using the QIAQuick Gel Extraction Kit per manufacturer’s instructions (Qiagen, Valencia, CA, 
USA). DNA sequencing analysis of the purified PCR product was completed by Eurofins 
Genomics (Louisville, KY, USA) and the sequencing results were aligned to K-Ras 
(NM_004985.4) using Genomatix Dialign for analyses [328]. 
 
Clonogenic assay 
Clonogenic Assay was completed as previously described [12]. Briefly, FT194 cells 
(untreated, FAC-treated, CV, and OCV) were seeded at 500 cells/cm2 (equivalent cell density to 
seeding in T75 flasks, as described in the “Chronic iron exposure in FTSECs” section above) in 
6-well plates and maintained in culture for 10 to 17 days prior to crystal violet staining. Following 
cell staining, 1ml of Sorensen’s Buffer (0.1M sodium citrate (pH 4.5) and 50% ethanol) was added 
to each well and incubated for 2 hours on a rotating shaker to dissolve the crystal violet into 
solution. Samples were then pipetted into a 96-well plate (100l per well) and analyzed on a 
BioTek plate reader at 570nm. 
 
Immunofluorescence  
FTSECs were seeded at 250 000 cells/well in 6-well plates onto glass coverslips and 
handled as previously described [12]. Briefly, at two days post-seeding, cells were fixed for 30 
minutes in 4% formaldehyde (diluted in PBS) followed by blocking for 1 hour (5% goat serum and 
0.1% Triton X-100 in PBS). The cells were next incubated overnight in primary antibody solution 
(prepared with 1% goat serum and 0.1% Triton X-100 in PBS) in a humidifying chamber at 4˚C, 
followed by a 1 hour incubation at room temperature in either goat anti-rabbit or goat anti-mouse 
secondary antibody (at 1:500 prepared in 1% goat serum and 0.1% Triton-X-100 in PBS) 
(#A11008/A11029, Alexa Fluor-488, Fisher Scientific, Pittsburgh, PA, USA)) before mounting 
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onto glass slides with Vectashield anti-fade solution (#NC9524612, Fisher Scientific, Pittsburgh, 
PA, USA). Images were captured at both 20X and 63X (oil objective) using a PerkinElmer 
UltraVIEW Confocal spinning disc microscope (PerkinElmer Corporation). The primary antibodies 
used were: (1) Pax8 rabbit polyclonal (1:250, #10336-1-AP, ProteinTech, Rosemont, IL, USA), 
(2) FoxJ1 mouse monoclonal (1:100, #sc-365216, Santa Cruz Biotechnology, Dallas, TX, USA), 
(3) SV40 LTAg mouse monoclonal (1:500, #554149, BD Biosciences, San Jose, CA, USA), (4) 
hTERT rabbit polyclonal (1:500, #sc-7212, Santa Cruz Biotechnology, Dallas, TX, USA), and (5) 
H2AX rabbit monoclonal (1:400, #9718, Cell Signaling Technology, Danvers, MA, USA).  
 
Assessment of DNA and RNA base damage via immunofluorescence  
For assessing DNA and RNA damage, cells were seeded onto glass coverslips and 
processed as described in the Immunofluorescence section, with the following changes. For 
assessment of DNA base damage, after 4% formaldehyde fixation and blocking, samples were 
incubated for 1 hour in RNase solution (containing 10mM Tris-HCl, 0.1% Triton X-100, 15mM 
NaCl, and 0.2mg/ml RNase in PBS). Next, samples were incubated in 2M HCl for 10 minutes at 
room temperature, followed by a rinse with 50mM Tris. Next (for both DNA and RNA base damage 
assessment, primary antibody incubation occurred with 8-OHG mouse monoclonal (1:200, 
#ab62623, Abcam, Cambridge, MA, USA) followed by secondary antibody incubations. Confocal 
images were captured as detailed in the Immunofluorescence section, above. 
 
Protein isolation, SDS-PAGE, and western blotting 
SDS-PAGE and western analyses were completed as previously described [235, 278]. 
Briefly,  normalized protein samples were loaded onto either 8% or 10% SDS-PAGE gels (as 
appropriate) and western blotting was completed with the following antibodies from Cell Signaling 
Technology (Danvers, MA, USA): (1) EVI1 rabbit monoclonal (#2593, 1:500), (2) Myc rabbit 
monoclonal (#13987, 1:500), (3) total Ras rabbit monoclonal (#3339, 1:1000), (4) -catenin rabbit 
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polyclonal (#9587, 1:1000), (5) BMI1 rabbit monoclonal (#6964, 1:1000), (6) LC3B rabbit 
polyclonal (#2775, 1:1000), and (7) Pan-Actin rabbit polyclonal (#4968, 1:500). SV40 LTAg mouse 
monoclonal (#554149, 1:1000) and p62 mouse monoclonal (#610832, 1:1000) antibodies were 
obtained from BD Biosciences (San Jose, CA, USA). FANCD2 mouse monoclonal (#sc-20022, 
1:1000), Cyclin D1 rabbit polyclonal (#sc-718, 1:1000), and FoxJ1 mouse monoclonal (#sc-
365216, 1:500) were obtained from Santa Cruz Biotechnology. 
 
Cell cycle analyses 
Cells were seeded at 250 000 cells/well in 6-well plates and grown for 2 days. Both non-
adherent and adherent cells were collected and fixed for 1 hour using ice-cold 70% ethanol (in 
PBS). After two PBS washes, cell pellets were suspended in propidium iodide stain solution 
consisting of 0.1% Triton X-100, 0.02mg/ml propidium iodide, and 0.2mg/ml RNase (prepared in 
PBS) and incubated at room temperature for 30 minutes. Samples were filtered (using a 0.4m 
nylon mesh) to remove aggregates and then analyzed using a BD Accuri C6 Flow Cytometer (BD 
Biosciences, San Jose, CA, USA). Gates were set using an unstained control sample.  
 
Boyden chamber cell migration assay 
Cell migration was completed per manufacturer’s protocol (#CBA-100, Cell Biolabs, San 
Diego, CA, USA) and as previously described [12]. Briefly, 30 000 FT194 cells (untreated, chronic 
iron-treated, CV, or OCV) were seeded in respective serum-free media into Boyden Chamber 
inserts in a 24-well plate, with respective complete media added to the lower chamber. For chronic 
iron-treated FT194 cells, 250nM FAC was included in both the insert (with the cells) and the lower 
chamber. Cells remained in culture for 24 hours, after which the migrated cells were stained with 
cell stain solution. Light microscope images were captured at 100x magnification and the migrated 
cells counted.  
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RNA isolation and real-time PCR 
The RNeasy Kit (QIAGEN, Valencia, CA, USA) was utilized for RNA isolation following the 
manufacturer’s instructions, as previously reported [12, 233]. Real-time PCR was performed using 
the TaqMan™ RNA-to-CT™ 1-Step Kit from ThermoFisher (#4392938, Waltham, MA, USA) 
[233]. The following custom-designed FAM-labelled probes/primers were used: (1) EVI1 Exon I 
(specific for EVI1), (2) EVI1 Exon III (specific for EVI1 and MDS1/EVI1), (3) EVI1Del190-515, (4) 
MDS1, (5) MDS1/EVI1 (see [65, 80] for primer and probe sequences), and (6) custom designed 
hTERT: 
  Forward Primer: 5’-CGCAGGGCTCCATCCT-3’ 
  Reverse Primer: 5’-TCCCCGCAAACAGCTTGT-3’ 
Probe Sequence: 5’-CTCTGCAGCCTGTGCTAC-3’ 
CT values were normalized to either -actin (#401846, Applied Biosystems, Foster City, 
CA, USA) or Cyclophilin A (PPIA, # Hs04194521_s1, ThermoFisher, Waltham, MA, USA) as 
appropriate. RNA-fold changes were calculated using the correlative 2−ΔΔCT method. 
 
siRNA-mediated knockdown in FTSECs 
siRNA transfections were completed as previously described [12, 235], with the following 
modifications. Briefly, FTSECs were seeded at 350 000 cells/well in 6-well plates and allowed to 
adhere overnight. The following day, cells were transfected with the respective siRNA using 
RNAiMAX (#13778-075, Invitrogen, Carlsbad, CA, USA). Non-Targeting control (#D-001810-10-
20), -catenin (#L-003482-00), and EVI1 (siB, custom designed as detailed in [81]) ON-
TARGETplus siRNAs were obtained from GE Dharmacon (Lafayette, CO, USA). For BMI1 
knockdown, Control siRNA was obtained from Bioneer (#SN-1003) and BMI1 siRNA was obtained 
from QIAGEN (#SI05044473); one round of siRNA transfections was performed for all siRNA 
knockdown experiments described herein.  
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Statistical analyses 
GraphPad version 6.04 Prism software (GraphPad, La Jolla, CA, USA) was used to complete 
all statistical analyses; p-values were calculated using the nonparametric Student’s t-test and all 
error bars depict the mean ± standard deviation of at least three independent experiments, unless 
otherwise stated. NS represents non-significant p-values; * represents p-values ≤ 0.05; ** 
represents p-values ≤ 0.01; *** represents p-values ≤ 0.001; and **** represents p-values ≤ 
0.0001. Any indicated fold changes or percent reductions were calculated as an average of three 
independent replicates. 
 
 
 
 
Figure 54. Chronic iron treatment in T80 cells and characterization of parental FTSECs. (A) 
Cell counts were obtained from T80 cells treated with 250M FAC over a period of ~200 days. 
Cell counts from untreated and FAC-treated cells on days 47, 67, 91, and 139 are presented. 
Error bars represent average ± SD. (B) Representative immunofluorescence images for Pax8, 
SV40 LTAg, and hTERT in FT194 cells (p=15) captured at 20x magnification.  
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Results 
Generation of chronic iron exposed and transformed FTSECs 
Although evidence exists that links elevated free iron (NTBI) to ovarian cancer 
pathogenesis [35, 118, 208, 322, 325], the mechanisms underlying its contribution has yet to be 
defined experimentally. Since it is theorized that the cell of origin for HGSOC may derive from 
either the OSE or the FTE [171, 319], we thus utilized immortalized human ovarian surface 
epithelial cells (T80, which stably express SV40 Large T Antigen (which inactivates p53 and Rb) 
and human telomerase reverse transcriptase (hTERT)) as well as immortalized FT194 (which 
were also generated via stable expression of SV40 LTAg and hTERT [161]) to investigate the 
long-term effects of NTBI exposure. Indeed, precursor lesions of the fallopian tube contain p53 
signatures (enriched in inactivated p53 [111]) and 95% of HGSOC cases are characterized by 
p53 inactivating mutations [62] and thus, the effect of long-term iron exposure under these 
conditions was investigated. However, maintaining T80 cells for nearly 200 days in the presence 
 
Figure 55. Generation of chronic iron exposed and transformed FTSECs. (A) Schematic 
summarizing the maintenance of FT194 cells in FAC. (B) Schematic depicting the method for 
transforming FT194 cells via retroviral infection of H-RasV12A, c-MycT58A, and SV40 LTAg.  
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of 250M FAC (as a source of NTBI, using a dose previously identified to not alter short-term T80 
cell viability [233]) resulted in reduced cell numbers (p=0.2447, Figure 54A).  
Since chronic iron treatment in immortalized human OSE did not increase cell numbers, 
we next investigated its effect on immortalized FTSECs. We first confirmed that the phenotype of 
our FTSECs were positive for the Müllerian marker, Pax8, and negative for the ciliated cell marker, 
FoxJ1 [161, 173, 329, 330]. Indeed, we confirmed that FT194 cell lines were Pax8+ (100%) and 
FoxJ1- in addition to expressing SV40 LTAg+ (~99%) and hTERT+ (Figure 54B; results for FoxJ1 
were negative (as expected since ciliated FoxJ1+ FTSECs cannot be maintained in two-
 
Figure 56. Morphological changes and clonogenic growth in chronic iron-exposed and 
transformed FTSECs. (A) Representative light microscope images of FT194 untreated and 
250nM FAC-treated cells (p=19). Images were captured at 100x magnification and a subpanel 
of the image was enlarged in PowerPoint. (B) Representative light microscope images of 
FT194 Control Virus (CV) and Oncogenic Cocktail Virus (OCV) cells (p=RV+3). Images were 
captured at 100x magnification and a subpanel of the image was enlarged in PowerPoint. (C) 
FT194 untreated and FAC-treated cells were seeded at 500 cells/cm2 (p=31) and stained 17 
days post-seeding (113 days). Three independent replicates are shown. (D) FT194-CV and 
FT194-OCV cells were seeded at 500 cells/cm2 (p=RV+6) and stained 10 days post-seeding. 
Three independent replicates are shown.  
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dimensional culture systems [161]) (results not shown)). To next investigate whether iron may 
contribute in the transition of fallopian tube precursors to HGSOC, we chronically maintained 
FT194 cells in culture media supplemented with FAC (see Materials and Methods for additional 
details); Figure 55A summarizes details for cell handling of FTSECs. Briefly, we began by 
seeding cells at low density, then supplemented the media with a range of FAC doses based on 
physiological levels of NTBI and prior supporting literature [120, 208, 233, 296, 331]. Within 
approximately two weeks, we observed a reduction in cell size as well as increased cell numbers 
of FT194 cells treated with 250nM FAC (relative to untreated cells maintained concurrently in 
 
Figure 57. Chronic iron exposure and transformed FTSECs elicit altered migratory and 
proliferative capacities. (A) Untreated and 250nM FAC-treated FT194 cells were seeded at 500 
cells/cm2 and maintained over a period of 35-134 days (p=17-39). Representative cell counts 
from untreated and FAC-treated cells on days 48, 67, 90, and 138 are presented. (B) FT194-
CV and FT194-OCV cells were seeded at 500 cells/cm2 (p=RV+7) and maintained in culture for 
10 days prior to counting; the graph represents three independent replicates. Light microscope 
images of migrated untreated and FAC-treated (C; p=30, day 104) as well as CV and OCV (D; 
p=RV+10) FT194 cells. Images were captured at 100x magnification, as detailed in the Materials 
and Methods. For quantification, migrated cells were counted from each independent replicate. 
Error bars represent average ± SD. 
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culture). In addition, we generated transformed FTSECs through retroviral transduction of an 
“oncogenic cocktail virus (OCV)” consisting of c-MycT58A, H-RasV12A, and SV40 LTAg cDNAs, 
using previously published methods [12, 172]. A schematic of the transformation process is 
depicted in Figure 55B. Representative light microscope images for FT194 untreated and FAC 
cells (Figure 56A) as well as FT194 control virus-infected (CV) and oncogenic cocktail virus 
(OCV)-infected cell lines (Figure 56B) displays morphological changes after 60 days of chronic 
250nM FAC treatment and after integration of the transduced oncogenes, respectively.  
We next assessed the clonogenic potential of these iron-treated and transformed FT194 
cells by seeding cells at 500 cells/cm2 and monitoring colony growth. As shown in Figure 56C, 
untreated FTSECs grew in colonies although FAC-treated cells were more dispersed (particularly 
noted at low density), whereas FT194-OCV cells showed a marked increase in colony growth 
relative to CV (Figure 56D). We thus counted untreated, FAC-treated, FT194-CV, and FT194-
 
Figure 58. Altered expression of EMT markers with chronic iron exposure. RNA was isolated 
from untreated and FAC-treated FT194 cells (p=20, day 69) to assess mRNA expression of 
the indicated EMT markers via real-time PCR. Data represents three independent 
experiments, and error bars represent average ± SD. 
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OCV cells which were equivalently seeded at 500 cells/cm2 and identified a significant increase 
in cell numbers in FAC-treated relative to untreated FT194 cells (~2-fold increase, p=0.0015) and 
with FT194-OCV relative to FT194-CV (~2.5-fold increase, p<0.0001; Figure 57A and 57B), 
suggesting an increase in cell growth potential. We questioned whether these cell lines were also 
more migratory, and thus completed a migration assay using Boyden chambers. As shown in 
Figure 57C, we observed a significant increase in cell migration with FAC-exposed relative to 
untreated cells (p=0.0013); however, the migration capacity was significantly reduced in FT194-
OCV relative to FT194-CV (p=0.0022, Figure 57D). Quantitative PCR analyses for markers of 
epithelial-to-mesenchymal (EMT) transition were next assessed in untreated and FAC-treated 
FT194 cells; we identified a significant increase in the mRNA transcripts of ZEB1 (p=0.0005) and 
Claudin-1 (CLDN1, p=0.0281), though there was a significant reduction in SNAIL (SNAI1, 
p=0.0001), SLUG (SNAI2, p<0.0001), and TWIST (p=0.0052) with no change observed in ZEB2 
(p=0.3592; Figure 58).  
 
Figure 59. Reduced aneuploidy in chronic iron exposed and transformed FTSECs. (A & B) Cell 
cycle analyses were completed for untreated and chronic FAC-treated FT194 cells (p=21-22, 
day 71-74) as well as FT194-CV and FT194-OCV cells (p=RV+3). For all panels, the results 
shown are representative of three independent experiments.  
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We next completed cell cycle analyses and identified that untreated FT194 cells contained 
a large proportion of aneuploid cells (>4N), whereas an aneuploid population was markedly 
reduced following chronic iron treatment (Figure 59A). We compared this cell cycle profile to 
FT194-CV and FT194-OCV cells and noted similar changes in the number of aneuploid cells 
following OCV-induced transformation, although the number of aneuploid cells in the OCV 
population were more relative to FAC-exposed FT194 cells (likely due to the timewise 
maintenance of the cells in culture) (Figure 59A and 59B). Although increased DNA content is a 
commonly accepted feature of cancer progression, aneuploidy has also been implicated in 
impairing cell proliferation and tumorigenesis [332]. Collectively, these results suggest that 
chronic iron treatment and oncogenic transformation of FTSECs increases cell numbers and may 
potentially select for cells lacking an aneuploid profile. 
 
 
Figure 60. Chronic iron exposed FTSECs display increased DNA damage. 
Immunofluorescence for H2AX and 8-OHG (either without (middle panels) or with (right 
panels) RNase treatment) in untreated and FAC-treated (p=26-28, day 90-97) FT194 cells. 
Representative images were captured at 20x (H2AX) or 63x (oil objective, 8-OHG) 
magnification. Error bars represent average ± SD. 
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Chronic iron-treated FTSECs display increased DNA damage, in contrast to transformed FTSECs 
Iron is known to generate ROS, which subsequently promotes DNA damage [31, 34]. We 
thus assessed, via an immunofluorescence approach, DNA damage in our long-term iron-
exposed and transformed FT194 cells. As shown in Figure 60, there was a trend towards 
increased expression of DNA double stranded break marker (H2AX) in FAC-treated cells 
(relative to untreated), although these results were not significant. In contrast, DNA base damage 
(assessment of nuclear oxidized guanine (8-OHG to assess base oxidation damage and a marker 
of oxidative stress [333]) was significantly increased with chronic iron exposure in FT194 cells 
(relative to untreated) (p<0.0001). In contrast, we did not observe a significant change in DNA 
damage in transformed FT194-OCV cells (relative to FT194-CV) for either H2AX (p=0.0821) or 
nuclear 8-OHG (p=0.9559; Figure 61). In addition, we identified an increase in cytoplasmic base 
oxidation damage, likely representing damaged RNA [334], in both FAC-exposed and OCV cell 
lines. 
 
Figure 61. Transformed FTSECs do not display increased DNA Damage. Immunofluorescence 
for H2AX and 8-OHG (either without (middle panels) or with (right panels) RNase treatment) in 
CV and OCV (p=RV+7-RV+8) FT194 cells. Representative images were captured at 20x 
(H2AX) or 63x (oil objective, 8-OHG) magnification. Error bars represent average ± SD. 
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Since there is evidence that divalent metals can promote DNA damage resulting in gene 
mutations [195], we hypothesized that chronic iron exposure may be able to cause such mutations 
as well [335]. To address this question, we isolated genomic DNA from untreated and chronic 
FAC-treated FT194 cells for reverse-transcriptase PCR using K-Ras specific primers, a common 
mutated gene in tumorigenesis, as previously described [233]. Sequencing analysis, however, 
 
Figure 62. Chronic iron exposed and transformed FTSECs retain Pax8+ and FoxJ1- expression. 
Lysates collected from A549 (p=n+6), parental FT194 (p=15), untreated and FAC-treated 
FT194 (p=31), as well as CV and OCV FT194 (p=RV+12) cells were subjected to SDS-PAGE 
and western analyses with the indicated antibodies. Data is representative of three independent 
replicates.  
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Figure 63. Chronic iron exposed FTSECs retain Pax8+ and FoxJ1- expression. 
Immunofluorescence images for Pax8, SV40 LTAg, and hTERT in FT194 untreated and FAC-
treated (p=24-29, days 80-90) from three independent experiments are shown. Images were 
captured at 20x magnification.  
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did not identify a mutation at codon 12 in FAC-treated cells relative to untreated (results not 
shown).  
To ensure that the changes noted above occurred in cells that maintained the parental 
FT194 characteristics [173, 330] (see Figure 54B), we validated that the expression of Pax8, 
FoxJ1, SV40 LTAg, and hTERT were unaltered via western blotting and immunofluorescence 
(Figure 62, Figure 63, and Figure 64). Indeed, neither chronic iron exposure nor cellular 
transformation altered the expression of Pax8 (100% positive), SV40 LTAg (~98-99% positive) 
and hTERT (Figure 63 and Figure 64). Furthermore, FoxJ1 was not detected in any FTSEC cell 
line although A549 cells were weakly positive for this ciliated marker (results not shown) while 
negative for Pax8. Collectively, these results show that the proportion of Pax8+/FoxJ1- cells was 
not altered with chronic iron exposure or oncogenic transformation and further, long-term iron 
exposure increased the levels of oxidative RNA and DNA damage in the absence of K-Ras 
mutations. 
 
 
Figure 64. Transformed FTSECs retain Pax8+ and FoxJ1- expression. Immunofluorescence 
images for Pax8, SV40 LTAg, and hTERT in FT194-CV and FT194-OCV cells (p=RV+7) from 
three independent experiments are shown. Images were captured at 20x magnification.  
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Characterization of chronic iron-treated and transformed FTSECs reveals altered expression of 
EVI1 variants  
Since evidence in myeloid leukemias implicates N-Ras activation in positively regulating 
EVI1 expression [336] and since EVI1 (located at chromosome 3q26.2) lies within a locus 
commonly amplified in HGSOC [62, 65], we next investigated whether overexpression of H-Ras 
in the transformed FT194 cells could modulate EVI1 protein levels. Interestingly, we found 
moderately increased expression of wild type EVI1 and EVI1Del190-515 (also referred to as 324 
[81]) with reduced MDS1/EVI1 in transformed FT194 cells relative to controls (Figure 66B). In 
support, as shown in Figure 65A, wild type EVI1 and EVI1Del190-515 were also markedly elevated 
following H-Ras overexpression in T80 cells and similar increases in these EVI1 variants were 
observed in transformed human endometriotic cells (transformed via stable expression of H-
RasV12A and c-MycT58V, see Chapter 3 and [12]; Figure 65B). Although we did not observe a 
change in Ras protein following chronic FAC exposure (relative to untreated), we did identify a 
marked increase in the protein expression of wild type EVI1 and the EVI1Del190-515 variant, with 
reduced expression of MDS1/EVI1 (Figure 66A). Indeed, it is remarkable that elevated 
 
Figure 65. Analysis of EVI1 protein expression in transformed T80 and endometriotic cell lines. 
(A) Western blot analyses were completed using lysates collected from T80, H-Ras 
overexpressing T80, and K-Ras overexpressing T80 cells and analyzed for EVI1 expression. 
(B) Western blot analyses were completed for PE-A and PE-B CV/OCV cell lines, for which 
lysates were analyzed in our prior published work [12] (see Chapter 3) and re-run on 8% SDS-
PAGE gel to assess EVI1 expression.  
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expression of wild type EVI1 and EVI1Del190-515 were previously reported to be associated with a 
poor patient outcome whereas elevated expression of MDS1/EVI1 was associated with an 
improved patient outcome [65].  
To provide support for the protein level alterations, we next assessed the mRNA 
expression of these EVI1 variants via real-time PCR (using custom Taqman probes and primers, 
as previously reported [65, 80]). As shown in Figure 67 (left panels, following ~70 treatment days), 
we observed ~2.5-fold increase in EVI1 Exon I (specific to wild type EVI1, p<0.0001), ~2.5-fold 
 
Figure 66. Chronic iron exposure and cellular transformation alters protein expression of 
oncogenes. Western Blot analyses were completed using lysates from the untreated and FAC-
treated (A; p=28, day 99) as well as CV and OCV (B; p=RV+9) FT194 cells with the indicated 
antibodies. Three technical replicates are shown and the dotted line indicates the same 
samples run on 10% (top) or 8% (bottom) SDS-PAGE gels.  
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increase in EVI1 Exon III (specific to both EVI1 and MDS1/EVI1 variants, p=0.0011), and ~4-fold 
increase in EVI1Del190-515 (p=0.0016) in FAC-treated cells relative to untreated, whereas MDS1 
(specific to MDS1, p<0.0001) and MDS1/EVI1 (specific to MDS1/EVI1, p<0.0001) were 
significantly (~98%) reduced in chronic iron exposed FT194. Furthermore, prolonged 
maintenance of these cells (~104 treatment days) showed that these changes in expression were 
sustained (Figure 67, right panels), with ~3-fold increase in EVI1 Exon I (p<0.0001), ~4-fold 
increase in EVI1 Exon III (p=0.0008), and ~5-fold increase in EVI1Del190-515 (p=0.0045). In 
transformed FTSECs, EVI1 variants were also altered in a similar pattern following prolonged 
culturing (in late passage, p=RV+12) (Figure 68, right panels) relative to early passage (p=RV+3; 
Figure 68, left panels). Specifically, we identified increased expression of EVI1 Exon I (~1.7-fold, 
p=0.0007), EVI1 Exon III (~1.7-fold, p<0.0001), and EVI1Del190-515 (~3-fold, p=0.0026) as well as 
reduced expression of MDS1 and MDS1/EVI1 variants though these changes were not significant 
 
Figure 67. Altered mRNA expression of EVI1 variants with chronic iron exposure in FTSECs. 
RNA was isolated from untreated and FAC-treated early (p=20, day 69) and late (p=31, day 
104) passage FT194 cells to assess mRNA expression of the EVI1 splice variants via real-time 
PCR. Data represents three independent experiments, and error bars represent average ± SD. 
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(p=0.2579 and p=0.0576, respectively). Altogether, these gene expression changes implicate 
chronic iron exposure and c-Myc/H-Ras activation in the regulation of EVI1 variant expression. 
Since precursors to HGSOC are postulated to arise from either the ovarian surface 
epithelium or fallopian tube epithelium [110, 171, 319], we thus next investigated whether the 
expression of EVI1 variants differed between T80 ovarian surface epithelial cells (which did not 
show increased cell numbers with chronic FAC treatment, see Figure 54A) and FTSECs. Indeed, 
our prior research showed that T80 cells have low expression of wild type EVI1 and no expression 
of EVI1Del190-515 or MDS1/EVI1 [65]. As presented in Figure 69A, western blot analyses comparing 
T80 and FTSEC, amongst other ovarian tumor cell lines (namely, HEY and TOV21G epithelial 
ovarian carcinoma) show that T80 cells had significantly lower expression of wild type EVI1 and 
EVI1Del190-515 with undetectable MDS1 nor MDS1/EVI1 expression relative to FT194. The highest 
 
Figure 68. Altered mRNA expression of EVI1 variants with cellular transformation in FTSECs. 
RNA was isolated from CV and OCV early (p=RV+3) and late (p=RV+12) passage FT194 cells 
to assess mRNA expression of the EVI1 splice variants via real-time PCR. Data represents 
three independent experiments, and error bars represent average ± SD. 
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expression of these variants was observed in the two ovarian cancer cell lines, and these protein 
patterns were also consistent at the mRNA level (Figure 69B).  
To address whether chronic iron exposure could select for cells better able to grow under 
stress and thus may be promoting growth of cells expressing high levels of EVI1 variants, we 
completed clonal isolation through single-cell seeding of untreated FT194 cells. Western analysis 
of these cell clones identified that the ratio between MDS1/EVI1, wild-type EVI1 and EVI1Del190-515 
in the clonally isolated cell lines did not differ to that from the parental population and thus was 
dissimilar to that noted in the FAC-exposed cells (Figure 70). These results suggest that the 
altered expression of EVI1 variants following chronic iron exposure is unlikely due to the selection 
of cells expressing an elevated profile of EVI1 variants. 
 
Figure 69. T80 (OSE) display reduced expression of EVI1 variants relative to FTSECs. (A) 
Western blot analyses using lysates from gynecological cell lines (T80, FT194, HEY, and 
TOV21G) are presented; samples were originally collected for analysis in our prior published 
work [12] (see Chapter 3), but re-run on a 8% SDS-PAGE gel to assess EVI1 variants. Data 
represents three independent replicates. (B) RNA was isolated from gynecological cell lines, 
originally collected for analysis in our prior published work [12] (see Chapter 3), but re-analyzed 
by normalizing to cyclophilin A (PPIA) for real-time PCR analysis of EVI1 variants. Data 
represents three independent replicates, and error bars represent average ± SD. 
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Altered expression of key tumorigenic modulators in chronic iron-exposed and transformed 
FTSECs 
We next characterized the protein expression of other common oncogenes characteristic 
of HGSOC in both chronic iron-exposed and transformed FT194 cells; specifically, we examined 
c-Myc (amplified at 8q24.21 in over 20% of ovarian cancer patients [62]), -catenin (which is 
correlated with poor patient prognosis in ovarian cancer [337]), Cyclin D1 (a cell cycle mediator 
whose expression is regulated by -catenin and is also associated with poor patient outcome 
[337, 338]), and B cell-specific Moloney murine leukemia virus integration site 1 (BMI1; purported 
to have a role in the pathogenesis of ovarian cancer [339]). As shown in Figure 66A, we observed 
a marked increase in the protein expression of all of these oncogenic markers in FAC-treated 
cells relative to untreated. We also noted a marked increase in the expression of FANCD2, a 
protein that regulates replication fork integrity and DNA repair [340]. This may be another indicator 
of increased cellular proliferation caused by FAC, which would require more robust support for 
replication fork integrity maintenance. It is interesting that cells from patients with Fanconi Anemia 
(FA, a rare disorder characterized by defects in DNA damage repair) harbor genomic amplification 
of EVI1 [341], thus implicating a potential link between FANCD2 and EVI1 (see also Figure 65B). 
 
Figure 70. Clones from FT194 cells display similar expression of EVI1 variants relative to 
untreated FT194 than to FAC-treated FT194. Protein lysates collected from clones derived 
from parental FT194 cells were assessed via western blot analyses with the indicated 
antibodies and compared to untreated and FAC-treated FT194 cells (samples from Figure 66A 
were re-run for comparison).  
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Also, a significant increase of Cyclin D1 was noted, which is characteristic of active proliferation, 
in addition to elevated BMI1, also associated with tumorigenesis [339]. These results were 
confirmed in two independent FT194 cell lines maintained up to 94 days with 250nM FAC (results 
not shown). Altogether, these data suggest that chronic iron treatment of FTSECs may promote 
the expression of oncogenes associated with HGSOC as well as markers involved in DNA repair. 
We also assessed the expression of the above-described markers in FT194-CV and FT194-OCV 
cells. Exogenous mutant c-Myc protein was markedly elevated in OCV relative to CV cells (as 
expected, Figure 66B). Note that c-MycT58A contains the electronegative FLAG tag on its N-
terminus, which results in a slower mobility on SDS-PAGE relative to endogenous Myc. Although 
BMI1 protein was increased consistently, FANCD2 was unchanged, -catenin was reduced, and 
Cyclin D1 was only subtly elevated in FT194-OCV (relative to FT194-CV). These results indicate 
that there are alterations in the expression of key oncogenes following chronic FAC exposure but 
these changes differed to some extent with transformation.  
 
Figure 71. Analysis of iron regulatory markers following chronic iron exposure in FTSECs. 
RNA was isolated from untreated and FAC-treated (p=20, day 69) to assess mRNA 
expression of iron regulatory markers. Data is representative of three independent replicates, 
and error bars represent average ± SD. 
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Since prior research implicates altered iron regulation in immortalized and transformed 
fallopian tube precursors [26], we characterized the mRNA expression of key iron pathway 
mediators in our chronic iron-exposed FTSECs. Indeed, we identified a significant increase in the 
expression of transferrin receptor (CD71, p=0.0360) concurrent with significantly reduced 
expression of the iron storage protein ferritin (FTH1, p=0.0028) and the iron exporter ferroportin 
(FPN1, p<0.0001), with no observed changes in the mRNA expression of the divalent metal 
transporter (DMT1, p=0.5492) or the iron-sulfur cluster assembly protein (ISCU, p=0.1989; see 
Figure 71). These observations suggest that there may be increased intracellular iron retention 
in FTSECs following chronic iron exposure.  
Since we noted that Myc was elevated following chronic iron exposure of FTSECs, we 
next addressed whether hTERT expression was altered (hTERT is involved in telomere 
maintenance, is commonly overexpressed in cancer [68]) and is regulated transcriptionally by c-
Myc [69]). As shown in Figure 72A, we identified a ~2- to 3-fold increase in hTERT mRNA 
expression in FAC-treated cells (relative to untreated) (early passage p=0.010 (top) and late 
 
Figure 72. hTERT mRNA expression is altered in chronic iron-exposed and transformed 
FTSECs. RNA was isolated from untreated and FAC-treated (A) early (p=20, day 69) and late 
(p=31, day 104) as well as CV and OCV (B) early (p=RV+3) and late (p=RV+12) FT194 cells 
to assess hTERT mRNA expression via real-time PCR. Data represents three independent 
experiments, and error bars represent average ± SD. 
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passage p=0.0220 (bottom)). Surprisingly, there was a significant reduction (up to 80%) in hTERT 
transcripts in FT194-OCV relative to FT194-CV (p<0.0001, Figure 72B). These results uncover 
alterations in hTERT mRNA expression with both chronic iron treatment and in transformed 
FTSECs. 
 
EVI1 variants, -catenin, and FANCD2 are regulated in an autophagy-independent and 
proteasome-dependent manner in chronic iron-treated FT194 cells 
Since we previously reported that the autophagic pathway was altered in response to 
acute iron overload conditions in gynecological cells [233] and that EVI1 expression may regulate 
 
Figure 73. EVI1 variants are regulated in an autophagy-independent manner in chronic iron 
exposed FT194 cells. (A) Untreated and FAC-treated FT194 cells (p=23, day 78) were treated 
with 10M or 25M HCQ for 18 hours. Lysates were collected and subjected to western blot 
analyses with the indicated antibodies. The dotted line indicates the same samples run on 10% 
(top) or 8% (bottom) SDS-PAGE gels, and data is representative of four independent replicates. 
(B) Untreated and FAC-treated FT194 cells (p=28, day 99) were treated with 25M HCQ and/or 
5M MG132 for 18 hours, and western blot analyses were completed with the indicated 
antibodies. The dotted line indicates the same samples run on 10% (top) or 8% (bottom) SDS-
PAGE gels, and data is representative of three independent replicates.  
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the expression of PDZ-binding kinase (PBK) which leads to increased autophagy to confer 
chemoresistance [342], we next investigated whether chronic iron exposure may also alter the 
autophagic pathway. We identified a subtle reduction in both LC3B-I and LC3B-II (the non-
conjugated and conjugated forms, respectively) protein without a clear notable change in 
p62/sequestosome protein (Figure 66A), suggesting that autophagic flux may be altered in cells 
following chronic iron exposure (relative to untreated cells). To identify whether autophagic flux is 
altered under these conditions, we treated untreated and chronic FAC-treated FT194 cells with 
10µM or 25µM hydroxychloroquine (HCQ) for 18 hours to inhibit autophagic flux [11, 226]. We 
found that LC3B and p62 accumulated with HCQ treatment in both untreated and FAC-treated 
cells, suggesting that initiation of the autophagic pathway was still active in both cell lines (as a 
reduction in autophagy initiation would show no change in LC3 and p62 expression with HCQ 
treatment) (Figure 73A). We also found that the protein expression of Myc was unchanged, 
 
Figure 74. EVI1 variants are regulated in an autophagy-independent manner in chronic iron 
exposed FT194 cells. RNA was isolated from untreated and FAC-treated FT194 cells following 
(A; p=26, day 92) 18 hours treatment with 25M HCQ, or (B; p=39, day 136) 18 hours 
treatment with 100nM Act D, to assess the indicated EVI1 splice variants via real-time PCR. 
Data represents three independent experiments, and error bars represent average ± SD. 
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whereas EVI1Del190-515, FANCD2, and -catenin were reduced following treatment with HCQ 
independent of iron treatment, suggesting an alternative mechanism of protein regulation. Indeed, 
co-treating FAC-exposed FT194 cells with both HCQ and MG132 (a proteasome inhibitor [343]) 
recovered wild type EVI1 and EVI1Del190-515 protein expression, as well as FANCD2 and -catenin 
expression, relative to HCQ alone (Figure 73B), suggesting that these markers are regulated in 
a proteasome-dependent manner.  
To determine whether targeting autophagy may alter mRNA expression of the EVI1 
variants, we next performed real-time PCR following treatment with HCQ. While there was no 
significant reduction of wild type EVI1 mRNA in either untreated (p=0.8732) or FAC-treated 
(p=0.5491) cells, we observed significantly reduced EVI1Del190-515 mRNA with HCQ in untreated 
(p=0.0098) but not FAC-treated (p=0.5981) cells (Figure 74A). Furthermore, there was a 
significant reduction of MDS1/EVI1 mRNA with HCQ in untreated cells (p<0.0001) but not in FAC-
treated cells (p=0.8922), suggesting that the protein expression of these EVI1 splice variants is 
regulated by autophagy in untreated cells, which is lacking with chronic iron exposure. Since we 
 
Figure 75. EVI1 variants are regulated in a -catenin-independent manner in chronic iron 
exposed FT194 cells. Western blot analyses were completed with the indicated antibodies 
following siRNA knockdown of EVI1 (siB, A; p=32, day 113), -catenin (B; p=36, day 124), and 
BMI1 (C p=29-30, day 102-104). Data is representative of three independent experiments.  
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observed a significant reduction in the mRNA levels of EVI1Del190-515 and MDS1/EVI1 with HCQ, 
we next determined whether transcriptional inhibition with Act D [344] also altered mRNA 
transcripts of EVI1. Indeed, as shown in Figure 74B, transcriptional inhibition reduced the 
expression of EVI1Del190-515 and MDS1/EVI1 variants to undetectable levels in both untreated and 
FAC-treated cells, while wild-type EVI1 mRNA was significantly increased in untreated (p=0.0014) 
and FAC-treated (p=0.0059) FT194 cells relative to controls. Together, these results suggest that 
inhibiting transcription increases the stability of wild type EVI1 mRNA and provides novel insight 
into the regulation and expression of other EVI1 variants. 
 
Knockdown of EVI1 variants reduces hTERT mRNA whereas -catenin and BMI1 knockdown 
reduce Myc and Cyclin D1 proteins. 
Since the protein expression of oncogenic EVI1 variants, BMI1, and -catenin were 
dramatically elevated following chronic iron exposure in FT194 cells (see Figure 66A), we next 
investigated the effect of knocking down each marker in FAC-treated cells on downstream targets. 
As shown in Figure 75A, siRNA-mediated knockdown of all EVI1 variants with siB [80, 81] did 
not alter the expression of -catenin, Myc, or BMI1. Knocking down -catenin resulted in a 
 
Figure 76. EVI1 regulates hTERT mRNA expression in chronic FAC-exposed cells. RNA was 
isolated from untreated and FAC-treated FT194 cells following transfection with siRNAs 
targeting EVI1, siB (A; p=27, day 86), -catenin (B; p=24, day 81), and BMI1 (C; p=31, day 
109), to assess hTERT mRNA expression (relative to respective control non-targeting siRNA in 
both untreated and FAC-treated cells) via real-time PCR. Data represents three independent 
replicates, and error bars represent average ± SD. 
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reduction of Myc, Cyclin D1, and BMI1 protein levels in FAC-treated FT194 cells without affecting 
the protein expression of the EVI1 splice variants (Figure 75B), whereas knocking down BMI1 
showed a possible reduction in -catenin, but no marked change in Cyclin D1, Myc or EVI1 protein 
expression relative to control (Figure 75C).  
Since we observed both elevated hTERT mRNA and EVI1 expression with chronic FAC 
treatment, and since there is evidence for a possible link between EVI1 and hTERC (the RNA 
component of hTERT) amplification in non-small cell lung cancers [345]), we next determined 
whether hTERT mRNA expression was altered with knockdown of EVI1. Interestingly, siB-
transfected FAC-treated FT194 cells showed a significant reduction in hTERT mRNA relative to 
control non-targeting siRNA (p=0.0032) (Figure 76A). In contrast, there was no reversal of hTERT 
mRNA following -catenin siRNA or BMI1 knockdown in FAC-treated cells (p=0.1773 (Figure 
76B) and p=0.8309 (Figure 76C)). These results indicate that hTERT may be transcriptionally 
regulated via EVI1 variants.  
We next questioned whether maintaining FAC-treated FT194 cells in the absence of iron 
would reverse the expression of key oncogenic markers. However, as shown in Figure 77, 
 
Figure 77. Chronic iron-treated FTSECs retain expression of key oncogenic markers in the 
absence of FAC. FAC-treated FT194 cells (p=34, day 120) were maintained in the absence of 
250nM FAC for four days, as indicated in the Materials and Methods. Western blot analyses 
were completed with the indicated antibodies and data is representative of three independent 
experiments.  
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maintaining chronic FAC-treated FT194 cells for 4 days without FAC-supplemented media elicited 
no change in the protein expression of the EVI1 variants, Myc, -catenin, BMI1, or Cyclin D1. 
Thus, these results suggest that chronic iron treatment of FTSECs may have caused permanent 
changes (i.e., genomic or epigenetic).  
 
Discussion 
Recent evidence suggests that iron may contribute to ovarian cancer pathogenesis. 
Indeed, NTBI levels are elevated in patients with hereditary hemochromatosis and have been 
linked to the development of HGSOC [322, 325]. Iron deposits have also been identified in the 
fallopian tubes of patients with HGSOC [118], implicating elevated levels of iron at locations where 
the proposed precursors to HGSOC have been identified [111]. Further, tubal ligation (which 
prevents retrograde menstruation, in turn reducing heme and transferrin accumulation in the 
peritoneal cavity) is associated with a decreased risk of ovarian cancer; indeed, salpingectomy 
results in the absence of OVCA and any consequent metastatic ovarian cancers [6]. Although 
exposing primary FTSECs to catalytic sources of iron increased their proliferative capacity [214], 
a causative relationship between iron exposure and increased ovarian cancer risk has not yet 
been clearly identified. However, a thorough experimental investigation of the mechanism of 
action of chronic iron exposure is needed.  
As summarized in Figure 78, we show that chronic iron (presented as FAC (NTBI)) 
exposure of FTSECs results in increased DNA damage coincident with increased cell numbers 
and migratory potential relative to untreated FTSECs. Interestingly, these changes were 
associated with increased expression of oncogenic markers such as EVI1, EVI1Del190-515, hTERT, 
Myc, -catenin, BMI1, and Cyclin D1. As increased activities of the Fanconi Anemia pathway is 
associated with a subpopulation of ovarian cancers [346], the increased FANCD2 expression by 
FAC is a notable observation. While oncogenic transformation (mediated by H-Ras and c-Myc) 
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also increased cell numbers with increased expression of EVI1, EVI1Del190-515, and BMI1, these 
transformed cells failed to display alterations in DNA damage and surprisingly, elicited a reduction 
in cellular migration as well as reduced expression of hTERT and -catenin. These results 
demonstrate that chronic iron exposure may promote the transition of fallopian tube precursors to 
ovarian cancer through mechanisms which differ from those mediated by H-Ras/c-Myc-induced 
cellular transformation. 
Our results also potentially suggest a role for iron in promoting the transition of fallopian 
tube but not ovarian precursors (T80). Indeed, in contrast to FTSECs, T80 cells failed to respond 
to chronic NTBI treatment. Stem cell niches have been identified near both the ovarian surface 
epithelium and fallopian tube epithelium, but the contribution of each of these niches to the 
development of HGSOC remains unclear [347-349]. Our attempts to investigate the expression 
of key stem cell markers (i.e., Oct4A, Sox2, LEF1, LGR5, and ALDH1) in our chronic iron exposed 
 
Figure 78. Model of FAC-induced pathogenesis of FTSECs compared to oncogenically 
transformed FTSECs. FAC-exposed FTSECs (for >2 months) demonstrated increases 
migration in addition to increased DNA damage/repair marker expression such as FANCD2. 
Furthermore, these cells had elevated hTERT mRNA. Transformed cells (as well as the iron 
exposed cells) elicited increased cell numbers and expression of EVI1, Myc, BMI1, and Cyclin 
D1. EVI1 knockdown markedly reduced hTERT transcript levels. -catenin and BMI1 
knockdown diminished c-Myc and Cyclin D1 proteins.  
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FTSECs were unsuccessful due to lack of detection via western blotting; however, further work 
to address their contribution to the observed functional responses is needed.  
Research shows that cellular transformation with SV40 LTAg can promote chromosomal 
aberrations including aneuploidy [350, 351], and we identified that FT194-CV and untreated 
FT194 cells contained a population of cells with >4N DNA content (aneuploid cells). It is 
interesting that this population of cells was similarly reduced following oncogenic transformation 
with H-RasV12A and c-MycT58A as well as following chronic iron exposure; we propose that these 
aneuploid cells may represent a population of senescent cells that are being selected against 
under these conditions [352, 353]. Indeed, it has been shown that aneuploidy can promote 
senescence and reduce “cellular fitness” [354]. Furthermore, senescent cells that are able to 
overcome arrest have increased tumorigenic propensity and are associated with activated -
catenin signaling [355].  
Since we identified marked alterations in EVI1 variants upon both chronic iron exposure 
and oncogenic transformation and that the removal of exogenous iron from the chronically 
exposed cells failed to reverse the expression of EVI1, it is not surprising that EVI1 expression 
was not altered via -catenin knockdown. This is in contrast to reports that -catenin was able to 
regulate EVI1 expression [356, 357]. Nonetheless, further investigations identifying the 
mechanisms underlying these EVI1 changes are worthwhile including DNA copy number changes 
and epigenetic profiles. Another important difference between chronic iron-treated and 
transformed FT194 cells is hTERT mRNA levels, which were significantly increased following 
chronic FAC exposure but significantly reduced in transformed cells (relative to their respective 
controls). Interestingly, we identified that EVI1 knockdown reduced hTERT mRNA expression. To 
our knowledge, this is the first indication that EVI1 may contribute to regulation of hTERT 
expression, although links between EVI1 amplification and telomerase have been previously 
reported [345, 358].  
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The proto-oncogene c-Myc, located at 8q24.21, is also commonly amplified in OVCA [62], 
and was markedly elevated at the protein level with chronic iron exposure (relative to untreated 
FT194 cells). Upregulation of c-Myc protein could be contributed by -catenin since its knockdown 
reduced Myc protein in FAC-treated cells (relative to non-targeting control siRNA; in support, -
catenin was previously reported to regulate c-Myc expression in other cancer cells [359, 360]). 
Knocking down -catenin also reduced BMI1 protein expression in FAC-treated FT194 cells, and 
it is interesting that -catenin knockdown in colon cancer cells also resulted in reduced BMI1 
expression [361]. To our knowledge, this phenomenon has not been previously described in 
FTSECs, and it is important to note that BMI1 was recently described as a potential OVCA 
biomarker [339]. It is possible that this link between BMI1 and -catenin is important for the 
oncogenic changes induced by chronic iron exposure in FTSECs, and this observation warrants 
further investigation.  
In conclusion, we have identified that chronic iron exposure of FTSECs increases cell 
numbers and migration, promotes DNA damage, and increases the expression of oncogenes 
commonly associated with HGSOC, albeit through different mechanisms from c-Myc and H-Ras 
induced cellular transformation. These results suggest that iron may contribute to the transition of 
fallopian tube epithelial cells (and unlikely to transition of OSE) to HGSOC. Further research is 
needed to elucidate the mechanisms underlying this transition; such studies would provide 
valuable insight into the development of this deadly cancer that could aid in the development of 
novel therapeutic strategies. 
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Chapter 5 
 
Future Directions and Significance of the Study 
 
Overview of the Major Findings and Study Limitations 
In Chapter 2, we characterized the expression pattern of autophagic markers in 
endometriosis by identifying reduced mRNA and protein expression of key autophagic markers 
(i.e. LC3B) in the ectopic endometria of endometriosis-induced mice. We demonstrated for the 
first time that inhibiting the autophagy pathway reduced the number of endometriotic lesions that 
developed in this mouse model. An important consideration is in the use of a mouse model for 
endometriosis studies; although these models recapitulate similar changes in expression as 
observed in women with endometriosis [224], mice do not naturally develop this disease because 
most rodents do not menstruate (although there are few exceptions to this, see [362]). Ideally, 
endometriosis studies would be undertaken in non-human primate models [363], but such studies 
are also limited in terms of available resources and ethical considerations. In contrast to the 
above-described in vivo results, LC3B protein expression was elevated in human endometriotic 
tissues relative to controls. Since endometriosis is typically not diagnosed until after 7 to 10 years 
[104, 262], we hypothesize that the human samples represent a more advanced stage of disease 
while the endometriotic lesions from induced mice represent an early stage. We also consider 
that the control tissue samples from the human tissue microarray were obtained from patients 
afflicted by other benign gynecological issues, which were not accounted for in this study. For 
appropriate comparison, eutopic endometrium from healthy donors would be ideal, but this is 
regretfully difficult to obtain.  
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Endometriosis is widely considered as an autoimmune disorder [246], and tumor-
associated macrophages have been identified in patients with endometriosis [236]. For these 
reasons we assessed macrophage presence as well as cytokine/chemokine levels from the 
peritoneal fluid of endometriosis-induced mice. While we did not observe any differences relative 
to control mice, treating endometriosis-induced mice with HCQ significantly increased 
macrophage presence and IP-10 cytokine levels. However, our study did not differentiate between 
macrophage activation status. It is possible that endometriosis-induced mice may have an 
increase population of M2 (tumor-associated) macrophages relative to non-induced mice as 
observed in humans [236]. In addition, these analyses were completed 2 weeks following 
induction of endometriosis; similar endometriosis mouse models typically assess lesions ~3 
weeks post-injection [230, 364]. While this may have been too early of a timepoint to observe 
changes in the mice, it was important to consider that prolonging HCQ treatment may have 
resulted in fewer and smaller endometriotic lesions.  
In Chapter 3, we generated novel transformed human endometriotic cell lines and 
characterized dysregulated expression of iron pathway mediators. These cell lines provide a 
useful tool for researchers in the endometriosis field, for which well-characterized cell lines are 
limited (see Chapter 1). However, we were limited in the analyses that could be completed due 
to the fact that the control cell lines (PE-A-CV and PE-B-CV) underwent senescence and stopped 
growing within 10 passages. We also identified increased expression of the ferritinophagy 
mediator (NCOA4) in malignant gynecological cell lines and human OVCA tumors relative to 
controls (non-malignant epithelial cell lines and normal adjacent tissues, respectively). This 
assessment of NCOA4 expression was completed in three OVCA cell lines derived from different 
histological subtypes (HEY cells were derived from a patient with HGSOC, TOV21G are clear cell 
OVCA, and TOV112D are endometrioid OVCA). A recent study assessing the genomic profiles 
of commonly used ovarian cancer cell lines identified that HEY, SKOV3, and A2780 cell lines are 
unlikely to be high-grade serous (as was originally reported), and found that TOV21G cells are 
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hyper-mutated (greater than 10 mutations per million base pairs, see [365]). Thus, expanding 
these analyses to include multiple, well-characterized OVCA cell lines [366] would greatly add to 
the field of knowledge and could provide insight into the contribution of NCOA4 to the 
pathophysiology of these specific subtypes.  
We also found that overexpressing the NCOA4 isoform in three gynecological cell lines 
(T80, HEY, and PE-A-OCV) resulted in reduced colony formation ability, suggesting that NCOA4 
may act as a tumor suppressor in ovarian cancer. This observation differs from that identified in 
prostate and breast cancers [269, 270], where NCOA4 was tumor suppressive and NCOA4 
had an oncogenic role. However, we note that our cell lines still expressed endogenous NCOA4. 
Prior research has identified that NCOA4 (also known as ARA70) has a dominant negative form 
which is missing the second AR-binding motif [367]. Interestingly, this same motif is absent in 
NCOA4, and thus overexpressing this isoform in cells which still expressed NCOA4 may have 
resulted in the reduced growth phenotype. Our results showing significantly increased NCOA4 
mRNA and protein expression may suggest that NCOA4 is oncogenic in OVCA, but our analysis 
of human OVCA tissues did not differentiate between these two isoforms. 
In Chapter 4, we found that chronic exposure with non-transferrin bound iron (NTBI) 
promoted oncogenic changes of human fallopian tube secretory epithelial cells (FTSECs), but not 
human ovarian surface epithelial cells (T80). These changes were somewhat similar to those 
induced by overexpression of oncogenic c-Myc and H-Ras (with p53 inhibition), although some 
key differences (such as migratory capacity) were noted. Though this study provides important 
evidence into the potential contribution of iron to the transition of fallopian tube precursors to 
ovarian cancer, we did not directly identify the mechanisms by which iron mediates these 
changes. We characterized increased DNA damage, which is as expected, and identified 
expression changes of markers commonly associated with HGSOC (such as an overexpression 
of EVI1 wildtype and EVI1Del190-515 and reduction of MDS1/EVI1, as well as elevated -catenin, 
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Myc, BMI1, Cyclin D1, and FANCD2). We hypothesize that amplification of EVI1 (located at the 
3q26.2 locus) may be an early event in ovarian cancer pathogenesis, but we did not yet elucidate 
a mechanism by which EVI1 expression was elevated. Identifying the “driving” factors that are 
critical for the pathogenesis of ovarian cancers is of paramount importance for future OVCA 
studies. If we can understand the step-wise progression from precursor lesion to ovarian cancer, 
then we will vastly improve our ability to detect this disease at early stages and improve patient 
outcome. 
Interestingly, there is evidence to suggest that fallopian tube epithelium may also be a 
precursor to endometriotic lesions, which can then progress to clear cell and endometrioid ovarian 
cancer [15, 165, 221], and the presence of endometriotic lesions may be able to promote a 
favorable environment for tumor progression [22]. A recent mouse study demonstrated that 
oviductal tumors (equivalent to human fallopian tube) were characteristically more similar to 
endometrioid OVCA than tumors derived from ovarian epithelial cells [368]. Furthermore, studies 
have identified that type I tumors (comprised of endometrioid, clear cell, mucinous, and low-grade 
serous OVCAs) are able to progress to type II (high-grade serous OVCAs) upon p53 inactivation 
or PIK3CA activation [61]. Based on the identified expression profiles (p53 inhibition as well as 
Myc and -catenin overexpression without amplification or mutation of Ras) we hypothesize that 
the chronic iron-treated FTSECs may be characteristically similar to either HGSOC or aggressive 
endometrioid OVCA. Future studies with these cells would include an assessment of the mutation 
status of PIK3CA, PTEN, BRCA1 and BRCA2 to better specify the histological subtype of OVCA 
that these cells represent. We additionally demonstrated that oncogenic transformation (via Myc 
and Ras overexpression) elicited expression changes in EVI1, albeit through potentially different 
mechanisms that were not fully elucidated.  
Figure 79 depicts a model linking together the findings and discussions presented within 
this dissertation in relation to the initiation and progression of precursors to ovarian cancer. 
Shedding of fallopian tube cells, which may be a common event [165], could land on the adjacent 
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ovary and survive. These cells, along with endometrial glands (perhaps refluxed through 
retrograde menstruation), may then grow and develop into endometriotic lesions; autophagy may 
be an important pathway towards promoting this phenomenon. The presence of these lesions 
then alters the local microenvironment through elevated ROS (which accumulates due to the 
increased iron present in the lesions), thus affecting the patient’s immune cells and creating a 
tumor-prone region. The dysregulated iron levels and ROS thus promote DNA damage and 
mutagenesis in susceptible FTSECs (FTSECs harboring p53 inactivating mutations, as observed 
in STICs). These transformed cells also shed from the fimbria, and may land on the ovary to 
develop into an endometriosis-associated ovarian cancer tumor. 
 
 
 
Figure 79. Schematic summarizing the major findings and discussions of this Dissertation. 
Figure created by Dr. Meera Nanjundan, with modifications by Stephanie Rockfield. 
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Future Perspectives 
Endometriosis is commonly characterized as an autoimmune disorder [246], and thus 
further clinical investigations into the use of HCQ as a novel treatment for endometriosis patients 
is direly needed. Critically, the observational studies mentioned above have not identified the 
associated changes in autophagic flux [11] in relation to endometriosis nor have they elucidated 
the mechanisms involved in endometriosis pathogenesis. Interestingly, histone modifications 
(such as acetylated and methylated lysine residues) are altered in patients with endometriosis 
[228, 369, 370]; these epigenetic alterations are instrumental in regulating gene transcription to 
influence gene expression. Indeed, H3K4me3, H2K9me2, H3K56ac, H4K16ac, and H4K20me2 
are all examples of histone modifications already identified to regulate the expression of 
autophagy genes [371]. For instance, reduced tri-methylated H3K4 is associated with H4K16 
deacetylation upon autophagy activation while H4K16 deacetylation corresponds with reduced 
autophagy gene expression [372]. Furthermore, G9a is a methyltransferase which regulates 
H3K9 di-methylation at the promoter regions of different autophagic genes; upon autophagy 
activation G9a dissociates from the histone to allow demethylation [371, 373]. However, a 
 
Figure 80. Dysregulated histone modifications at the promoter regions of autophagy genes in 
endometriosis. To test the hypothesis that the dysregulated expression of autophagy mediators 
observed in both eutopic and ectopic tissues from endometriosis-induced mice is regulated by 
aberrant histone regulation, we will utilize preserved tissue samples to complete chromatin 
immunoprecipitation (using an antibody specific for acetylated lysine) followed by DNA 
sequencing.  
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correlation between dysregulated histone modifications and autophagic gene expression 
specifically in endometriosis has not been clearly identified and would be beneficial to study 
further. We could thus utilize eutopic and ectopic tissues from endometriosis-induced mice (for 
which we have available samples remaining) and complete chromatin immunoprecipitation (ChIP) 
analysis followed by DNA sequencing to assess H3 acetylation at the promoter region of 
autophagy genes that were significantly reduced in both the murine ectopic and eutopic 
endometrium (namely, ATG5, ATG9a, and ATG2b, see Figure 80). Cadherin-1 (CDH1) promoter 
region has already been identified as being hypoacetylated in human endometriotic lesions 
compared to control endometrium from patients without endometriosis [374], and assessing this 
marker could serve as a positive control. Since we observed reduced expression of these 
autophagy genes, we expect that histone 3 acetylation will be reduced in these promoter regions. 
This work would provide novel mechanistic insight into autophagy regulation in endometriosis and 
may support future investigations into the use of histone deacetylase inhibitors as an innovative 
treatment strategy for endometriosis patients. 
NCOA4 is expressed as two alternative splice variants (NCOA4 and NCOA4), which 
have been described with opposing functions in both breast and prostate cancers [267, 269, 270]. 
The specific contributions of these splice variants in ovarian cancer pathogenesis would be 
important to address. Indeed, we observed that siRNA-mediated knockdown of NCOA4 reduced 
cell viability in gynecological cells, further implicating an important role for NCOA4 in OVCA 
pathophysiology. Interestingly, overexpressing NCOA4 also reduced growth potential (assessed 
via clonogenic assay) in gynecological cells, although these cells still retained basal expression 
of NCOA4. In order to elucidate the roles of these specific splice variants, we would need to 
knockout both NCOA4 and NCOA4, for which we have obtained guide RNAs to utilize the 
CRISPR/Cas9 gene editing system (see Figure 81 for the designed gRNAs, as also published in 
[3]). However, I experienced technical difficulty in maintaining NCOA4 knockout cell lines (using 
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the transformed human endometriotic PE-B-OCV cells). These cells did not survive well following 
prolonged maintenance in selection-based media (unpublished results) and thus the knockdown 
could not be validated.  
Chronic treatment with non-transferrin bound iron (NTBI) in FTSECs promoted their 
increase in cell numbers in a manner similar to overexpressing oncogenes commonly identified 
in HGSOC (namely, p53 and Rb inactivation (via SV40 LTAg), c-Myc activation, and H-Ras 
activation). These changes were also associated with increased expression of the oncogenic 
EVI1 variants (wildtype EVI1 and EVI1Del190-515). Based on these expression patterns we expect 
that the chronic iron treated cells would be more tumorigenic than the untreated cells, and the 
next step would be to complete this analysis using a mouse xenograft model while concurrently 
comparing to the tumorigenic potential of the transformed (OCV) relative to control (CV) cells 
(Figure 82A). It would also be important to assess the contribution of iron to OVCA pathogenesis 
using transgenic mouse models to provide a proof-of-concept that these observations made in 
vitro are recapitulated in vivo. An initial consideration to investigate this could be to inject ferric 
ammonium citrate (our source of NTBI) into the ovarian bursa (a process which is successfully 
completed in other mouse models, see [375]). However, our investigation of chronic iron exposure 
(46 days of treatment) of murine oviduct cells did not show any change in morphology or growth 
(Dr. Nanjundan’s unpublished results), and we hypothesize that these cells may not be 
 
Figure 81. Schematic of the experimental design to knockout NCOA4 isoforms using 
CRISPR/Cas9-mediated gene editing. The designed guide RNAs (gRNA) were previously 
published [3] and independently validated using the gRNA Design Tool  
1. Design gRNAs 
(exonic sequence analysis)
2. Insert into Cas9 vector 
(restriction enzyme)
3. Verify successful insertion 
(restriction enzyme digest and sequencing)
NCOA4 gRNA-1
NCOA4 gRNA-2
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susceptible to the increased presence of iron as mice do not naturally menstruate [376]. An 
alternative approach would be to instead cross an existing mouse model for HGSOC (targeted 
overexpression of SV40 LTAg in the oviduct [6]) with an existing mouse model for the iron 
overload disorder hereditary hemochromatosis (genomic deletion of the hemochromatosis protein 
gene HFE [7], Figure 82B), since a correlation between hemochromatosis and ovarian cancer 
has already been identified [322, 325]. We hypothesize that the progeny from this cross would 
result in earlier development (less than six weeks) of ovarian tumors relative to the HGSOC mice 
with intact HFE, and this would be a critical observation towards understanding the contribution 
of iron to HGSOC pathogenesis. 
The next important question to address is how iron mediates these oncogenic changes in 
fallopian tube precursors, and the answer may be identified through an investigation of histone 
modifiers. An interesting study investigating overexpression of the lysine-specific demethylase 
 
Figure 82. Summary of proposed mouse models to investigate the contribution of iron to the 
transition of fallopian tube precursors to ovarian cancer. (A) We propose completing 
subcutaneous mouse xenograft studies to elucidate the tumorigenic potential of either chronic 
iron-treated or transformed FTSECs relative to their respective controls. (B) We propose 
generating a cross strain between established ovarian cancer (see [6]) and iron overload 
(hemochromatosis, see [7]) mouse models to assess whether iron overload promotes the 
development of ovarian cancer tumors in vivo.  
Assess Tumorigenicity
Expect to Observe Increased Tumor 
Burden in HFE-/-/mOGP-TAg mice
Assess tumors & perform IHC for 
NCOA4, p53, PAX8, Ki-67, H2AX, 
FTH, & CD71
A
B
NOD/SCID
FAC
FTSECs
Untreated
FTSECs
NOD/SCID
FTSEC-OCVFTSEC-CV
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Untreated
FTSECs
FTSEC-OCVFTSEC-CV
mOGP-TAg
C57BL/6
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C57BL/6
mOGP-TAg
C57BL/6
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KDM4A (also known as Jumanji Domain Containing 2A (JMJD2A)) found chromosomal copy 
number gains in regions commonly aberrant in cancers [377]; of particular interest is amplification 
of the 3q and 8q arms (depicted in Figure 6A of the referenced article), the most commonly 
amplified regions in HGSOC [64]. TCGA analysis indicates that KDM4A/JMJD2A mRNA is 
significantly elevated in HGSOC (results not shown), and, importantly, KDM4A/JMJD2A 
demethylase activity depends on iron binding within its active site [378, 379]. Furthermore, EVI1 
is already known to interact with histone methyltransferases (including G9a and SUV39H1 [93, 
94]) to regulate transcription of target genes. Upon analyzing the promoter region of EVI1 (using 
the ALGGEN PROMO and MatInspector Databases [380-382], see Table 4) we identified 23 
Table 4. List of transcription factors predicted to bind to the promoter of EVI1. This table 
includes their association with either iron signaling or -catenin/Wnt signaling pathways. 
 
Transcription 
Factor
Associated 
with Iron?
Target in the Iron 
Pathway
Associated with  -
catenin/Wnt?
1 AP-2alphaA Yes Frataxin Yes
2 c-Ets-1 Yes Transferrin Receptor Yes
3 c-Myb Yes Anemia (low iron) Yes
4 C/EBPalpha Yes Hepcidin Yes
5 C/EBPbeta Yes Hepcidin Yes
6 Elk-1 Yes Iron Chelation No
7
HNF-3alpha (aka 
FOXA1)
Yes Mitochondrial Ferritin Yes
8 HOXD10 No - Yes
9 IRF-1 Yes NRAMP Yes
10 IRF-2 No - No
11
LEF-1 (aka 
TCF1alpha)
Yes Iron Overload Yes
12 MEF-2A Yes Frataxin No
13 NF-1 Perhaps Iron Deficiency Yes
14 NF-AT1 Yes Iron (Coal Dust) Yes
15 NF-AT2 Yes Iron Chelation Yes
16 p53 Yes Iron Overload Yes
17 Pax-5 Yes MCOLN2 Yes
18 PR A No - Yes
19 SRY No - Yes
20 STAT1beta Yes Hepcidin No
21 TCF-4E Yes Serum ferritin Yes
22 XBP-1 No - Yes
23 YY1 Yes Mitochondrial Ferritin Yes
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common transcription factors with predicted binding sites, 15 of which demonstrated correlations 
to both iron signaling and -catenin/Wnt signaling (since -catenin protein levels were also 
increased with chronic iron exposure). We thus propose that chronic iron exposure may be 
promoting transcription of EVI1, perhaps through -catenin/Wnt signaling, while concurrently 
increasing KDM4A/JMJD2A activity to promote amplification of the 3q and 8q chromosomes in 
FTSECs (Figure 83). Further investigations to validate the transcription factors involved as well 
as KDM4A activity would be required to address this hypothesis.  
Iron is a known mutagenic agent and is able to directly promote DNA damage [34, 195, 
197, 383]. Fragile sites are regions within the chromosome that are easily susceptible to DNA 
damage [384], especially by mutagenic and carcinogenic agents [385]. It is interesting that fragile 
sites have been identified near chromosome locations harboring many of the genes that we 
identified as elevated with chronic iron treatment, including EVI1, Myc, -catenin, and FANCD2 
(Table 5). It is possible that the presence of iron may be inducing DNA damage at these regions, 
and that this may be responsible for the aberrant expression patterns that we observed. One 
method to investigate this would be complete metaphase spreading, whereby condensed 
chromosomes are stained with Giemsa to identify banding patterns and then karyotyped [386]. 
Using this method would allow us to identify regions with large regions of DNA damage breaks 
 
Figure 83. Proposed model by which iron may mediate the transition of fallopian tube 
precursors to ovarian cancer. Chronic iron may promote the demethylase activity of 
KDM4A/JMJD2A, resulting in amplification of EVI1 at the 3q26.2 locus (top). Chronic iron 
may also alter the expression and/or activity of transcriptional regulators, resulting in reduced 
MDS1/EVI1 and elevated EVI1 and EVI1Del190-515 expression (bottom).  
MDS1/EVI1
Transcriptional 
Regulators
Promoter Analysis: 
See Table 4
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and may reveal a potential mechanism by which iron is mediating these observed oncogenic 
changes. Furthermore, completing comparative genomic hybridization (CGH, [387]) from DNA 
isolated from untreated and FAC-treated FTSECs would provide valuable information regarding 
genomic amplifications or deletions, with an emphasis on those regions identified as aberrant 
from the metaphase spreads. Assessing changes that are present in the genome over the time 
of chronic iron treatment would be invaluable towards identifying a potential timeline by which 
these oncogenic changes develop, and these studies would be critical in revealing a step-wise 
progression from fallopian tube precursors to HGSOC. 
 
Overall Conclusions and Closing Remarks 
Throughout this project, I have focused my investigations on understanding the 
mechanisms involved in the transition of precursor lesions, such as endometriosis and fallopian 
tube STICs, to epithelial ovarian cancer. We initially identified the importance of the autophagic 
pathway in the development of endometriotic lesions using a well-established mouse model for 
endometriosis (Chapter 2), and future investigations into the use of the FDA-approved drug 
hydroxychloroquine as a treatment strategy for these patients is a critical next step. We generated 
transformed endometriotic cells by overexpressing markers commonly associated with ovarian 
cancer and identified dysregulated expression of iron pathway mediators (Chapter 3). While 
Table 5. List of known fragile sites. These sites are located near genomic regions of genes 
demonstrating altered expression in chronic iron-exposed FTSECs. 
 
Gene Chromosome Fragile Sites Nearby? Fragile Site Location Fragile Site Name
EVI1/MECOM 3q26.2 Y 3q24 & 3q27 FRA3D & FRA3C
c-MYC 8q24.21 Y 8q24.1 & 8q24.3 FRA8C & FRA8D
-catenin 3p22.1 Y 3p24.2 FRA3A
FANCD2 3p25.3 Y 3p24.2 FRA3A
BMI1 10p12.2 No - -
Cyclin D1 11q13.3 Y 11q13 FRA11H
TERT 5p15.33 Y 5p14 FRA5E
Assessment of Fragile Sites Near Genes Altered in HGSOC
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similar phenomena has been described in transformed fallopian tube fimbrial cells [26], we 
characterized for the first time elevated mRNA and protein expression of NCOA4 in malignant 
gynecological cells as well as human ovarian cancer tumors. Elucidating the contribution of 
NCOA4 to the pathogenesis of ovarian cancer would certainly expand on our knowledge while 
providing support for a potentially novel target to improve therapeutic strategies and, ultimately, 
OVCA patient outcomes. Finally, we demonstrated that chronic iron exposure is able to promote 
oncogenic changes in fallopian tube epithelial cells, but not ovarian surface epithelial cells 
(Chapter 4). This critical finding provides insight into the role for iron in promoting the transition of 
fallopian tube precursors to epithelial ovarian cancer. Targeting HGSOC with ferroptosis inducers 
concurrently with established treatment strategies may thus pave the way towards improving 
patient response and ultimately improve survival – a feat which has not been accomplished for 
the past 40 years. 
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Appendix B 
 
Cell Lines and Antibodies utilized throughout this Dissertation 
 
Presented in Table A1 are the antibodies used for western blotting in this dissertation. 
Table A2 summarizes the details regarding the gynecological cell lines utilized in these studies 
 
 
Table A1. List of western blotting antibodies utilized. 
 
Name Source Catalog Host Dilutions
p62 (SQSTM1) BD Biosciences 610832 M mAb 1:1000
SV40 LTAg BD Biosciences 554149 M mAb 1:1000
NCOA4 Bethyl Laboratories A302–272a Rb pAb 1:1000
AMPK Cell Signaling Technologies 2603 Rb mAb 1:500
-catenin Cell Signaling Technologies 9587 Rb pAb 1:1000
Beclin-1 Cell Signaling Technologies 3738 Rb pAb 1:1000
BMI1 Cell Signaling Technologies 6964 Rb mAb 1:1000
c-MYC Cell Signaling Technologies 13987 Rb mAb 1:500
EVI1 Cell Signaling Technologies 2593 Rb mAb 1:500
FOXO1 Cell Signaling Technologies 2880 Rb mAb 1:1000
FTH1 Cell Signaling Technologies 3998 Rb pAb 1:500
GABARAPL1 Cell Signaling Technologies 13733 Rb mAb 1:1000
GAPDH Cell Signaling Technologies 5174 Rb mAb 1:1000
Lamin-A/C Cell Signaling Technologies 4777 M mAb 1:2000
LC3A Cell Signaling Technologies 4599 Rb pAb 1:1000
LC3B Cell Signaling Technologies 2775 Rb pAb 1:1000
p21 Cell Signaling Technologies 2946 M mAb 1:250
Pan-Actin Cell Signaling Technologies 4968 Rb pAb 1:500
Pan-AKT Cell Signaling Technologies 4685 Rb mAb 1:1000
PARP Cell Signaling Technologies 9542 Rb pAb 1:1000
phospho-AKT Cell Signaling Technologies 4060 Rb mAb 1:1000
phospho-MAPK Cell Signaling Technologies 9101 Rb pAb 1:750
Total RAS Cell Signaling Technologies 3339 Rb mAb 1:1000
ID1 Gift - Dr. Miguel Pujana - Rb 1:300
CD71 (TFRC) Santa Cruz Biotechnology sc-51829 M mAb 1:250
Cyclin D1 Santa Cruz Biotechnology sc-718 Rb pAb 1:1000
FANCD2 Santa Cruz Biotechnology Sc-20022 M mAb 1:1000
Western Blotting Antibodies Utilized 
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Appendix C 
 
Proteomic Profiling of Iron‐Treated Ovarian Cells Identifies AKT Activation that 
Modulates the CLEAR Network 
 
Note to Reader 
The results presented herein are as published (Rockfield, S., Guergues, J., Rehman, N., 
Smith, A., Bauckman, KA., Stevens, SM Jr., and Nanjundan, M. Proteomics, 2018. 
18(23):e1800244.), albeit reorganized and re-formatted for this dissertation. This reproduction 
was approved by Wiley-VCH (see Appendix A for copyright permissions).  
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Introduction 
Although iron is an essential nutrient needed to maintain survival, its ability to generate 
reactive oxygen species via Fenton reactions also classifies it as a mutagenic agent which may 
promote cancer pathogenesis [34, 300, 388] as well as cell death [389]. Specifically, iron overload 
disorders (i.e., haemochromatosis) are associated with increased cancer risk [388]. Furthermore, 
exogenous iron has been reported to induce ferroptosis [390] as well as other cell death-like 
responses [233]. However, well-defined signaling mechanisms involved in these iron-induced 
cellular responses have not yet been identified. Our earlier studies focused primarily on the 
Ras/MAPK signaling cascade and its contribution to the iron-induced biochemical changes and 
cell death responses in gynecological cell lines [233, 296]. Such transition metals including copper 
and iron have been shown to alter lysosome function and increase lysosomal biogenesis [391]. 
Moreover, we recently identified that ovarian epithelial cells harbored an abundance of lysosomes 
rich in iron particles, which may have contributed to enhanced clearing of excess intracellular iron 
[233]. Apart from the Ras/MAPK pathway, it is likely that numerous other signaling cascades may 
additionally contribute to these observed changes. 
In the present study, we utilized the focused reverse phase protein array (RPPA) 
technology to identify changes in signaling pathways in response to iron treatment in a variety of 
ovarian cell lines. In contrast to untargeted mass spectrometric approaches, RPPA technology 
has limitations due to the requirement for validated antibodies although it has been used in prior 
studies for targeted analysis of specific pathways, including the PI3K, MAPK, LKB1, JAK/STAT, 
apoptosis, cell polarity, TGF, and tyrosine kinase signaling cascades (i.e., EGFR) [392, 393]. 
Nonetheless, RPPA techniques have been employed for predicting drug sensitivity in a wide array 
of cancers [394]; however, to the best of our knowledge, this is the first targeted proteomic study 
investigating signaling pathways which are altered in response to iron. In this regard, we noted 
significant alterations in the AKT, MAPK, and mTOR pathways between HEY ovarian cancer and 
T80 immortalized ovarian surface epithelial cells. We validated these changes via western 
183 
 
analysis and investigated cellular responses to iron that may be mediated through these specific 
pathways. Herein, although we identified iron-induced changes in the AKT/mTOR pathways in 
our gynecological cell lines, further investigations are needed to delineate additional global 
proteomic alterations using an unbiased and untargeted mass spectrometric approach.  
 
Materials and Methods 
Cell culture  
T80 (human immortalized (with LTAg and hTERT) ovarian epithelial), T80 cells 
overexpressing H-Ras (T80+HRas), and HEY (human ovarian carcinoma) cell lines were kindly 
provided by Dr. Gordon Mills and Dr. Jinsong Liu (MD Anderson Cancer Center (Houston, TX, 
USA)). These cell lines were maintained in RPMI 1640 supplemented with 8% FBS and 1% 
penicillin/streptomycin as previously described [233]. TOV112D endometrioid ovarian carcinoma 
cells (obtained from ATCC, Manassas, VA, USA) and TOV21G clear cell ovarian cancer cells 
(kindly provided by Dr. Jonathan Lancaster, Moffitt Cancer Center, Tampa, FL, USA) were 
maintained in MCDB131:Medium 199 (1:1 ratio) supplemented with 8% FBS and 1% 
penicillin/streptomycin as previously described [233]. All cell lines were authenticated by STR 
profiling (Genetica Laboratories (Cincinnati, OH, USA)), and were confirmed to be negative for 
mycoplasma. 
 
Cellular treatments 
Ferric ammonium citrate (FAC) was obtained from Fisher Scientific (Pittsburgh, PA, USA). 
FAC was prepared as a 50mM stock in phosphate-buffered saline (PBS) and used at a final 
concentration of 250M for the indicated times, as previously described [233]. The mTOR inhibitor 
Torin 1 (#14379, Cell Signaling Technology (Danvers, MA, USA)) was prepared in dimethyl 
sulfoxide (DMSO) and used at a final concentration of 10nM as reported in [395]; control cells 
were treated with an equivalent percentage of DMSO. The AKT inhibitor GDC0941 (Selleckchem 
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(Houston, TX, USA)) was prepared in DMSO and used at a final concentration of 1M as 
previously published in [326].  
 
Lysate preparation for Reverse Phase Protein Arrays (RPPA) and data processing 
T80, T80+HRas, HEY, TOV21G, and TOV112D cells were treated for 1h, 18h, and 48h 
with 250M FAC (prepared in PBS, as detailed above) and the Untreated Control corresponded 
to 48h FAC. Protein lysates were collected as described below, and three biological replicates 
were assessed. Samples were analyzed at the RPPA Core Facility at MD Anderson Cancer 
Center (Houston, TX, USA) as previously described [80, 396]. Briefly, cell lysates were two-fold-
serial diluted five times (1:2 to 1:16 dilution) in dilution buffer containing SDS with 2-
mercaptoethanol followed by their application to nitrocellulose-coated slides (11 samples by 11 
samples array format). In total, there were 197 slides to which 170 antibodies were applied (with 
22 sets of replicated antibodies). Using an automated BioGenex autostainer (San Ramon, CA), 
slides were probed with antibodies and signals were developed using the Dako Catalyzed Signal 
Amplification system (DakoCytomation California Inc., Carpinteria, CA) in which visualization was 
enabled using 3,3’-diaminobenzine (DAB). Please see Supplementary Table 1 for a complete list 
of antibodies used in this study, including details of antibody-host organism, dilution, and 
manufacturer. Quality control (QC) testing was completed for each antibody staining as previously 
described in [397]. Using a flatbed scanner, slides were scanned to produce a 16-bit Tiff image 
from which spots were then identified and their intensity quantified for data processing and 
statistical analyses using MicroVigene (which employs a Supercurve method developed using an 
R package) as previously described [396] thus generating Supercurve Log2 values. These values 
were then normalized for protein loading, transformed to linear and then to Log2 values followed 
by median-centering for Hierarchical Cluster analysis (using Cluster 2.51) which utilizes a 
Pearson Correlation and a centered metric. Out of the 170 analytes, we identified 15 antibodies 
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that were not fully validated from the entire RPPA dataset and thus, we eliminated them from our 
final analyses for a final of 155 targets.  
 
Protein isolation, SDS-PAGE, and western analyses  
Protein lysates from cultured cells were prepared as previously described [278]. Protein 
lysates were quantified using the Bicinchoninic acid assay (BCA Assay, ThermoFisher). We then 
normalized all samples for each independent experiment equivalently (i.e., 1500g/ml). When 
sufficient protein was not obtained (at least 1mg/ml), we standardized all samples within the 
independent experiment to the lowest concentration.  Normalized samples were loaded onto 10% 
SDS-PAGE gels and transferred to polyvinylidene fluoride (PVDF) membranes. As indicated in 
the Figure Legends, samples which were re-run to prevent interference between antigens of 
similar molecular weights are separated with a dotted line. For all experiments, three biological 
replicates were performed. Western blotting was completed as described previously [235] with 
the following antibodies from Cell Signaling Technology (Danvers, MA, USA): TFEB rabbit 
polyclonal (#4240S, 1:1000), LC3B rabbit polyclonal (#2775S, 1:1000), FTH1 rabbit polyclonal 
(#3998S, 1:500), TFE3 rabbit polyclonal (#14779S, 1:1000), MiTF rabbit polyclonal 
(#12590S,1:1000), pS473 AKT rabbit monoclonal (#4060S, 1:1000), Total AKT rabbit monoclonal 
(#4685, 1:1000), pS21/S9 GSK3 rabbit polyclonal (#9331S, 1:1000), Pan-Actin rabbit polyclonal 
(#4968S, 1:500), pS235/pS236 S6 rabbit polyclonal (#4858P, 1:1000), total S6 rabbit polyclonal 
(#2217S, 1:2500), Lamin A/C mouse monoclonal (#4777S, 1:1000), and GAPDH rabbit polyclonal 
(#5174P, 1:1000). CD71 mouse monoclonal (sc-51829, 1:250) was obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). SQSTM1 mouse monoclonal (#610832, 1:1000) was obtained 
from BD Biosciences (San Jose, CA, USA). Multiple exposures (short/long exposures) were 
captured to film to identify signals within the linear range. Densitometric analyses were completed 
using ImageJ (NIH). 
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siRNA transfection 
T80 and HEY cells were seeded at 350,000 cells per well in 6-well plates and transfected 
with siRNA as described previously [235]. The following siRNAs were utilized: (1) non-targeting 
control (D-001810-10-20), (2) TFEB (L-009798-00-0005), (3) TFE3 (L-009363-00-0005), and (4) 
MiTF (L-008674-00-0005). Two rounds of siRNA transfection were completed for MiTF 
knockdown to obtain efficient knockdown, while one round was completed for TFEB and TFE3 
knockdown. For all siRNA experiments, three biological replicates were performed. 
 
Subcellular fractionation 
The NE-PER Nuclear and Cytoplasmic Extraction Reagents (#78835, Fisher Scientific 
(Pittsburgh, PA, USA)) were utilized according to the manufacturer’s protocol. Cytoplasmic and 
nuclear fractions were collected and run on 10% SDS-PAGE gels for western blotting, and three 
biological replicates were performed.   
 
Immunofluorescence staining  
T80 and HEY cells were seeded onto glass coverslips (250,000 cells per well), allowed to 
adhere overnight, treated with 250M FAC, and processed according to previously published 
methodology [233]. For colocalization studies, cells were fixed in 4% formaldehyde (in PBS), 
followed by blocking in 5% goat serum and 0.1% Triton-X-100 (in PBS) for 1h at room 
temperature. The cells were then stained with anti-TFEB mouse monoclonal (#H00007942, 
20g/mL, Abnova (Taipei City, Taiwan)) antibody overnight in a humidified chamber at 4°C 
followed by a 1h incubation with AlexaFluor-488 anti-mouse antibody (#A12379, 1:500, Fisher 
Scientific (Pittsburgh, PA, USA)). Next, the fixed cells were incubated with either anti-LAMP1 
(#9091, 1:200, Cell Signaling Technology (Danvers, MA, USA)) or LC3B rabbit polyclonal (#2775, 
1:2000, Cell Signaling Technology (Danvers, MA, USA)) antibody overnight in a humidified 
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chamber at 4°C followed by 1h incubation with AlexaFluor-546 anti-rabbit secondary (#A11035, 
1:500, Fisher Scientific (Pittsburgh, PA, USA)). Slides were viewed and imaged at 63X 
magnification using a PerkinElmer UltraVIEW Confocal Spinning Disc Microscope (PerkinElmer 
Incorporation). Three independent experiments were performed. Representative images were 
captured and colocalization was quantified via Pearson Correlation Coefficient using the Velocity 
Software (Version 6.1.1). 
 
Staining with LysoTracker Red 
HEY cells were seeded onto glass coverslips at 250,000 cells per well in 6-well plates, 
allowed to adhere overnight, and then treated with 250M FAC. LysoTracker Red staining was 
performed as previously reported [233]. Briefly, LysoTracker Red (#L7528, 75nM, Life 
Technologies (Carlsbad, CA)) was applied to the cells 1 hour prior to completion of FAC 
incubation. Cells were washed with PBS, fixed in 4% formaldehyde (in PBS) for 30 minutes, 
blocked with 5% goat serum and 0.1% Triton-X-100 (in PBS) for 1h at room temperature, and 
then incubated with TFEB mouse monoclonal antibody in a humidified chamber overnight at 4°C 
(see antibody details, above). Samples continued to be processed according to the methods 
described above.  
 
RNA isolation and real-time PCR 
The RNeasy Kit (QIAGEN (Valencia, CA, USA)) was utilized to isolate total RNA according 
to the manufacturer’s instructions. Real-time PCR was conducted using the One-step Master Mix 
from Applied Biosystems (#4392938 (Foster City, CA, USA)) with the following FAM-labeled 
probes/primers: (1) HO-1 (Hs01110250_m1), (2) SQSTM1 (Hs01061917_g1), (3) LAMP1 
(Hs00174766_m1), (4) UVRAG (Hs01075434_m1), (5) Beclin1 (Hs00186838_m1), (5) CTSD 
(Hs00157205_m1), (6) MCOLN1 (Hs01100653_m1), and (7) ATP6AP1 (Hs00184593_m1). CT 
values were normalized to β-actin (#401846, Applied Biosystems (Foster City, CA, USA)) and 
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RNA-fold changes were derived using the formula 2−ΔΔCT. For all analyses, three biological 
replicates were performed. 
 
Cloning of TFEB and generation of TFEB retroviral HEY cell lines 
Using the RNeasy Mini Kit (QIAGEN (Valencia, CA, USA)), RNA was isolated from T80 
and HEY cells for reverse transcriptase (RT)-polymerase chain reaction (PCR) to amplify TFEB. 
The primers used were: (1) 5’-GGG-GAA-TTC-ACC-GCC-ATG-GCG-TCA-CGC-ATA-GG-3’ 
(forward primer) and (2) GGG-GAA-TTC-TCA-CAG-CAC-ATC-GCC-CTC-3’ (reverse primer). 
The following PCR conditions were used: 48°C for 30 min, 94°C for 2 min, 40 cycles of 94°C for 
1 min, 55°C for 1 min, and 68°C for 5 min, with final extension at 72°C for 15 min. PCR products 
were analyzed on a 1% agarose gel followed by gel purification using the QIAquick Gel Extraction 
kit (QIAGEN (Valencia CA, USA)) following the manufacturer’s protocol. Products were next 
cloned into the pTOPO vector (Invitrogen (Carlsbad, CA, USA)). Positive clones were validated 
by sequencing (Molecular Genomics Core, Moffitt Cancer Center (Tampa, Florida, USA)) then 
subcloned into the pBABE-puro retroviral expression vector (Addgene plasmid #1764 [273]) at 
the EcoRI site.  
HEK293T packaging cells were transfected with TFEB or empty pBABE-puro (as a 
control) vector along with pCGP and pVSVG vectors (1:1:1 ratio) using Fugene HD (Roche 
(Indianapolis, IN, USA)). Retroviral particles were collected at 48 and 72 h post-transfection, 
filtered (0.45µm), and utilized to infect HEY cells with 8g/ml polybrene (first round of infection) 
or 16g/ml polybrene (second round of infection) followed by antibiotic selection in 2g/ml 
puromycin. 
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Statistical analyses  
Graphpad Prism program, version 6.04 (GraphPad (La Jolla, CA, USA)), was used for 
data analysis. P-values were calculated using the non-parametric Student's t-test. The error bars 
displayed reflect the mean  standard deviation (SD). NS represents non-significant values; * 
represents p  0.05; ** represents p  0.01; *** represents p  0.001; and **** represents p  
0.0001. For RPPA, normalized nonzero intensities of both phosphorylated and non-
phosphorylated proteins were uploaded to Perseus processing suite (Perseus version 1.6.1.1) 
where the intensities were log2 transformed. ANOVA and post hoc testing (FDR <0.05) were then 
performed to determine significant expression changes across all FAC treatment time points 
without a fold-change cutoff  (to not restrict the bioinformatic analysis which could limit enrichment 
analysis based on the limited size of the dataset). Non-transformed ratio averages of differentially 
expressed proteins found significant in each of the following comparisons: 1h/0h, 18h/0h, and 
48h/0h, were then uploaded to Ingenuity Pathway Analysis (IPA) to identify predicted activated or 
inhibited upstream regulators as well as over-represented canonical pathways and networks. For 
all IPA analyses, the Uniprot IDs were uploaded, along with phosphorylated protein ratios, 
phosphorylation sites, and non-phosphorylated protein expression ratios. Core analysis was 
performed separately for phosphorylated proteins and non-phosphorylated proteins via 
phosphorylation and expression analysis, respectively. The resulting predictions were considered 
for further analysis and validation based on a z-score in the range of approximately -2< z >2 
indicating directional inhibition or activation, respectively. Further filtering criteria were overlap p-
value of < 0.05 (Fisher’s exact test) in addition to consideration of biological relevance. 
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Results 
RPPA analysis identifies differential responses to FAC across multiple ovarian cell lines  
Although increased iron is well-established to modulate both cell survival and cell death, 
the mechanisms by which this occurs has not yet been delineated [300, 388, 389]. We previously 
reported that iron treatment promoted cell death in HRas overexpressing T80 (immortalized 
ovarian surface epithelial), HEY ovarian cancer (harboring KRas mutation), TOV21G clear cell 
ovarian carcinoma (harboring KRas mutation), and, to a lesser extent in TOV112D endometrioid 
ovarian cancer cells (lacking Ras mutation), with no change in parental T80 (lacking HRas 
overexpression or mutation) cells [233]. To identify signaling pathways altered in response to iron 
that could mediate these functional differences, we first completed reverse phase protein array 
(RPPA) to investigate proteomic changes in specific signaling pathways (155 total markers 
containing 40 phosphorylated markers which were assessed; see Supplementary Table 1 
(results available with the original publication, in Supplementary Figures) for antibody details) 
using protein lysates collected from untreated, 1, 18, and 48 hour ferric ammonium citrate (FAC)-
treated T80, T80+HRas, HEY, TOV21G, and TOV112D cells. The results obtained were analyzed 
utilizing Cluster/Treeview software to generate heatmaps. Supplementary Figure 1A (see 
original publication) depicts the heatmap generated by median-centering all 155 markers amongst 
all 5 cell lines. It is not surprising that we observed diverse baseline expression of these markers 
based on the different origins of these cells (HEY cells were previously described as serous 
ovarian cancer, but this classification has recently come into question [365]). Using a focused 
analyses comprised of 45 markers (derived from the total 155 markers and including 21 
phosphorylated markers), we identified iron-induced changes in pAKT (S473), pMAPK, and 
mTOR that diverged between the Ras-mutated cell lines and those lacking this alteration (Figure 
A1). In assessing changes associated with Ras status of these cells, we identified AKT, pS6, and 
pGSK3 as being divergent. We cautiously express the limitations of our RPPA/IPA approach as 
the number of phosphorylated proteins assessed were biased towards the AKT/mTOR pathway 
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(21 of the 40 phosphorylated markers). Thus, we may have missed changes in the 
phosphorylation status of other proteins that were not included in this RPPA analysis. 
We also utilized Ingenuity Pathway Analysis (IPA) software using colors, shapes, and 
directionality to indicate strength in association between differential phosphorylation and 
 
Figure A1. Reverse phase protein analysis of T80 and HEY cells treated with 250M FAC for 
1, 18, 48 hours. Reverse phase protein array results displayed as heatmaps with T80, 
T80+HRas, HEY, TOV21G, and TOV112D. Heatmap depicts the analysis focusing on the 
AKT and mTOR signaling pathways in all five cell lines. Three independent experiments are 
shown.  
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upstream regulator and pathway predictions. Interestingly, based on the significant list of 
differentiated phosphorylated proteins from each condition, we identified predicted activation of 
MAPK1 and AKT signaling pathways in HEY relative to T80 cells (Supplementary Figure 2, see 
original publication). HEY cells showed predicted activation of AKT (z=1.944, p= 1.03E-07) and 
MAPK1 (z= 2.403, p= 1.92E-06) robustly at 1 hour followed by a general decrease in activation 
of these predicted upstream regulators at 18 hours for AKT (z= 0.653, p= 1.46E-08) and MAPK1 
(z= 1.132, p= 5.85E-06) as well as 48 hours for AKT (z= 0.492, p= 2.76E-04) and MAPK1 (z= 
0.561, p= 7.71E-06). The general decrease in activation was represented by downstream targets 
showing expression changes opposite to that expected for predicted activation, which is 
demonstrated by yellow lines indicating phosphorylation status inconsistent with the state of the 
downstream molecule (Supplementary Figure 2A, see original publication). In contrast, T80 cells 
 
Figure A2. IPA analysis of RPPA results from Figure A1. Predicted activity of the mTOR 
signaling pathway was found significantly activated in HEY cells for 1h/0h comparison and 
significantly inhibited in T80 cells for 48h/0h comparison. For detailed information regarding 
the IPA Figure Legend, see Supplementary Figure 2. Red color indicates observed 
upregulation while green color indicates observed downregulation. Orange indicates 
predicted activation while blue indicates predicted inhibition. A glowing shape indicates that 
the observed pathway activation was opposite of that predicted. An orange line indicates a 
relationship predicted to lead to activation of the indicated pathway. A blue line indicates a 
relationship predicted to lead to inhibition of the indicated pathway while a yellow line indicates 
that an observed activation is inconsistent with the state of the downstream molecule. 
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showed no predicted activation of AKT initially at 1 or 18 hours but was then predicted to be 
significantly inhibited by 48 hours (z= -2.164, p= 1.99E-06). Additionally, T80 cells had an initial 
predicted activation of MAPK1 (z= 1.961, p=2.68E-05) but no predicted activation or inhibition at 
18 or 48 hours (Supplementary Figure 2B, see original publication). IPA also displayed a 
significant difference in mTOR signaling between HEY and T80 cells with FAC treatment (Figure 
A2). Specifically, we observed a significant increase in activation of mTOR at 1 hour in FAC-
treated HEY cells (z= 2.236, p= 4E-08), while T80 cells had a predicted increase in inhibition by 
48 hours for mTOR (z= -2, p= 2.09E-07). Altogether, these results show that iron promotes 
different signaling responses between ovarian epithelial (T80) and ovarian cancer (HEY) cells. 
 
Figure A3. TFEB expression is altered in response to FAC in ovarian cells. Western analysis 
of T80 and HEY cells treated at the indicated time points with 250M FAC. The dotted line 
separates samples which were re-run to prevent interference between antigens of similar 
molecular weights. Data shown are representative of three independent experiments. 
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Since our analyses demonstrated that activation of AKT, GSK3, and mTOR were 
increased in cell lines associated with Ras mutations (i.e., HEY), we therefore validated 
phosphorylation of these molecules in both T80 and HEY cells treated with FAC. Indeed, although 
pAKT (S473) was elevated with FAC treatment in both T80 and HEY cells, this was more 
pronounced in HEY cells (~5-fold increase at 1 hour FAC in T80; ~16-fold increase at 1 hour FAC 
in HEY relative to T80 Untreated) (Figure A3). A similar observation was noted for pGSK3 
(S9/S21) (~3-fold increase at 1 hour FAC in T80; ~8-fold increase at 1 hour FAC in HEY); this 
was as expected since AKT activation phosphorylates GSK3 [398]. We also assessed 
phosphorylation of S6 (a downstream target of mTOR) [273]. We noted that S6 phosphorylation 
(at Ser235 and Ser236) was elevated and relatively unchanged in response to FAC treatment in 
T80 cells, while its phosphorylation pattern increased transiently in HEY cells between 1 to 6 
hours following FAC treatment (~2-fold increase at 1 hour FAC, relative to T80 Untreated).   
 
Altered expression of TFEB and TFE3 in response to FAC in ovarian cells  
AKT and mTOR are well-known negative regulators of autophagy [399, 400]. MiTF family 
of transcription factors (including TFEB, TFE3, and MiTF) have been shown to regulate lysosome 
formation and alter autophagic response via transcriptional upregulation of the CLEAR network 
[401, 402]. Since MiTF transcription factors are regulated via mTOR kinase activity [402-404] and 
since activation of AKT pathway negatively regulates TFEB activity independently from mTOR 
[405, 406], we next investigated whether TFEB protein levels differ between T80 and HEY cells 
following iron treatment. We observed that TFEB baseline expression was markedly lower in HEY 
relative to T80 cells (Figure A3). Relative to T80 cells, TFEB expression was even further reduced 
between 18-24 hours of FAC treatment (relative to untreated) in HEY cells (Figure A3). We also 
assessed other MiTF family members including TFE3 and MiTF [401, 407]; while MiTF was not 
detectable in our cells (data not shown), we clearly observed TFE3 protein expression in both cell 
lines which remained unchanged in T80 and reduced in HEY (~50%) following 24 hours of FAC 
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treatment (relative to T80 untreated). Since we previously reported that FAC can modulate 
autophagic response [233], we assessed changes in LC3B (an autophagosomal marker) protein 
levels to allow comparison between the T80 and HEY cell lines. We observed increased lipidation 
(LC3B-II form) in both T80 (~5-fold) and HEY (~13-fold) cells following 18 hours FAC treatment 
relative to T80 Untreated (Figure A3). In addition, we noted increased SQSTM1 following long-
term FAC treatments in both T80 and HEY; specifically, basal SQSTM1 protein was markedly 
lower in HEY cells relative to T80. As expected, we identified that baseline transferrin receptor 
(CD71) protein was elevated in HEY cells (~3-fold, relative to T80) and was reduced in both cell 
lines following 24 hours of FAC (~76% (T80) and ~33% (HEY)) relative to T80 Untreated. In 
contrast, the ferritin heavy chain  (FTH1, which is part of the iron storage complex) was increased 
in T80 cells beginning at 3 hours of FAC (~3-fold) but was delayed in appearance in the HEY 
cells, in which it reached detectable levels at only 18 hours of FAC treatment (~3-fold increase) 
relative to T80 Untreated.  
 
 
 
Figure A4. Contribution of mTOR to TFEB expression in FAC-treated ovarian cells. Western 
analysis of T80 cells (left panels) and HEY cells (right panels) treated at the indicated time 
points with 250M FAC in the absence or presence of 10nM Torin 1. Data shown are 
representative of three independent experiments. 
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Contribution of mTOR and AKT to the FAC-mediated changes in TFEB expression 
Since MiTF family members are substrates of mTOR kinases [402-404] which hinders 
their movement to the nuclear compartment where they are required to transcriptionally regulate 
the CLEAR network, we assessed whether inhibition of mTOR kinase could lead to altered cellular 
responses to iron in ovarian cells. Therefore, we utilized the mTOR inhibitor Torin 1 in the absence 
or presence of FAC in T80 and HEY cells. Indeed, as shown in Figure A4, the inhibitor ablated 
the phosphorylation of an mTOR substrate, S6 [408], in both cell lines. We observed that TFEB 
protein was reduced at an earlier timeframe (1 hour) upon iron treatment in combination with Torin 
1 in both T80 and HEY cells (relative to FAC alone). Further, we noted an increase in LC3B 
lipidation in T80 cells following 1 hour of FAC treatment with Torin 1.  
It was recently reported that the AKT signaling pathway regulates TFEB activity 
independently from mTORC [405, 406]. Since our analyses showed activation of the AKT pathway 
following iron treatment in T80 and HEY cells (see Figures A1 and A2), we next investigated 
whether AKT contributes to modulating downstream effectors of TFEB. To inhibit AKT, we utilized 
the PI3K inhibitor GDC0941. As shown in Figure A3, pAKT was not detected up to 24 hours in 
either T80 or HEY cells with the FAC/GDC0941 combinatorial treatment while total AKT remained 
 
Figure A5. Contribution of AKT to TFEB expression in FAC-treated ovarian cells. T80 cells (left 
panels) and HEY cells (right panels) were treated at the indicated time points with 250M FAC 
in the absence or presence of 1M GDC0941. Data shown are representative of three 
independent experiments. 
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unchanged. While phosphorylation of S6 was weak/undetectable in HEY cells following the 
combinatorial treatment, pS6 was reduced in T80 cells relative to FAC treatment alone. We found 
no marked difference in TFEB expression with the combined FAC with GDC0941 treatment in 
T80 cells relative to FAC alone, whereas TFEB expression reduced at an earlier timepoint with 
combined treatment (6 hours) relative to FAC alone (18 hours). Neither FTH1 protein nor LC3B 
lipidation were altered with combined FAC and GDC0941 treatment (Figure A5). Together, these 
data suggest that mTOR may regulate TFEB expression in both T80 and HEY cells, while AKT 
may regulate TFEB expression in HEY cells.  
 
Altered TFEB localization patterns in response to FAC in ovarian cells  
Since lysosome biogenesis and autophagy can be altered following translocation of MiTF 
family members to the nuclear compartment (where they transcriptionally regulate the CLEAR 
network [409, 410]), we next determined whether FAC treatment could modulate TFEB 
localization by assessing its expression in the cytoplasmic and nuclear compartments. Indeed, 
we identified reduced cytoplasmic levels of TFEB following FAC treatment which coincided with 
increased nuclear TFEB expression after 24 hours treatment in both T80 and HEY cells 
(Supplementary Figure 3A, see original publication). Furthermore, immunofluorescence staining 
of TFEB showed increased cytoplasmic puncta formation at 24 hours iron treatment (relative to 
untreated) in both T80 and HEY cells (Supplementary Figure 3B and 3C, see original 
publication) which was more pronounced in HEY cells. Collectively, these data show differing 
protein expression of the MiTF family transcription factors (TFEB and TFE3) and SQSTM1 
between immortalized and malignant ovarian cells that may contribute to our previously reported 
biochemical and functional responses to iron in these cells [233, 296].  
Since TFEB regulates lysosome biogenesis and lysosomes are required for 
autophagosome turnover [411, 412], we next assessed whether the FAC-induced increase in 
TFEB puncta observed in HEY cells via immunofluorescence (Supplementary Figure 3C, see 
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original publication) was associated with lysosomes and/or autophagosomes. We completed 
colocalization studies (as determined by a yellow fluorescence signal) via immunofluorescence 
for TFEB with lysosomal-associated membrane protein 1 (LAMP1), LysoTracker Red (which 
detects acidic organelles), and/or with autophagosomes (assessed via LC3B protein). We 
identified increased colocalization between TFEB and LAMP1 (~2-fold, p=0.0175) (Figure A6, 
left panel) as well as with LysoTracker Red (~2-fold, p=0.1959) (Figure A6, middle panel); 
however, we did not observe any significant colocalization between TFEB and LC3B upon 24 
hours FAC relative to untreated HEY cells (Figure A6, right panel). These results suggest that 
TFEB may participate in lysosomal functions.  
Since our analyses (see Figures A1, A2, and A3) showed altered activation of the mTOR 
and AKT pathways, which are known to regulate TFEB [401, 403-406], we next assessed the 
localization of TFEB following combined treatment (Torin 1 or GDC0941 with FAC) via subcellular 
 
Figure A6. TFEB localization in FAC-treated OVCA cells. HEY cells were treated with 250M 
FAC for 0, 6, and 24 hours. Colocalization (yellow arrowhead) of TFEB with LAMP1 (left 
panels), with Lysotracker Red (middle panels), with LC3B (right panels) along with DAPI are 
shown. Data shown are representative of three independent experiments. 
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fractionation. While we did not see an increase in TFEB translocation to the nuclear compartment 
with the Torin 1 and FAC co-treatment in either T80 or HEY cells (Figure A7A), we did observe 
an increased proportion of TFEB that was localized to the nuclear compartment relative to that in 
the cytoplasmic compartment with the GDC0941 and FAC co-treatment in both T80 and HEY 
cells (Figure A7B). 
 
Induction of HO-1 and the CLEAR network via iron and the contribution of mTOR and AKT 
pathways in ovarian cells 
It has been previously reported that MiTF family members can upregulate the CLEAR 
network [412] which contributes to increased lysosome and autophagosome numbers. Therefore, 
to assess whether this CLEAR network is upregulated in response to iron, we completed real-
time PCR using RNA isolated from FAC-treated T80 and HEY cells for selected markers of this 
network (for a review of these markers, see [413]). As shown in Figure A8, we observed 
increased expression of SQSTM1 (~3-fold, p<0.0001), LAMP1 (~2-fold, p=0.0005), MCOLN1 (~2-
fold, p=0.0091), CTSD1 (~2-fold, p=0.0003), ATP6AP1 (~2-fold, p=0.0002), and UVRAG (~2-fold, 
p=0.0051) with 24 hours FAC in T80 cells. In contrast, at 3 hours FAC treatment in HEY cells, we 
 
Figure A7. TFEB localization is mediated in an mTOR-independent yet AKT-dependent 
manner. (A) Western analysis of cytoplasmic and nuclear fractions from T80 and HEY cells 
treated with 250M FAC in the absence or presence of 10nM Torin 1. (B) Western analysis 
of cytoplasmic and nuclear fractions from T80 and HEY cells treated with 250M FAC in 
the absence or presence of 1M GDC0941. Data shown are representative of three 
independent experiments. 
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initially observed reduced expression of LAMP1 (~45%, p<0.0001), MCOLN1 (~31%, p=0.0035), 
CTSD1 (~43%, p<0.0001), ATP6AP1 (~39%, p<0.0001), UVRAG (~29%, p=0.0084), and BECN1 
(~38%, p<0.0001) while SQSTM1 was dramatically increased at 24 hours treatment (~8-fold, 
p=0.0487). We also assessed HO-1 mRNA levels and show that it was markedly increased in 
HEY cells (~89-fold, p=0.0159) relative to T80 cells (~4-fold, p=0.0010) following 24 hours FAC 
 
Figure A8. FAC upregulates the CLEAR network in T80 and HEY cells. RNA was isolated and 
utilized for real-time PCR to assess transcript expression for heme oxygenase 1 (HO-1) and 
CLEAR network genes (SQSTM1, LAMP1, MCOLN1, CTSD1, ATP6AP1, UVRAG, and 
BECN1). T80 (left panels) and HEY (right panels) cells were treated at the indicated time 
points with 250M FAC. Data shown are representative of three independent experiments. 
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0
5 0
1 0 0
1 5 0
H E Y : H M O X
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
H E Y : A T P 6 A P 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
H E Y : M C O L N 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
H E Y : C T S D 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
H E Y : B E C N 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
H E Y : L A M P 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
H E Y : U V R A G
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0
5
1 0
1 5
H E Y : S Q S T M 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0
2
4
6
T 8 0 :  H M O X
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
T 8 0 :  A T P 6 A P 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T 8 0 :  M C O L N 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T 8 0 :  C T S D 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
T 8 0 :  B E C N 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T 8 0 :  L A M P 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T 8 0 : U V R A G
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
 
C
h
a
n
g
e
0
h
1
h
3
h
6
h
1
8
h
2
4
h
0
1
2
3
4
T 8 0 :  S Q S T M 1
F A C  T re a tm e n t
R
N
A
-
F
o
l
d
 
C
h
a
n
g
e
SQSTM1
R
N
A
-F
o
ld
 C
h
a
n
g
e
T80
HO-1
LAMP1
R
N
A
-F
o
ld
 C
h
a
n
g
e
MCOLN1
R
N
A
-F
o
ld
 C
h
a
n
g
e
CTSD1 ATP6AP1
UVRAG
R
N
A
-F
o
ld
 C
h
a
n
g
e
BECN1
SQSTM1 HO-1
LAMP1 MCOLN1
CTSD1
ATP6AP1
UVRAG BECN1
HEY
NS
NS
NS
****
****
NS
**
NS
****
***
NS
NS
NS
***
***
NS
NS
NS
*
**
*
NS
NS
***
***
NS
NS
NS
****
***
NS
*
NS
**
**
NS
****
NS
*
NS
**
NS
NS
*
*
NS
**
***
*
*
*
****
****
***
NS
NS
**
**
NS
NS
***
****
****
****
NS
**
****
***
***
NS
NS
**
***
*
*
**
****
****
***
NS
0.0
1.0
2.0
3.0
4.0
0.0
2.0
4.0
6.0
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
2.0
2.5
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
0.
5
10
15
0.0
5
100
15
2.
0.0
0.5
1.0
1.5
2.0 2.0
201 
 
treatment. Together, these results suggest that TFEB alters transcription of the CLEAR network 
in ovarian cells and could therefore protect cells from the damaging effects of iron overload 
conditions. 
We next investigated whether the FAC-mediated upregulation of HO-1 and the CLEAR 
network was regulated by mTOR by completing real-time PCR using RNA isolated from FAC and 
Torin 1-treated T80 and HEY cells. We observed little to no change in the majority of the 
transcripts assessed within the CLEAR network in both cell lines, though we noted in T80 cells 
that HO-1 was significantly reduced with FAC and Torin 1 co-treatment at 24 hours (~41%, 
p=0.0138) relative to FAC only (Supplementary Figure 4, see original publication). This suggests 
that the majority of the CLEAR network genes assessed appear to be regulated in an mTOR-
independent manner in these ovarian cells, yet upregulation of HO-1 mRNA in T80 cells in 
response to iron occurs in an mTOR-dependent manner. 
Since TFEB localization was altered with co-treatment of GDC0941 and FAC relative to 
FAC alone (see Figure A7B), we next assessed whether the combinatorial treatment of FAC with 
AKT inhibitor affected the expression of HO-1 or the CLEAR network. Interestingly, co-treatment 
appeared to further promote the expression of CLEAR network genes relative to FAC only (Figure 
A9). Indeed, in T80 cells, we noted significant increases for mRNA transcripts of SQSTM1 
(p=0.0028), HO-1 (p=0.0073), LAMP1 (p=0.0025), MCOLN1 (p<0.0001), CTSD1 (p=0.0003), 
ATP6AP1 (p=0.0018), UVRAG (p=0.0175), and BECN1 (p=0.0094) relative to FAC treatment 
alone. In HEY cells, while we observed elevated expression of SQSTM1 (p=0.0051), LAMP1 
(p=0.0012), MCOLN1 (p=0.0057), CTSD1 (p=0.0008), and ATP6AP1 (p=0.0025) mRNA, we 
noted reduced levels of HO-1 mRNA following combinatorial treatment (FAC with GDC0941) 
relative to FAC alone (p=0.0031). Altogether, these data suggest that AKT could mediate the 
activity of TFEB in response to iron in these ovarian cells and furthermore, AKT could potentially 
regulate the expression of HO-1 in HEY cells. 
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TFEB overexpression upregulates HO-1 and the CLEAR network in malignant ovarian cancer 
cells  
We next set out to determine whether MiTF transcription factors contribute to modulating 
the CLEAR network and HO-1 expression in ovarian cells. We first completed siRNA-mediated 
knockdown of MiTF transcription factors (TFEB and TFE3). TFEB knockdown in T80 cells (~81% 
 
Figure A9. FAC upregulates the CLEAR network in T80 and HEY cells in an AKT-dependent 
manner. RNA was isolated and utilized for real-time PCR to assess transcript expression for 
heme oxygenase 1 (HO-1) and CLEAR network genes (SQSTM1, LAMP1, MCOLN1, CTSD1, 
ATP6AP1, UVRAG, and BECN1). T80 (left panels) and HEY (right panels) cells were treated 
in the absence or presence of 250M FAC for 24 hours with or without 1M GDC0941. Data 
shown are representative of three independent experiments. 
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reduction) was accompanied by reduced FTH1 (~21%) protein at 24 hours FAC relative to control 
(non-targeting) siRNA (Supplemental Figure 5A, see original publication). In HEY cells, neither 
FTH1 nor LC3B-II proteins were altered upon TFEB knockdown (~75% reduction). We then used 
real-time PCR to assess whether SQSTM1 and HO-1 mRNA (the most dramatically increased 
markers upon iron treatment, see Figure A8) were altered upon TFEB knockdown with FAC but 
did not observe any changes in expression (relative to control siRNA at 24 hours FAC) in either 
cell line (Supplemental Figure 5B, see original publication); this suggests that other MiTF family 
members may contribute to their regulation. TFE3 knockdown in T80 cells (~80% reduction) 
correlated with ~29% reduction of LC3B-II protein with 24 hours of FAC treatment (Supplemental 
Figure 3C, see original publication). In HEY cells, TFE3 knockdown (~94% reduction) resulted in 
reduced protein for both FTH1 and LC3B-II (~25% and ~22%, respectively) at 24 hours FAC 
treatment (Supplemental Figure 5C, see original publication). Although TFE3 knockdown did not 
significantly alter SQSTM1 or HO-1 mRNA with 24 hours FAC (relative to control) in T80 cells, we 
observed significant reductions in SQSTM1 without (~65%, p<0.0001) and with (~47%, p=0.0003) 
 
Figure A10. Overexpression of TFEB in HEY cells. Western analysis of Control and TFEB 
overexpressing HEY cells were untreated or treated with 250M FAC for 24 hours. All three 
independent cell lines are shown. 
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FAC treatment (Supplemental Figure 5D, see original publication)) in HEY cells. These results 
suggest that TFE3 contributes to SQSTM1 regulation in HEY cells and that there may be 
redundancy across the MiTF transcription factors in their ability to regulate the CLEAR network.  
We next overexpressed TFEB in HEY cells (which express lower levels of this molecule, 
see Figure A3). As shown in Figure A10, TFEB overexpression increased FTH1 protein as well 
as SQSTM1 relative to control cell lines and also increased TFEB translocation to the nuclear 
compartment following FAC treatment in the overexpressing cell lines (relative to controls) 
(Figure A11). We also observed significant increases in an array of the genes assessed in the 
TFEB overexpressing HEY cell lines (Figure A12): SQSTM1 (~7-fold without FAC (p<0.0001) 
and ~2-fold with FAC (p=0.0223)), LAMP1 (~1.5-fold without FAC (p=0.0168) and ~2-fold with 
FAC (p=0.0127)), MCOLN1 (~2-fold without FAC (p=0.0043) and ~4-fold with FAC (p=0.0002)), 
CTSD1 (~2-fold without FAC (p=0.0036) and ~3-fold with FAC (p=0.00831)), and UVRAG (~1.6-
fold without FAC (p=0.0059) and ~2-fold with FAC (p=0.0003)) mRNA, relative to controls. We 
also identified a significant increase in HO-1 mRNA levels in the TFEB overexpressing cells in 
the absence of iron (~8-fold (p<0.0001)). Altogether, these data show that TFEB overexpression 
 
Figure A11. Localization of TFEB in TFEB-overexpressing HEY cells. Western analysis of 
cytoplasmic and nuclear fractions from Control and TFEB overexpressing HEY cells treated 
with 250M FAC for 24 hours. Data shown are representative of three independent 
experiments. 
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in the HEY cell line can further elevate the transcriptional levels of genes involved in the CLEAR 
network as well as increase HO-1 expression. 
 
Discussion 
Although the role of iron in cancer pathogenesis is still not fully understood, it has been 
suggested that iron (as found in iron overload conditions) induces reactive oxygen species (via 
its role in Fenton reactions) and thus promotes mutagenesis [34]. On the other hand, increased 
iron can also promote cell death via nonapoptotic means including necroptosis (activated by tumor 
 
Figure A12. Overexpression of TFEB in HEY cells upregulates HO-1 and the CLEAR network. 
Real-time PCR analysis of Control and TFEB overexpressing HEY cells treated with 250M FAC 
for 24 hours was completed as detailed in Figures A8 and A9. Data shown are representative 
of three independent experiments. 
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necrosis factor) and ferroptosis (characterized by increased lipid peroxidation and reduced 
glutathione levels). However, our knowledge of how iron elicits this effect remains unknown [389]. 
The RPPA/IPA work presented herein sets the foundation for the next step of conducting a more 
global, untargeted mass spectrometric approach, which would be beneficial towards more 
comprehensively identifying signaling mechanisms that are altered in response to iron which 
mediate cellular death responses. Indeed, we previously reported that iron overload conditions 
promote cell death in an ovarian carcinoma cell line (HEY) with minimal changes in survival 
function in immortalized ovarian epithelial cells (T80) [233]. This differential functional response 
appeared to be dependent on the status of the Ras/MAPK signaling cascade [233], but this study 
presented herein applies a proteomic technology (though focused to a subset of phosphorylated 
proteins, including AKT/mTOR) for elucidating the mechanism by which iron promotes cell death 
in HEY cells. Limitations of RPPA include assessment of a limited set of targets and the availability 
of validated antibodies for assessing phosphorylation status. Nonetheless, RPPA methodology 
has been used to predict drug sensitivity in a wide array of cancers [394]. However, to our 
knowledge, this approach has not been used to assess status of signaling pathways in response 
to iron and thus, we used this technology to identify differences amongst multiple ovarian cell lines 
in response to treatment with FAC. We demonstrate that activation of specific signaling networks 
occur following iron treatment, specifically the mTOR/AKT pathway (identified as two of the more 
significantly altered pathways in T80 and HEY cells in response to iron treatment) which is 
differentially regulated between the HEY and T80 cell lines. Importantly, the results from this 
analysis were validated in functional studies, which enabled us to identify that TFEB (a regulator 
of autophagy and lysosome biogenesis [404]) protein was elevated in T80 relative to HEY cells 
and translocated to the nuclear compartment in response to iron to upregulate the CLEAR 
network as well as HO-1.  
Collectively, we acknowledge that RPPA analysis is a targeted approach for assessing 
signaling changes, as the investigated markers are dependent on the availability of validated 
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antibodies [393] and hence its discovering capabilities are low. Future investigations would 
assess global proteomic changes between iron-treated and control cells using mass 
spectrometry. Overall, our results, via the use of RPPA and IPA technology, identify specific 
signaling pathways dysregulated upon exposure to iron, and provides justification for further work 
to identify other pathways through which this transition metal may promote the pathogenesis of 
cancers. 
 
